ESSEX SEAN (US)
LERNER LORENA (US)
HU QI-YING (US)
QUÉVA CHRISTOPHE (US)
CLAIMS 1. A compound of Formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: A is –N(CH2RN1)(CH2RN2) or a 4-7-membered heterocyclyl ring containing at least one N, wherein the 4-7-membered heterocyclyl ring is optionally substituted with 0-6 R3; each X is independently –O–, –N(R1)–, or –N(R2)–; R1 is selected from the group consisting of optionally substituted C1-C31 aliphatic and steroidyl; R2 is selected from the group consisting of optionally substituted C1-C31 aliphatic and steroidyl; R3 is optionally substituted C1-C6 aliphatic; RN1 and RN2 are each independently hydrogen, hydroxy-C1-C6 alkyl, C2-C6 alkenyl, or a C3-C7 cycloalkyl; L1 is selected from the group consisting of an optionally substituted C1-C20 alkylene chain and a bivalent optionally substituted C2-C20 alkenylene chain; L2 is selected from the group consisting of an optionally substituted C1-C20 alkylene chain and a bivalent optionally substituted C2-C20 alkenylene chain; and L3 is a bond, an optionally substituted C1-C6 alkylene chain, or a bivalent optionally substituted C3-C7 cycloalkylene; and with the proviso that when A is –N(CH3)(CH3) and X is O, L3 is not an C1-C6 alkylene chain. 2. The compound of claim 1, wherein R1 and R2 are each independently optionally substituted C1-C31 alkyl or optionally substituted C2-C31 alkenyl. 3. The compound of claim 1 or 2, wherein R1 and R2 are the same. 4. The compound of any of claims 1-3, wherein R1 and R2 are each independently optionally substituted C10-C20 alkyl. 5. The compound of any of claims 1-4, wherein R1 and R2 are each independently branched C10-C20 alkyl. 6. The compound of claim 1 or 2, wherein R1 and R2 are the different. 7. The compound of any of claims 1, 2, and 6, wherein R1 is optionally substituted C6-C20 alkenyl and R2 is optionally substituted C10-C20 alkyl. 8. The compound of any of claims 1, 2, 6, and 7, wherein R1 is C6-C20 alkenyl and R2 is branched C10-C20 alkyl. 9. The compound of any of claims 1-8, wherein L1 is an optionally substituted C1-C10 alkylene chain and L2 is an optionally substituted C1-C10 alkylene chain. 10. The compound of any of claims 1-9, wherein L1 is an optionally substituted C1-C5 alkylene chain and L2 is an optionally substituted C1-C5 alkylene chain. 11. The compound of any of claims 1-10, wherein L1 is an optionally substituted C1-C3 alkylene chain and L2 is an optionally substituted C1-C3 alkylene chain. 12. The compound of any of claims 1-11, wherein L1 and L2 are each –CH2CH2CH2–. 13. The compound of any of claims 1-12, wherein L3 is a C1-C3 alkylene chain. 14. The compound of any of claims 1-12, wherein L3 is a bond. 15. The compound of any of claims 1-12, wherein L3 is a bivalent C3-C7 cycloalkylene. 16. The compound of any of claims 1-15, wherein the number of carbon atoms between the S of the thiolate and the closest N comprised in A is 2-10. 17. The compound of any of claims 1-16, wherein the number of carbon atoms between the S of the thiolate and the closest N comprised in A is 2-8. 18. The compound of any of claims 1-17, wherein the number of carbon atoms between the S of the thiolate and the closest N comprised in A is 2-5. 19. The compound of any of claims 1-18, wherein the number of carbon atoms between the S of the thiolate and the closest N comprised in A is 2-4. 20. The compound of any of claims 1-19, wherein the number of carbon atoms between the S of the thiolate and the closest N comprised in A is 3. 21. The compound of any one of claims 1-20, wherein the compound is a compound of Formula (I-a): or a pharmaceutically acceptable salt or solvate thereof, wherein: m is 0, 1, 2, 3, 4, 5, or 6. 22. The compound of claim 21, wherein A contains one or more S. 23. The compound of claim 21 or 22, wherein A is an optionally substituted 4-7-membered heterocyclyl ring containing exactly one N. 24. The compound of any one of claims 21-23, wherein A is an optionally substituted 5-6- membered heterocyclyl ring. 25. The compound of any one of claims 21-24, wherein A is an optionally substituted 6 membered heterocyclyl ring containing exactly one N. 26. The compound of any of claims 21-25, wherein the compound is a compound of Formula (I-b): or a pharmaceutically acceptable salt or solvate thereof, wherein: n is 0, 1, 2, or 3; and m is 0, 1, 2, 3, 4, 5, or 6. 27. The compound of any of claims 21-26, wherein A is a tertiary amine. 28. The compound of any of claims 21-27, wherein the compound is a compound of Formula (I-bii): or a pharmaceutically acceptable salt or solvate thereof, wherein: m is 0, 1, 2, or 3; and p and q are each independently 0, 1, 2, or 3, wherein q + p is less than or equal to 3. 29. The compound of any of claims 21-28, wherein L3 is a bond. 30. The compound of any of claims 21-28, wherein L3 is –CH2–. 31. The compound of any of claims 21-30, wherein n is 1. 32. The compound of any of claims 21-30, wherein n is 2. 33. The compound of any of claims 21-30, wherein n is 3. 34. The compound of any of claims 21-33, wherein m is 0 or 1. 35. The compound of any of claims 21-34, wherein R3 is C1-C6 alkyl or C1-C6 alkenyl, wherein each C1-C6 alkyl or C1-C6 alkenyl is optionally substituted with 1-3 C3-C6 cycloalkyl or –OH. 36. The compound of any of claims 21-35, wherein R3 is C1-C3 alkyl. 37. The compound of any of claims 21-36, wherein R3 is –CH3. 38. The compound of any one of claims 1-20, wherein the compound is a compound of Formula (I-c): or a pharmaceutically acceptable salt or solvate thereof. 39. The compound of claim 38, wherein X is O. 40. The compound of claim 38, wherein X is NR1 or NR2. 41. The compound of any one of claims 38-40, wherein RN1 and RN2 are each independently selected from hydrogen, hydroxy-C1-C3 alkyl, C2-C4 alkenyl, or C3-C4 cycloalkyl. 42. The compound of any one of claims 38-41, wherein RN1 and RN2 are each independently selected from hydrogen, –CH2CH=CH2, –CH2CH2OH, . 43. The compound of any one of claims 38-42, wherein RN1 and RN2 are the same. 44. The compound of any one of claims 38-42, wherein RN1 and RN2 are different. 45. The compound of any one of claims 38-42, wherein one of RN1 and RN2 is hydrogen and the other one is 46. A compound, wherein the compound is selected from the group consisting of , , , or a pharmaceutically acceptable salt or solvate thereof. 47. The compound of claim 46, wherein the compound is or a pharmaceutically acceptable salt or solvate thereof. 48. The compound of claim 46, wherein the compound is or a pharmaceutically acceptable salt or solvate thereof. 49. The compound of claim 46, wherein the compound is or a pharmaceutically acceptable salt or solvate thereof. 50. A compound, wherein the compound is selected from the group consisting of , or a pharmaceutically acceptable salt or solvate thereof. 51. A compound of Formula (A): , Formula (A) or a pharmaceutically acceptable salt thereof, wherein: n is an integer between 10 to 200, inclusive of all endpoints; LP1 is –[(CH2)0-3–C(O)O]1-3–, –(CH2)0-3–C(O)O–(CH2)1-3–OC(O)–, or –C(O)N(H)–; RP1 is C5-C25 alkyl or C5-C25 alkenyl; and RP2 is hydrogen or –CH3, with the proviso that Formula (A) is not HO-(CH2CH2O)n-C(O)N(H)-(CH2)17CH3. 52. The compound of claim 51, wherein LP1 is –CH2C(O)O–, –CH2CH2C(O)O–, – CH2C(O)OCH2C(O)O–, –CH2C(O)OCH2CH2OC(O)–, or –C(O)N(H)–. 53. The compound of claim 51 or 52, wherein the compound is a compound of Formula (A-a), Formula (A-b), Formula (A-c), Formula (A-d), or Formula (A-e): or a pharmaceutically acceptable salt thereof. 54. The compound of any one of claims 51-53, wherein RP1 is C14-C18 alkyl or C14-C18 alkenyl. 55. The compound of any one of claims 51-54, wherein RP1 is C14 alkyl, C16 alkyl, or C18 alkyl. 56. The compound of any one of claims 51-55, wherein n is on average about 20, about 40, about 45, about 50, about 68, about 75, or about 100. 57. The compound of any one of claims 46-56, wherein the compound selected from the group consisting of: HO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; H3CO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)15CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)13CH3, n is on average about 45; and HO-(CH2CH2O)n-C(O)N(H)-(CH2)17CH3, n is on average about 45; or a pharmaceutically acceptable salt thereof. 58. A lipid nanoparticle (LNP) comprising a compound of any one of claims 1-50. 59. The LNP of claim 58, further comprising a helper lipid, a structural lipid, and a polyethyleneglycol (PEG)-lipid. 60. The LNP of claim 59, wherein the PEG-lipid is a compound of Formula (A′): or a pharmaceutically acceptable salt thereof, wherein: n is an integer between 10 to 200, inclusive of all endpoints; LP1′ is a bond, –C(O)–, –[(CH2)0-3–C(O)O]1-3–, –(CH2)0-3–C(O)O–(CH2)1-3–OC(O)–, or –C(O)N(H)–; RP1′ is C5-C25 alkyl or C5-C25 alkenyl; and RP2′ is hydrogen or –CH3. 61. The LNP of claim 59, wherein the PEG-lipid is a compound of any one of claims 51- 57. 62. The LNP of any one of claims 59-61, wherein the PEG-lipid is a compound selected from the group consisting of: HO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; H3CO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)15CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)13CH3, n is on average about 45; and HO-(CH2CH2O)n-C(O)N(H)-(CH2)17CH3, n is on average about 45; or a pharmaceutically acceptable salt thereof. 63. The LNP of claim 59 or 60, wherein the PEG-lipid is a compound selected from the group consisting of: HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100; HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 20; HO-(CH2CH2O)n-(CH2)15CH3, n is on average about 20; and HO-(CH2CH2O)n-C18H35, n is on average about 20; or a pharmaceutically acceptable salt thereof. 64. The LNP of claim 59 or 60, wherein the PEG-lipid is a compound selected from the group consisting of: HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 50; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 40; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 50; and HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 40; or a pharmaceutically acceptable salt thereof. 65. The LNP of claim 59, wherein the PEG-lipid is DMG-PEG(2000) or DPG-PEG(2000). 66. A lipid nanoparticle (LNP) comprising a polyethyleneglycol (PEG)-lipid, an ionizable lipid, a helper lipid, and a structural lipid, wherein the LNP has a molar ratio of about 0.001% to about 5% PEG-lipid, and wherein the PEG-lipid is a compound of Formula (A′′): or a pharmaceutically acceptable salt thereof, wherein: n is an integer between 10 to 200, inclusive of all endpoints; LP1′′ is a bond, –[(CH2)0-3–C(O)O]1-3–, –(CH2)0-3–C(O)O–(CH2)1-3–OC(O)–, or – C(O)N(H)–; RP1′′ is C5-C25 alkyl or C5-C25 alkenyl; and RP2′′ is hydrogen or –CH3. 67. The LNP of claim 66, wherein LP1′′ is a bond, –CH2C(O)O–,–CH2CH2C(O)O–, – CH2C(O)OCH2C(O)O–, –CH2C(O)OCH2CH2OC(O)–, or –C(O)N(H)–. 68. The LNP of claim 66 or 67, wherein the PEG-lipid is a compound of Formula (A′′-a), Formula (A′′-b), Formula (A′′-c), Formula (A′′-cd), Formula (A′′-e), or Formula (A′′-f): or a pharmaceutically acceptable salt thereof. 69. The LNP of any one of claims 66-68, wherein RP1′′ is C14-C18 alkyl or C14-C18 alkenyl. 70. The LNP of any one of claims 66-69, wherein RP1′′ is C14 alkyl, C16 alkyl, or C18 alkyl. 71. The LNP of any one of claims 66-68, wherein the PEG-lipid is a compound of Formula (A′′-f1), Formula (A′′-f2), or Formula (A′′-f3): or a pharmaceutically acceptable salt thereof. 72. A lipid nanoparticle (LNP) comprising a polyethyleneglycol (PEG)-lipid, an ionizable lipid, a helper lipid, a structural lipid, and a nucleic acid molecule encoding a viral genome, wherein the LNP has a molar ratio of about 0.001% to about 5% PEG-lipid, and wherein the PEG-lipid is a compound of Formula (B): or a pharmaceutically acceptable salt thereof, wherein: n is an integer between 10 to 200, inclusive of all endpoints; and RB1 is C5-C25 alkyl or C5-C25 alkenyl. 73. The LNP of claim 72, wherein RB1 is C15-C17 alkyl or C15-C17 alkenyl. 74. The LNP of claim 72 or 73, wherein the PEG-lipid is a compound of Formula (B-a) or Formula (B-b): or a pharmaceutically acceptable salt thereof. 75. The LNP of any one of claims 66-74, wherein n is on average about 20, about 40, about 45, about 50, about 68, about 75, or about 100. 76. The LNP of any one of claims 66-75, wherein the PEG-lipid comprises a PEG moiety having an average molecular weight of about 200 daltons to about 10,000 daltons, about 500 daltons to about 7,000 daltons, about 800 daltons to about 6,000 daltons, about 1,000 daltons to about 5,000 daltons, or about 1,500 to about 3,500 daltons. 77. The LNP of any one of claims 66-76, wherein the PEG-lipid comprises a PEG moiety having an average molecular weight of about 800, about 900, about 1,000, about 1,500, about 1,750, about 2,000, about 2,250, about 2,500, about 2,750, about 3,000, about 3,250, about 3,500, about 3,750, about 4,000, about 4,500, or about 5,000 daltons. 78. The LNP of any one of claims 66-77, wherein the PEG-lipid comprises a PEG moiety having an average molecular weight of about 800, about 900, about 1,000 daltons, about 1,500, about 2,000, about 2,500, about 3,000, about 3,500, about 4,000, about 4,500, or about 5,000 daltons. 79. The LNP of any one of claims 66-71 and 75-78, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100; HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 20; HO-(CH2CH2O)n-(CH2)15CH3, n is on average about 20; and HO-(CH2CH2O)n-C18H35, n is on average about 20. 80. The LNP of claim 66-71 and 75-78, wherein the PEG-lipid is a compound selected from the group consisting of: HO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; H3CO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)15CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)13CH3, n is on average about 45; and HO-(CH2CH2O)n-C(O)N(H)-(CH2)17CH3, n is on average about 45. 81. The LNP of any one of claims 72 to 78, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 50; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 40; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 50; and HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 40. 82. The LNP of any one of claims 66-81, wherein the ionizable lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (former name: SS-18/4PE-13), COATSOME® SS-EC (former name: SS-33/4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, Di((Z)-non-2-en-1-yl)9-((4- dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), N-(2,3-dioleoyloxy)propyl)-N,N,N- trimethylammonium chloride (DOTAP), or a mixture thereof. 83. The LNP of any one of claims 66-81, wherein the ionizable lipid is a compound of Formula (II-1): or a pharmaceutically acceptable salt or solvate thereof, wherein: R1a and R1b are each independently C1-C8 aliphatic or –O(C1-C8 aliphatic)–, wherein the O atom, when present, is bonded to the piperidine ring; Xa and Xb are each independently –C(O)O–*, –OC(O)–*, –C(O)N(Rx1)–*, – N(Rx1)C(O)–*, –O(C=O)N(Rx1)–*, –N(Rx1)(C=O)O–*, or –O–, wherein –* indicates the attachment point to R2a or R2b, respectively, and wherein each occurrence of Rx1 is independently selected from hydrogen and optionally substituted C1-C4 alkyl; and R2a and R2b are each independently a sterol residue, a liposoluble vitamin residue, or an C13-C23 aliphatic. 84. The LNP of any one of claims 66-81, wherein the ionizable lipid is a compound of Formula (II-2): or a pharmaceutically acceptable salt or solvate thereof, wherein: R1a’ and R1b’ are each independently C1-C8 alkylene or –O(C1-C8 alkylene), wherein the O atom, when present, is bonded to the piperidine ring; Ya’ and Yb’ are each independently –C(O)O–*, –OC(O)–*, –C(O)N(Rx1)–*, – N(Rx1)C(O)–*, –O(C=O)N(Rx1)–*, –N(Rx1)(C=O)O–*, –N(Rx1)C(O)N(Rx1)–, or –O–, wherein –* indicates the attachment point to R2a or R2b, and wherein each occurrence of Rx1 is independently selected from hydrogen and optionally substituted C1-C4 alkyl; Za’ and Zb’ are each independently optionally substituted arylene–C0-C8 alkylene or optionally substituted arylene–C0-C8 heteroalkylene, wherein the alkylene or heteroalkylene group is bonded to Ya’ and Yb’, respectively; R2a’ and R2b’ are each independently a sterol residue, a liposoluble vitamin residue, or an C12-C22 aliphatic. 85. The LNP of claim 83, wherein the ionizable lipid is a compound of Formula (II-1a): 86. The LNP of claim 84, wherein the ionizable lipid is a compound of Formula (II-2a): 87. The LNP of any one of claims 66-81, wherein the ionizable lipid is a compound of any one of claims 1-50. 88. The LNP of any one of claims 59-87, wherein the helper lipid is selected from distearoyl-sn-glycero-phosphoethanolamine, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl- phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoylphosphatidylethanolamine 4-(N- maleimidomethyl)-cyclohexane-l-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl- ethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethylphosphatidylethanolamine, 18-1-trans PE, l-stearoyl-2- oleoylphosphatidyethanolamine (SOPE), hydrogenated soy phosphatidylcholine (HSPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylserine (DOPS), sphingomyelin (SM), dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dierucoylphosphatidylcholine (DEPC), palmitoyloleyolphosphatidylglycerol (POPG), dielaidoyl-phosphatidylethanolamine (DEPE), lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidyl serine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidicacid,cerebrosides, dicetylphosphate, lysophosphatidylcholine, dilinoleoylphosphatidylcholine, or a mixture thereof 89. The LNP of any one of claims 59-88, wherein the helper lipid is DSPC. 90. The LNP of any one of claims 59-89, wherein the structural lipid is a steroid. 91. The LNP of any one of claims 59-90, wherein the structural lipid is cholesterol. 92. The LNP of any one of claims 58-91, wherein the LNP induces a reduced immune response in vivo as compared to a control LNP lacking a PEG-lipid of Formula (A′′) or an ionizable lipid of any one of claims 1-50. 93. The LNP of claim 92, wherein the immune response is accelerated blood clearance (ABC) of the LNP. 94. The LNP of claim 92 or 93, wherein the immune response is an IgM response. 95. The LNP of any one of claims 66-71 and 75-94, further comprising a compound of Formula (I), a structural lipid that is cholesterol, a helper lipid that is DSPC, and a PEG-lipid that is a compound of Formula (A′′). 96. The LNP of claim 95, wherein the compound of Formula (I) is selected from the group consisting of: , or a pharmaceutically acceptable salt thereof. 97. The LNP of claim 95 or 96, wherein the PEG-lipid is a compound of selected from the group consisting of: HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100; HO-(CH2CH2O)n-CH2C(O)O-(CH2)13CH3, n is on average about 45; and HO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45. 98. The LNP of any one of claims 66-71 and 75-94, comprising a compound of Formula (II-1a), a structural lipid that is cholesterol, a helper lipid that is DSPC, and a PEG-lipid that is a compound of Formula (A′′). 99. The LNP of claim 99, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; H3CO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)15CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)13CH3, n is on average about 45; and HO-(CH2CH2O)n-C(O)N(H)-(CH2)17CH3, n is on average about 45. 100. The LNP of claim 99, wherein the PEG-lipid is HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100. 101. The LNP of any one of claims 72-94, comprising a compound of Formula (II-1a), a structural lipid that is cholesterol, a helper lipid that is DSPC, and a PEG-lipid that is a compound of Formula (B). 102. The LNP of claim 101, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 50; and HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 40. 103. The LNP of any of claims 58-81 and 88-97, wherein the LNP comprises a molar ratio of about 40% to about 70%, such as about 45% to about 55%, or about 49% to about 64% of a compound of any one of claims 1-50. 104. The LNP of any of claims 58-81, 88-97, and 103, wherein the LNP comprises a molar ratio of about 40%, about 45%, about 50%, about 55%, about 58%, or about 60% of a compound of any of claims 1-50. 105. The LNP of any one of claims 58-104, wherein the LNP comprises a molar ratio of about 40% to about 70%, such as about 45% to about 55%, or about 49% to about 64% ionizable lipid. 106. The LNP of any one of claims 58-105, wherein the LNP comprises a molar ratio of about 40%, about 45%, about 50%, about 55%, about 58%, or about 60% ionizable lipid. 107. The LNP of any one of claims 58-106, wherein the LNP comprises a molar ratio of about 0.1% to about 4%, such as about 0.2% to about 0.8 mol%, about 0.4% to about 0.6 mol%, about 0.7% to about 1.3%, about 1.2% to about 1.8%, or about 1% to about 3.5 mol% PEG- lipid. 108. The LNP of any one of claims 58-107, wherein the LNP comprises a molar ratio of about 0.25%, about 0.5%, about 1.5%, or about 3% PEG-lipid. 109. The LNP of any one of claims 58-108, wherein the LNP comprises a molar ratio of about 5% to about 50%, such as about 5% to about 10%, about 25% to about 35%, or about 35% to about 50% structural lipid. 110. The LNP of any one of claims 58-109, wherein the LNP comprises a molar ratio of about 20%, about 22.5%, about 25%, about 27.5%, about 30%, about 32.5%, about 35%, about 37.5%, about 40%, about 42.5%, about 45%, or about 50% structural lipid. 111. The LNP of any one of claims 58-110, wherein the LNP comprises a molar ratio of about 5% to about 50%, such as about 5% to about 10%, about 10% to about 25%, or about 25% to about 50% helper lipid. 112. The LNP of any one of claims 58-111, wherein the LNP comprises a molar ratio of about 5%, about 7%, about 9%, about 12%, about 15%, about 20%, about 25%, or about 30% helper lipid. 113. The LNP of any one of claims 58-112, wherein the LNP comprises a molar ratio of about 45% to about 55% of ionizable lipid, about 5% to about 9% helper lipid, about 36% to about 44% structural lipid, and about 2.5% to about 3.5% PEG-lipid. 114. The LNP of claim 113, wherein the LNP comprises a molar ratio of about 45% to about 55% of a compound of any one of claims 1-50, about 5% to about 9% DSPC, about 36% to about 44% cholesterol, and about 2.5% to about 3.5% DMG-PEG(2000). 115. The LNP of any one of claims 58-112, wherein the LNP comprises a molar ratio of about 49% to about 60% of ionizable lipid, about 18% to about 22% helper lipid, about 22% to about 28% structural lipid, and about 0.2% to about 0.8% PEG-lipid. 116. The LNP of any one of claims 115, wherein the LNP comprises a molar ratio of about 49% to about 60% of a compound of any one of claims 1-50, about 18% to about 22% helper lipid, about 22% to about 28% structural lipid, and about 0.2% to about 0.8% PEG-lipid, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; H3CO-(CH2CH2O)n-CH2C(O)O-(CH2)17CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)15CH3, n is on average about 45; HO-(CH2CH2O)n-CH2C(O)O-(CH2)13CH3, n is on average about 45; and HO-(CH2CH2O)n-C(O)N(H)-(CH2)17CH3, n is on average about 45. 117. The LNP of any one of claims 58-112, wherein the LNP comprises a molar ratio of about 44% to about 54% ionizable lipid, about 19% to about 25% helper lipid, about 25% to about 33% structural lipid, and about 0.2% to about 0.8% PEG-lipid. 118. The LNP of claim 117, wherein the LNP comprises molar ratio of about 44% to about 54% compound of Formula (II-1a), about 19% to about 25% DSPC, about 25% to about 33% cholesterol, and about 0.2% to about 0.8% PEG-lipid, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100; HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 20; HO-(CH2CH2O)n-(CH2)15CH3, n is on average about 20; HO-(CH2CH2O)n-C18H35, n is on average about 20; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 50; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 40; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 50; and HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 40. 119. The LNP of any one of claims 58-112, wherein the LNP comprises a molar ratio of about 44% to about 54% ionizable lipid, about 19% to about 25% helper lipid, about 24% to about 32% structural lipid, and about 1.2% to about 1.8% PEG-lipid. 120. The LNP of claim 119, wherein the LNP comprises a molar ratio of about 44% to about 54% compound of Formula (II-1a), about 19% to about 25% DSPC, about 24% to about 32% cholesterol, and about 1.2% to about 1.8% PEG-lipid, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100; HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 20; HO-(CH2CH2O)n-(CH2)15CH3, n is on average about 20; HO-(CH2CH2O)n-C18H35, n is on average about 20; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 50; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 40; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 50; and HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 40. 121. The LNP of any one of claims 58-112, wherein the LNP comprises a molar ratio of about 44% to about 54% ionizable lipid, about 8% to about 14% helper lipid, about 35% to about 43% structural lipid, and about 1.2% to about 1.8% PEG-lipid. 122. The LNP of claim 121, wherein the LNP comprises a molar ratio of about 44% to about 54% compound of Formula (II-1a), about 8% to about 14% DSPC, about 35% to about 43% cholesterol, and about 1.2% to about 1.8% PEG-lipid, wherein the PEG-lipid is selected from the group consisting of: HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 100; HO-(CH2CH2O)n-(CH2)17CH3, n is on average about 20; HO-(CH2CH2O)n-(CH2)15CH3, n is on average about 20; HO-(CH2CH2O)n-C18H35, n is on average about 20; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 50; HO-(CH2CH2O)n-C(O)-(CH2)14CH3, n is on average about 40; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 100; HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 50; and HO-(CH2CH2O)n-C(O)-(CH2)16CH3, n is on average about 40. 123. The LNP of any one of claims 58-71 and 75-122, wherein the lipid nanoparticle encapsulates a payload molecule. 124. The LNP of claim 123, wherein the payload molecule comprises one or more of nucleic acids, anionic proteins, anionic peptides, or a combination thereof. 125. The LNP of claim 124, wherein the payload molecule comprises a nucleic acid molecule. 126. The LNP of claim 125, wherein the nucleic acid molecule comprises a single-stranded RNA (ssRNA), an siRNA, a microRNA, an mRNA, a circular RNA, a small activating RNA, a guide RNA for CRISPR, a self-amplifying RNA, a viral RNA (vRNA), a single-stranded DNA (ssDNA), a double-stranded DNA (dsDNA), a complementary DNA (cDNA), a closed circular DNA (ccDNA), a replicon, or a combination thereof. 127. The LNP of claim 125 or 126, wherein the nucleic acid molecule comprises a nucleotide sequence encoding one or more therapeutic proteins. 128. The LNP of claim 127, wherein the therapeutic protein is a cytokine (e.g., erythropoietin), a coagulation factor, an antibody, a bispecific T cell engager, or a combination thereof. 129. The LNP of any one of claims 125-128, wherein the nucleic acid molecule comprises a nucleotide sequence derived from a viral genome. 130. The LNP of claim 129, wherein the viral genome is a positive single-stranded RNA viral genome a positive single-stranded RNA viral genome. 131. The LNP of claim 129 wherein the viral genome encodes an oncolytic virus (e.g., Coxsackievirus A21 (CVA21), Seneca Valley virus (SVV), Togaviridae, or Alphavirus (e.g., Sindbis virus, Semliki Forest virus, Ross River virus, or Chikungunya virus)). 132. The LNP of claim 124, wherein the payload molecule comprises a synthetic RNA viral genome encoding a coxsackievirus, and optionally wherein the coxsackievirus is a CVA21 strain. 133. The LNP of claim 124, wherein the payload molecule comprises a synthetic RNA viral genome encoding an SVV. 134. The LNP of claim 132 or 133, wherein the payload molecule further encodes an exogenous protein, wherein the exogenous protein is a fluorescent protein, an enzymatic protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand for a cell-surface receptor. 135. The LNP of any one of claims 72-122, wherein the viral genome is a positive single- stranded RNA viral genome. 136. The LNP of claim 135, wherein the viral genome encodes an oncolytic virus (e.g., Coxsackievirus A21 (CVA21) or Seneca Valley virus (SVV), Togaviridae, or Alphavirus (e.g., Sindbis virus, Semliki Forest virus, Ross River virus, or Chikungunya virus)). 137. The LNP of claim 135, wherein the viral genome is a synthetic RNA viral genome encoding a coxsackievirus, and optionally wherein the coxsackievirus is a CVA21 strain. 138. The LNP of claim 135, wherein the viral genome is a synthetic RNA viral genome encoding an SVV. 139. The LNP of any one of claims 72-122 and 135-138, wherein the viral genome further comprises an exogenous protein, wherein the exogenous protein is a fluorescent protein, an enzymatic protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand for a cell-surface receptor. 140. The LNP of any one of claims 72-122 and 125-139, wherein the LNP has a lipid- nitrogen-to-phosphate (N:P) ratio of about 1 to about 25. 141. The LNP of any one of claims 72-122 and 125-140, wherein the LNP has a N:P ratio of about 14. 142. The LNP of any one of claims 72-122 and 125-140, wherein the LNP has a N:P ratio of about 9. 143. A pharmaceutical composition comprising a compound of any of claims 1-57 or a LNP of any of claims 58-142 and pharmaceutically acceptable excipient, carrier or diluent. 144. A pharmaceutical composition comprising: (1) a payload molecule; and (2) a LNP of any one of claims 66-71 and 75-142. 145. The pharmaceutical composition of claim 143 or 144, wherein the pharmaceutical composition has a half-life in vivo comparable to that of a pre-determined threshold value. 146. The pharmaceutical composition of claim 143 or 144, wherein the pharmaceutical composition has a half-life in vivo greater than that of a pre-determined threshold value. 147. The pharmaceutical composition of claim 143 or 144, wherein the pharmaceutical composition has a half-life in vivo shorter than that of a pre-determined threshold value. 148. The pharmaceutical composition of claim 143 or 144, wherein the pharmaceutical composition has an AUC in vivo comparable to that of a pre-determined threshold value. 149. The pharmaceutical composition of claim 143 or 144, wherein the pharmaceutical composition has an AUC in vivo greater than that of a pre-determined threshold value. 150. The pharmaceutical composition of claim 143 or 144, wherein the pharmaceutical composition has an AUC in vivo less than that of a pre-determined threshold value. 151. The pharmaceutical composition of any one of claims 145-150, wherein the pre- determined threshold value is determined in a control composition comprising the same payload molecule and LNP except that the LNP lacks a PEG-lipid of Formula (A′) or an ionizable lipid of any one of claims 1-50. 152. The pharmaceutical composition of any one of claims 143-151, wherein the LNP has an average diameter of about 50 nm, about 60 nm, about 70 nm, about 80 nm, about 90 nm, about 100 nm, about 110 nm, about 120 nm, or about 125 nm. 153. The pharmaceutical composition of any one of claims 143-152, wherein the encapsulation efficiency of the payload molecule by the LNP is about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100%. 154. The pharmaceutical composition of any one of claims 143-153, wherein the pharmaceutical composition has a total lipid concentration of about 10 mM, about 20 mM, about 30 mM, about 40 mM, or about 50 mM. 155. The pharmaceutical composition of any one of claims 143-154, wherein the pharmaceutical composition is formulated at a pH of about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, or about 6. 156. The pharmaceutical composition of any one of claims 143-155, wherein the pharmaceutical composition is formulated for multiple administrations. 157. The pharmaceutical composition of claim 156, wherein a subsequent administration is administered at least 3 days, at least 5 days, at least 7 days, at least 9 days, at least 11 days, at least 14 days, or at least 21 days after a first administration. 158. The pharmaceutical composition of any one of claims 144-157, wherein the payload molecule comprises a nucleic acid molecule. 159. The pharmaceutical composition of any one of claims 144-158, wherein the payload molecule comprises a synthetic RNA viral genome encoding a Coxsackievirus or an SVV. 160. The pharmaceutical composition of any one of claims 144-157, wherein the viral genome comprised in the LNP is a synthetic RNA viral genome encoding a Coxsackievirus or an SVV. 161. The pharmaceutical composition of any one of claims 144-160, further comprising a pharmaceutically acceptable carrier. 162. A method of treating a disease or disorder, comprising administering to a patient in need thereof a lipid nanoparticle of any of claims 58-142 or a pharmaceutical composition of any one of claims 143-161. 163. The method of claim 162, wherein the disease or disorder is cancer. 164. The method of claim 163, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, renal cell carcinoma, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B- cell chronic lymphocytic leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), Merkel cell carcinoma, diffuse large B-cell lymphoma (DLBCL), sarcoma, a neuroblastoma, a neuroendocrine cancer, a rhabdomyosarcoma, a medulloblastoma, a bladder cancer, and marginal zone lymphoma (MZL). 165. The method of claim 163, wherein the cancer is selected from the groups consisting of lung cancer, breast cancer, colon cancer, pancreatic cancer, bladder cancer, renal cell carcinoma, ovarian cancer, gastric cancer, and liver cancer. 166. The method of claim 163, wherein the cancer is renal cell carcinoma, lung cancer, or liver cancer. 167. The method of any one of claims 164-166, wherein the lung cancer is small cell lung cancer or non-small cell lung cancer (e.g., squamous cell lung cancer or lung adenocarcinoma). 168. The method of any one of claims 164-166, wherein the liver cancer is hepatocellular carcinoma (HCC) (e.g., Hepatitis B virus associated HCC). 169. The method of claim 164, wherein the prostate cancer is treatment-emergent neuroendocrine prostate cancer. 170. The method of claim 163, wherein the cancer is lung cancer, liver cancer, prostate cancer (e.g., CRPC-NE), bladder cancer, pancreatic cancer, colon cancer, gastric cancer, breast cancer, neuroblastoma, renal cell carcinoma, ovarian cancer, rhabdomyosarcoma, medulloblastoma, neuroendocrine cancer, Merkel cell carcinoma, or melanoma. 171. The method of claim 163, wherein the cancer is small cell lung cancer (SCLC) or neuroblastoma. 172. The method of any one of claims 163-171, wherein the administration of the pharmaceutical composition delivers a payload into tumor cells. 173. The method of any one of claims 163-172, wherein the administration of the pharmaceutical composition inhibits the tumor growth. 174. The method of any one of claims 162-173, wherein the LNP or pharmaceutical composition is administered parenterally. 175. The method of any one of claims 162-174, wherein the LNP or pharmaceutical composition is administered is administered intratumorally and/or intravenously. |
[306] In some embodiments, the recombinant RNA molecules described herein encode a Picornavirus selected from a coxsackievirus, poliovirus, and Seneca Valley virus (SVV). In some embodiments, the recombinant RNA molecules described herein encode a coxsackievirus. [307] In some embodiments, the synthetic RNA viral genome described herein encode a Seneca Valley virus (SVV). [308] In some embodiments, the synthetic RNA viral genomes described herein encode a coxsackievirus. In some embodiments, the coxsackievirus is selected from CVB3, CVA21, and CVA9. The nucleic acid sequences of exemplary coxsackieviruses are provided GenBank Reference No. M33854.1 (CVB3), GenBank Reference No. KT161266.1 (CVA21), and GenBank Reference No. D00627.1 (CVA9). [309] In some embodiments, the payload molecule encodes an oncolytic virus. In some embodiments, the oncolytic virus is, or is derived from, Coxsackievirus, Seneca Valley virus, Togaviridae, or Alphavirus (such as Sindbis virus, Semliki Forest virus, Ross River virus, or Chikungunya virus). In some embodiments, the oncolytic virus is, or is derived from, Coxsackievirus A21 (CVA21). In some embodiments, the oncolytic virus is, or is derived from, Seneca Valley virus (SVV). Other Payload Molecules [310] The LNP of the disclosure may comprise a payload molecule selected from the group consisting of a nucleic acid, a polypeptide, a small molecule, a carbohydrate, an enzyme, a dye, a fluorochrome, and a combination thereof. In some embodiments, the LNP of the disclosure comprises a combination of payload molecules. The combination of payload molecules may be covalently linked, non-covalently associated, or have no association. Non-limiting examples of combinations of payload molecules include an antibody-drug conjugate and a Cas protein/gRNA complex. [311] In some embodiments, the payload molecule may be a Cas protein/gRNA complex. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR Associated) nuclease system is an engineered nuclease system based on a bacterial system that can be used for mammalian genome engineering. Generally, the system comprises a Cas protein (Cas nuclease) and a guide RNA (gRNA). The gRNA is comprised of two parts; a crispr-RNA (crRNA) that is specific for a target genomic DNA sequence, and a tracr RNA (trRNA) that facilitates Cas binding. The crRNA and trRNA may be present as separate RNA oligonucleotides, or may be present in the same RNA oligonucleotide, referred to as a single guide-RNA (sgRNA). As used herein, the term “guide RNA” or “gRNA” refers to either the combination of an individual trRNA and an individual crRNA or an sgRNA. See, e.g., Jinek et al. (2012) Science 337:816-821; Cong et al. (2013) Science 339:819-823; and Ran et al. (2013) Nature Protocols 8(11):2281-2308; U.S. Patent Publication Nos. 2010-0093617, 2013- 0011828, 2010-0257638, 2010-0076057, 2011-0217739, 2011-0300538, 2013-0288251, and 2012-0277120; and U.S. Patent No. 8,546,553, each of which is incorporated herein by reference in its entirety. [312] In some embodiments, the payload molecule may be a base editing enzyme (e.g., cytidine deaminase or adenosine deaminase). In some embodiments, the base editing enzyme is fused to a CRISPR protein. In some embodiments, the CRISPR protein is bound to a guide RNA. Pharmaceutical Compositions [313] In some embodiments, the present disclosure includes a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure includes a pharmaceutical composition comprising a compound selected from Table 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure includes a pharmaceutical composition comprising a lipid nanoparticle (LNP) comprising a compound of Formula (I). In some embodiments, the present disclosure includes a pharmaceutical composition comprising a LNP comprising a compound of selected from Table1. In some embodiments, the present disclosure includes a pharmaceutical composition comprising a lipid nanoparticle (LNP) comprising a compound of Formula (A), (A′), or (A′′). In some embodiments, the present disclosure includes a pharmaceutical composition comprising a LNP of the present disclosure and a pharmaceutically acceptable excipient, carrier or diluent. In some embodiments, a pharmaceutical composition may comprise: (i) an LNP of the disclosure and, optionally, a payload molecule; and (ii) a pharmaceutically acceptable carrier, diluent or excipient. [314] A pharmaceutical composition can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic molecule is combined in a mixture with a pharmaceutically acceptable carrier, diluent, or excipient. A carrier is said to be a “pharmaceutically acceptable carrier” if its administration can be tolerated by a recipient subject. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers, diluents, or excipients are well-known to those in the art. (See, e.g., Gennaro (ed.), Remington's Pharmaceutical Sciences (Mack Publishing Company, 19th ed.1995).) Formulations can further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. [315] A pharmaceutical composition comprising LNPs of the disclosure may be formulated in a dosage form selected from the group consisting of: an oral unit dosage form, an intravenous unit dosage form, an intranasal unit dosage form, a suppository unit dosage form, an intradermal unit dosage form, an intramuscular unit dosage form, an intraperitoneal unit dosage form, a subcutaneous unit dosage form, an epidural unit dosage form, a sublingual unit dosage form, and an intracerebral unit dosage form. The oral unit dosage form may be selected from the group consisting of: tablets, pills, pellets, capsules, powders, lozenges, granules, solutions, suspensions, emulsions, syrups, elixirs, sustained-release formulations, aerosols, and sprays. [316] A pharmaceutical composition may be administered to a subject in a therapeutically effective amount. In prophylactic applications, pharmaceutical compositions comprising an LNP and optionally a payload molecule of the disclosure are administered to a subject susceptible to, or otherwise at risk of, a particular disorder in an amount sufficient to eliminate or reduce the risk or delay the onset of the disorder. In therapeutic applications, compositions comprising an LNP and optionally a payload molecule of the disclosure are administered to a subject suspected of, or already suffering from such a disorder in an amount sufficient to cure, or at least partially arrest, the symptoms of the disorder and its complications. An amount adequate to accomplish this is referred to as a therapeutically effective dose or amount. In both prophylactic and therapeutic regimes, payload molecules can be administered in several dosages until a sufficient response has been achieved. Typically, the response is monitored and repeated dosages are given if the desired response starts to fade. [317] According to the methods of the disclosure, a composition can be administered to subjects by a variety of administration modes, including, for example, by intramuscular, subcutaneous, intravenous, intra-atrial, intra-articular, parenteral, intranasal, intrapulmonary, transdermal, intrapleural, intrathecal, intratumoral, and oral routes of administration. For prevention and treatment purposes, a composition can be administered to a subject in a single bolus delivery, via continuous delivery (e.g., continuous transdermal delivery) over an extended time period, or in a repeated administration protocol (e.g., on an hourly, daily, weekly, or monthly basis). [318] Administration can occur by injection, irrigation, inhalation, consumption, electro- osmosis, hemodialysis, iontophoresis, and other methods known in the art. The route of administration will vary, naturally, with the location and nature of the disease being treated, and may include, for example auricular, buccal, conjunctival, cutaneous, dental, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-articular, intra-arterial, intra- abdominal, intraauricular, intrabiliary, intrabronchial, intrabursal, intracavernous, intracerebral, intracisternal, intracorneal, intracronal, intracoronary, intracranial, intradermal, intradiscal, intraductal, intraduodenal, intraduodenal, intradural, intraepicardial, intraepidermal, intraesophageal, intragastric, intragingival, intrahepatic, intraileal, intralesional, intralingual, intraluminal, intralymphatic, intramammary, intramedulleray, intrameningeal, instramuscular, intranasal, intranodal, intraocular, intraomentum, intraovarian, intraperitoneal, intrapericardial, intrapleural, intraprostatic, intrapulmonary, intraruminal, intrasinal, intraspinal, intrasynovial, intratendinous, intratesticular, intratracheal, intrathecal, intrathoracic, intratubular, intratumoral, intratympanic, intrauterine, intraperitoneal, intravascular, intraventricular, intravesical, intravestibular, intravenous, intravitreal, larangeal, nasal, nasogastric, oral, ophthalmic, oropharyngeal, parenteral, percutaneous, periarticular, peridural, perineural, periodontal, respiratory, retrotubular, rectal, spinal, subarachnoid, subconjunctival, subcutaneous, subdermal, subgingival, sublingual, submucosal, subretinal, topical, transdermal, transendocardial, transmucosal, transplacental, trantracheal, transtympanic, ureteral, urethral, and/or vaginal perfusion, lavage, direct injection, and oral administration. [319] In some embodiments, the pharmaceutical composition is formulated for systemic administration. In some embodiments, the systemic administration comprises intravenous administration, intra-arterial administration, intraperitoneal administration, intramuscular administration, intradermal administration, subcutaneous administration, intranasal administration, oral administration, or a combination thereof. In some embodiments, the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for local administration. In some embodiments, the pharmaceutical composition is formulated for intratumoral administration. [320] Effective doses of the compositions of the disclosure vary depending upon many different factors, including means of administration, target site, physiological state of the subject, whether the subject is human or an animal, other medications administered, whether treatment is prophylactic or therapeutic, as well as the specific activity of the composition itself and its ability to elicit the desired response in the individual. In some embodiments, the subject is a human. In some embodiments, the subject can be a nonhuman mammal. Typically, dosage regimens are adjusted to provide an optimum therapeutic response, i.e., to optimize safety and efficacy. [321] Determination of effective dosages in this context is typically based on animal model studies followed up by human clinical trials and is guided by determining effective dosages and administration protocols that significantly reduce the occurrence or severity of the subject disorder in model subjects. Compositions of the disclosure may be suitably administered to the subject at one time or over a series of treatments and may be administered to the subject at any time from diagnosis onwards. Compositions of the disclosure may be administered as the sole treatment, as a monotherapy, or in conjunction with other drugs or therapies, as a combinatorial therapy, useful in treating the condition in question. [322] Dosage of the pharmaceutical composition can be varied by the attending clinician to maintain a desired concentration at a target site. Higher or lower concentrations can be selected based on the mode of delivery. Dosage should also be adjusted based on the release rate of the administered formulation. [323] In some embodiments, the pharmaceutical composition of the disclosure is administered to a subject for multiple times (e.g., multiple doses). In some embodiments, the pharmaceutical composition is administered two or more times, three or more times, four or more times, etc. In some embodiments, administration of the pharmaceutical composition may be repeated once, twice, 3, 4, 5, 6, 7, 8, 9, 10, or more times. The pharmaceutical composition may be administered chronically or acutely, depending on its intended purpose. [324] In some embodiments, the therapeutically effective amount of a composition of the disclosure is between about 1 ng/kg body weight to about 100 mg/kg body weight. In some embodiments, the range of a composition of the disclosure administered is from about 1 ng/kg body weight to about 1 μg/kg body weight, about 1 ng/kg body weight to about 100 ng/kg body weight, about 1 ng/kg body weight to about 10 ng/kg body weight, about 10 ng/kg body weight to about 1 μg/kg body weight, about 10 ng/kg body weight to about 100 ng/kg body weight, about 100 ng/kg body weight to about 1 μg/kg body weight, about 100 ng/kg body weight to about 10 pg/kg body weight, about 1 μg/kg body weight to about 10 pg/kg body weight, about 1 μg/kg body weight to about 100 pg/kg body weight, about 10 pg/kg body weight to about 100 pg/kg body weight, about 10 pg/kg body weight to about 1 mg/kg body weight, about 100 μg/kg body weight to about 10 mg/kg body weight, about 1 mg/kg body weight to about 100 mg/kg body weight, or about 10 mg/kg body weight to about 100 mg/kg body weight. Dosages within this range can be achieved by single or multiple administrations, including, e.g., multiple administrations per day or daily, weekly, bi-weekly, or monthly administrations. Compositions of the disclosure may be administered, as appropriate or indicated, as a single dose by bolus or by continuous infusion, or as multiple doses by bolus or by continuous infusion. Multiple doses may be administered, for example, multiple times per day, once daily, every 2, 3, 4, 5, 6 or 7 days, weekly, every 2, 3, 4, 5 or 6 weeks or monthly. In some embodiments, a composition of the disclosure is administered weekly. In some embodiments, a composition of the disclosure is administered biweekly. In some embodiments, a composition of the disclosure is administered every three weeks. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques. [325] For administration to a human adult subject, the therapeutically effective amount may be administered in doses in the range of 0.0006 mg to 1000 mg per dose, including but not limited to 0.0006 mg per dose, 0.001 mg per dose, 0.003 mg per dose, 0.006 mg per dose, 0.01 mg per dose, 0.03 mg per dose, 0.06 mg per dose, 0.1 mg per dose, 0.3 mg per dose, 0.6 mg per dose, 1 mg per dose, 3 mg per dose, 6 mg per dose, 10 mg per dose, 30 mg per dose, 60 mg per dose, 100 mg per dose, 300 mg per dose, 600 mg per dose and 1000 mg per dose, and multiple, usually consecutive daily doses may be administered in a course of treatment. In some embodiments, a composition of the disclosure is administered at a dose level of about 0.001 mg/kg/dose to about 10 mg/kg/dose, about 0.001 mg/kg/dose to about 6 mg/kg/dose, about 0.001 mg/kg/dose to about 3 mg/kg/dose, about 0.001 mg/kg/dose to about 1 mg/kg/dose, about 0.001 mg/kg/dose to about 0.6 mg/kg/dose, about 0.001 mg/kg/dose to about 0.3 mg/kg/dose, about 0.001 mg/kg/dose to about 0.1 mg/kg/dose, about 0.001 mg/kg/dose to about 0.06 mg/kg/dose, about 0.001 mg/kg/dose to about 0.03 mg/kg/dose, about 0.001 mg/kg/dose to about 0.01 mg/kg/dose, about 0.001 mg/kg/dose to about 0.006 mg/kg/dose, about 0.001 mg/kg/dose to about 0.003 mg/kg/dose, about 0.003 mg/kg/dose to about 10 mg/kg/dose, about 0.003 mg/kg/dose to about 6 mg/kg/dose, about 0.003 mg/kg/dose to about 3 mg/kg/dose, about 0.003 mg/kg/dose to about 1 mg/kg/dose, about 0.003 mg/kg/dose to about 0.6 mg/kg/dose, about 0.003 mg/kg/dose to about 0.3 mg/kg/dose, about 0.003 mg/kg/dose to about 0.1 mg/kg/dose, about 0.003 mg/kg/dose to about 0.06 mg/kg/dose, about 0.003 mg/kg/dose to about 0.03 mg/kg/dose, about 0.003 mg/kg/dose to about 0.01 mg/kg/dose, about 0.003 mg/kg/dose to about 0.006 mg/kg/dose, about 0.006 mg/kg/dose to about 10 mg/kg/dose, about 0.006 mg/kg/dose to about 6 mg/kg/dose, about 0.006 mg/kg/dose to about 3 mg/kg/dose, about 0.006 mg/kg/dose to about 1 mg/kg/dose, about 0.006 mg/kg/dose to about 0.6 mg/kg/dose, about 0.006 mg/kg/dose to about 0.3 mg/kg/dose, about 0.006 mg/kg/dose to about 0.1 mg/kg/dose, about 0.006 mg/kg/dose to about 0.06 mg/kg/dose, about 0.006 mg/kg/dose to about 0.03 mg/kg/dose, about 0.006 mg/kg/dose to about 0.01 mg/kg/dose, about 0.01 mg/kg/dose to about 10 mg/kg/dose, about 0.01 mg/kg/dose to about 6 mg/kg/dose, about 0.01 mg/kg/dose to about 3 mg/kg/dose, about 0.01 mg/kg/dose to about 1 mg/kg/dose, about 0.01 mg/kg/dose to about 0.6 mg/kg/dose, about 0.01 mg/kg/dose to about 0.3 mg/kg/dose, about 0.01 mg/kg/dose to about 0.1 mg/kg/dose, about 0.01 mg/kg/dose to about 0.06 mg/kg/dose, about 0.01 mg/kg/dose to about 0.03 mg/kg/dose, about 0.03 mg/kg/dose to about 10 mg/kg/dose, about 0.03 mg/kg/dose to about 6 mg/kg/dose, about 0.03 mg/kg/dose to about 3 mg/kg/dose, about 0.03 mg/kg/dose to about 1 mg/kg/dose, about 0.03 mg/kg/dose to about 0.6 mg/kg/dose, about 0.03 mg/kg/dose to about 0.3 mg/kg/dose, about 0.03 mg/kg/dose to about 0.1 mg/kg/dose, about 0.03 mg/kg/dose to about 0.06 mg/kg/dose, about 0.06 mg/kg/dose to about 10 mg/kg/dose, about 0.06 mg/kg/dose to about 6 mg/kg/dose, about 0.06 mg/kg/dose to about 3 mg/kg/dose, about 0.06 mg/kg/dose to about 1 mg/kg/dose, about 0.06 mg/kg/dose to about 0.6 mg/kg/dose, about 0.06 mg/kg/dose to about 0.3 mg/kg/dose, about 0.06 mg/kg/dose to about 0.1 mg/kg/dose, about 0.1 mg/kg/dose to about 10 mg/kg/dose, about 0.1 mg/kg/dose to about 6 mg/kg/dose, about 0.1 mg/kg/dose to about 3 mg/kg/dose, about 0.1 mg/kg/dose to about 1 mg/kg/dose, about 0.1 mg/kg/dose to about 0.6 mg/kg/dose, about 0.1 mg/kg/dose to about 0.3 mg/kg/dose, about 0.3 mg/kg/dose to about 10 mg/kg/dose, about 0.3 mg/kg/dose to about 6 mg/kg/dose, about 0.3 mg/kg/dose to about 3 mg/kg/dose, about 0.3 mg/kg/dose to about 1 mg/kg/dose, about 0.3 mg/kg/dose to about 0.6 mg/kg/dose, about 0.6 mg/kg/dose to about 10 mg/kg/dose, about 0.6 mg/kg/dose to about 6 mg/kg/dose, about 0.6 mg/kg/dose to about 3 mg/kg/dose, about 0.6 mg/kg/dose to about 1 mg/kg/dose, about 1 mg/kg/dose to about 10 mg/kg/dose, about 1 mg/kg/dose to about 6 mg/kg/dose, about 1 mg/kg/dose to about 3 mg/kg/dose, about 3 mg/kg/dose to about 10 mg/kg/dose, about 3 mg/kg/dose to about 6 mg/kg/dose, or about 6 mg/kg/dose to about 10 mg/kg/dose. In some embodiments, a composition of the disclosure is administered at a dose level of about 0.001 mg/kg/dose, about 0.003 mg/kg/dose, about 0.006 mg/kg/dose, about 0.01 mg/kg/dose, about 0.03 mg/kg/dose, about 0.06 mg/kg/dose, about 0.1 mg/kg/dose, about 0.3 mg/kg/dose, about 0.6 mg/kg/dose, about 1 mg/kg/dose, about 3 mg/kg/dose, about 6 mg/kg/dose, or about 10 mg/kg/dose. Compositions of the disclosure can be administered at different times of the day. In one embodiment the optimal therapeutic dose can be administered in the evening. In another embodiment the optimal therapeutic dose can be administered in the morning. As expected, the dosage will be dependent on the condition, size, age, and condition of the subject. [326] Dosage of the pharmaceutical composition can be varied by the attending clinician to maintain a desired concentration at a target site. Higher or lower concentrations can be selected based on the mode of delivery. Dosage should also be adjusted based on the release rate of the administered formulation. [327] In some embodiments, the pharmaceutical composition of the disclosure is administered to a subject for multiple times (e.g., multiple doses). In some embodiments, the pharmaceutical composition is administered two or more times, three or more times, four or more times, etc. In some embodiments, administration of the pharmaceutical composition may be repeated once, twice, 3, 4, 5, 6, 7, 8, 9, 10, or more times. The pharmaceutical composition may be administered chronically or acutely, depending on its intended purpose. [328] In some embodiments, the interval between two consecutive doses of the pharmaceutical composition is less than 4, less than 3, less than 2, or less than 1 weeks. In some embodiments, the interval between two consecutive doses is less than 3 weeks. In some embodiments, the interval between two consecutive doses is less than 2 weeks. In some embodiments, the interval between two consecutive doses is less than 1 week. In some embodiments, the interval between two consecutive doses is less than 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 days. In some embodiments, the interval between two consecutive doses of the pharmaceutical composition is at least 4, at least 3, at least 2, or at least 1 weeks. In some embodiments, the interval between two consecutive doses of the pharmaceutical composition of the disclosure is at least 3 weeks. In some embodiments, the interval between two consecutive doses of the pharmaceutical composition of the disclosure is at least 2 weeks. In some embodiments, the interval between two consecutive doses of the pharmaceutical composition of the disclosure is at least 1 week. In some embodiments, the interval between two consecutive doses of the pharmaceutical composition of the disclosure is at least 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 days. In some embodiments, the subject is administered a dose of the pharmaceutical composition of the disclosure once daily, every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days. In some embodiments, the subject is administered a dose of the pharmaceutical composition of the disclosure once every 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks. In some embodiments, the subject is administered a dose of the pharmaceutical composition of the disclosure once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. [329] In some embodiments, the pharmaceutical composition of the disclosure is administered multiple times, wherein the serum half-life of the LNP in the subject following the second and/or subsequent administration is at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, or 95% of the serum half-life of the LNP following the first administration. [330] In some embodiments, the second and subsequent doses of the pharmaceutical composition comprising an payload molecule may maintain an activity of the payload molecule of at least 50% of the activity of the first dose, or at least 60% of the first dose, or at least 70% of the first dose, or at least 75% of the first dose, or at least 80% of the first dose, or at least 85% of the first dose, or at least 90% of the first dose, or at least 95% of the first dose, or more, for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after second administration or subsequent administration. [331] In some embodiments, the pharmaceutical composition of the disclosure has an duration of therapeutic effect in vivo of about 1 hour or longer, about 2 hours or longer, about 3 hours or longer, about 4 hours or longer, about 5 hours or longer, about 6 hours or longer, about 7 hours or longer, about 8 hours or longer, about 9 hours or longer, about 10 hours or longer, about 12 hours or longer, about 14 hours or longer, about 16 hours or longer, about 18 hours or longer, about 20 hours or longer, about 25 hours or longer, about 30 hours or longer, about 35 hours or longer, about 40 hours or longer, about 45 hours or longer, or about 50 hours or longer. In some embodiments, the pharmaceutical composition of the disclosure has an duration of therapeutic effect in vivo of at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 1.5 days, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days. [332] In some embodiments, the pharmaceutical composition of the disclosure has a half-life in vivo comparable to that of a pre-determined threshold value. In some embodiments, the pharmaceutical composition of the disclosure has a half-life in vivo greater than that of a pre- determined threshold value. In some embodiments, the pharmaceutical composition of the disclosure has a half-life in vivo shorter than that of a pre-determined threshold value. In some embodiments, the pre-determined threshold value is the half-life of a control composition comprising the same payload molecule and LNP except that the LNP comprises (i) a PEG-lipid that is not of Formula (A), (A′), or (A′′) (for example, the PEG-lipid of the LNP in the control composition may be PEG2k-DPG); or (ii) a cationic lipid that is not of Formula (I). [333] In some embodiments, the pharmaceutical composition of the disclosure has an AUC (area under the blood concentration-time curve) following a repeat dose that is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% of the AUC following the previous dose. In some embodiments, the pharmaceutical composition has an AUC that is at least 60% of the AUC following the previous dose. In some embodiments, following a repeat dose, AUC of the pharmaceutical composition decreases less than 70%, less than 60%, less than 60%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to the AUC following the previous dose. In some embodiments, following a repeat dose, AUC of the pharmaceutical composition decreases less than 40% compared to the AUC following the previous dose. [334] In some embodiments, the pharmaceutical composition of the disclosure comprises a nucleic acid molecule encoding viral genome of an oncolytic virus, and wherein administration of the pharmaceutical composition to a subject bearing a tumor delivers the nucleic acid molecule into tumor cells. In some embodiments, the nucleic acid molecule is a RNA molecule. In some embodiments, administration of the pharmaceutical composition results in replication of the oncolytic virus in tumor cells. In some embodiments, administration of the pharmaceutical composition to a subject bearing a tumor results in selective replication of the oncolytic virus in tumor cells as compared to normal cells. [335] In some embodiments, administration of the pharmaceutical composition of the disclosure to a subject bearing a tumor inhibits growth of the tumor. In some embodiments, administration of the pharmaceutical composition inhibits growth of the tumor for at least 1 week, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 9 months, at least 12 months, at least 2 years, or longer. In some embodiments, inhibiting growth of the tumor means controlling the size of the tumor within 100% of the size of the tumor just before administration of the pharmaceutical composition for a specified time period. In some embodiments, inhibiting growth of the tumor means controlling the size of the tumor within 110%, within 120%, within 130%, within 140%, or within 150%, of the size of the tumor just before administration of the pharmaceutical composition. [336] In some embodiments, administration of the pharmaceutical composition to a subject bearing a tumor leads to tumor shrinkage or elimination. In some embodiments, administration of the pharmaceutical composition leads to tumor shrinkage or elimination for at least 1 week, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 9 months, at least 12 months, at least 2 years, or longer. In some embodiments, administration of the pharmaceutical composition leads to tumor shrinkage or elimination within 1 week, within 2 weeks, within 3 weeks, within 4 weeks, within 1 month, within 2 months, within 3 months, within 4 months, within 6 months, within 9 months, within 12 months, or within 2 years. In some embodiments, tumor shrinkage means reducing the size of the tumor by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, compared to the size of the tumor just before administration of the pharmaceutical composition. In some embodiments, tumor shrinkage means reducing the size of the tumor at least 30% compared to the size of the tumor just before administration of the pharmaceutical composition. [337] Pharmaceutical compositions can be supplied as a kit comprising a container that comprises the pharmaceutical composition as described herein. A pharmaceutical composition can be provided, for example, in the form of an injectable solution for single or multiple doses, or as a sterile powder that will be reconstituted before injection. Alternatively, such a kit can include a dry-powder disperser, liquid aerosol generator, or nebulizer for administration of a pharmaceutical composition. Such a kit can further comprise written information on indications and usage of the pharmaceutical composition Methods of Use [338] In some embodiments, the disclosure provides methods of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition (e.g., pharmaceutical composition) of the disclosure. In some embodiments, the present disclosure includes a method of treating a disease or disorder comprising administering to a patient in need thereof the lipid nanoparticle described herein. In some embodiments, the disease or disorder comprises a cancer. [339] The method may be a method of treating a subject having or at risk of having a condition that benefits from the payload molecule, particularly if the payload molecule is a therapeutic agent. Alternatively, the method may be a method of diagnosing a subject, in which case the payload molecule may be is a diagnostic agent. [340] In some embodiments, the instant disclosure includes a method of delivering a payload to a cell, comprising administering to a subject in need thereof a lipid particle or pharmaceutical composition described herein. In some embodiments, the instant disclosure includes a method a delivering a polynucleotide to a cell, comprising administering to a subject in need thereof a lipid particle or a pharmaceutical composition comprising (i) a compound of Formula (I); (ii) a compound selected from Table 1, or (iii) a compound of Formula (A), (A′), or (A′′). In some embodiments, a polynucleotide encodes a polypeptide or a functional variant or fragment thereof, such that expression of the polypeptide or the functional variant or fragment thereof is increased. In another embodiment, a polynucleotide encodes an immunotherapeutic or a functional variant or fragment thereof. In some embodiments, a polynucleotide that encodes an immunotherapeutic or a functional variant or fragment thereof. In some embodiments, the present disclosure includes a polynucleotide that comprises a viral genome or a functional variant or fragment thereof. In some embodiments, a polynucleotide encodes an antigen, a protein, a CAS9 protein, or a base editing enzyme or a fusion protein thereof (e.g., a base editing enzyme fused to a CRISPR protein bound to a guide RNA). In some embodiments, the polynucleotide comprise a siRNA, saRNA, miRNA, or guide RNA. [341] In yet a further related embodiment, the present disclosure includes a method of treating a disease or disorder characterized by overexpression of a polypeptide in a subject, comprising providing to the subject a lipid particle or pharmaceutical composition of the present disclosure, wherein the therapeutic agent is polynucleotide. [342] In another related embodiment, the present disclosure includes a method of treating a disease or disorder characterized by under expression of a polypeptide in a subject. [343] In some embodiments, a disease or disorder is cancer. In some embodiments, cancer selected from the group consisting of lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, Merkel cell carcinoma, B-cell lymphoma, multiple myeloma, leukemia, renal cell carcinoma, and neuroblastoma. In some embodiments, cancer is lung cancer. In some embodiments, lung cancer is small cell lung cancer or non-small cell lung cancer. In some embodiments, cancer is liver cancer. In some embodiments, liver cancer is hepatocellular carcinoma (HCC). In some embodiments, renal cancer is renal clear cell cancer (RCC). In some embodiments, renal cell carcinoma is selected from the group consisting of clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma. In some embodiments, cancer is B-cell lymphoma. In some embodiments, B-cell lymphoma is selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. In some embodiments, cancer is leukemia. In some embodiments, leukemia is selected from the group consisting of B-cell leukemia, T-cell leukemia, acute myeloid leukemia, and chronic myeloid leukemia. [344] In yet another embodiment, the present disclosure includes a method of treating a subject, comprising administering the pharmaceutical composition comprising polynucleotide encoding a viral, bacterial or fungal protein to the subject in an amount sufficient to cause production of antibody in serum of the subject. In some embodiments, amount of a composition administered is sufficient to produce circulating antibodies; or to produce viral-specific CD8+ T cells in a subject; or to produce antigen-specific antibody. [345] In other embodiments, administration is parenterally. In some embodiments, administration is by subcutaneous injection, intradermal injection, or intramuscular injection; or a pharmaceutical composition is administered at least twice. In another embodiment, a method further comprising a step of measuring antibody titer or CD8+ T cells. [346] In some embodiments, a pharmaceutical composition described herein comprises a nucleic acid that encodes an antibody. In some embodiments, the antibody is capable of binding a cell-associated or secreted protein or a fragment or variant of a human protein. In another embodiment, an antibody is capable of binding to a viral, bacterial or fungal particle. Another aspect of the description is a method of treating a subject, comprising administering the pharmaceutical composition comprising a nucleic acid encoding an antibody to a subject to the subject in an amount sufficient to cause production of the antibody in serum of the subject. [347] In various embodiments, the disclosure relates to a method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a composition as described herein to the subject. [348] In some embodiments, the disclosure provides methods of delivering a payload molecule to a cell, the method comprising contacting the cell with the LNP or pharmaceutical composition thereof, wherein the LNP comprises the payload molecule. In some embodiments, the payload molecule is a nucleic acid molecule encoding a virus, and wherein contacting the cell with the LNP results in production of viral particles by the cell, and wherein the viral particles are infectious and lytic. [349] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising administering the LNP or the pharmaceutical composition thereof of the disclosure to the subject. In some embodiments, the method comprises multiple administrations. In some embodiments, the interval between two consecutive administrations of the pharmaceutical composition is less than 4, less than 3, less than 2, or less than 1 weeks. In some embodiments, the interval between two consecutive administrations is less than 2 weeks. In some embodiments, the interval between two consecutive administrations is less than 1 week. In some embodiments, the interval between two consecutive administrations is less than 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 days. In some embodiments, the interval between two consecutive administrations of the pharmaceutical composition is at least 4, at least 3, at least 2, or at least 1 weeks. In some embodiments, the interval between two consecutive administrations of the pharmaceutical composition of the disclosure is at least 2 weeks. In some embodiments, the interval between two consecutive administrations of the pharmaceutical composition of the disclosure is at least 1 week. In some embodiments, the interval between two consecutive administrations of the pharmaceutical composition of the disclosure is at least 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 days. In some embodiments, the method comprises administering to a subject the pharmaceutical composition of the disclosure every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days. In some embodiments, the method comprises administering to a subject the pharmaceutical composition of the disclosure once every 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks. In some embodiments, the method comprises administering to a subject the pharmaceutical composition of the disclosure once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. [350] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising administering the LNP or the pharmaceutical composition thereof of the disclosure to the subject, wherein the method comprises multiple administrations. In some embodiments, serum half-life of the LNP in the subject following the second and/or subsequent administration of the method is at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, or 95% of the serum half-life of the LNP following the first administration. [351] In some embodiments, the LNP has an AUC following a repeat dose that is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% of the AUC following the previous dose. In some embodiments, the LNP has an AUC that is at least 60% of the AUC following the previous dose. In some embodiments, following a repeat dose, AUC of the LNP decreases less than 70%, less than 60%, less than 60%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to the AUC following the previous dose. In some embodiments, following a repeat dose, AUC of the LNP decreases less than 40% compared to the AUC following the previous dose. [352] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising administering the LNP or the pharmaceutical composition thereof of the disclosure to the subject, wherein the LNP comprises a nucleic acid molecule encoding a viral genome of an oncolytic virus, wherein the subject has a tumor, and wherein administration of the LNP delivers the nucleic acid molecule into tumor cells. In some embodiments, administration of the LNP results in replication of the oncolytic virus in tumor cells. In some embodiments, administration of the LNP results in selective replication of the oncolytic virus in tumor cells as compared to normal cells. [353] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising administering the LNP or the pharmaceutical composition thereof of the disclosure to the subject, wherein administration of the LNP to a subject bearing a tumor inhibits growth of the tumor. In some embodiments, the method inhibits growth of the tumor for at least 1 week, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 9 months, at least 12 months, at least 2 years, or longer. In some embodiments, inhibiting growth of the tumor means controlling the size of the tumor within 100% of the size of the tumor just before administration of the pharmaceutical composition for a specified time period. In some embodiments, inhibiting growth of the tumor means controlling the size of the tumor within 110%, within 120%, within 130%, within 140%, or within 150%, of the size of the tumor just before administration of the pharmaceutical composition. [354] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising administering the LNP or the pharmaceutical composition thereof of the disclosure to the subject, wherein administration of the LNP to a subject bearing a tumor leads to tumor shrinkage or elimination. In some embodiments, the method results in tumor shrinkage or elimination for at least 1 week, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 9 months, at least 12 months, at least 2 years, or longer. In some embodiments, the method results in tumor shrinkage or elimination within 1 week, within 2 weeks, within 3 weeks, within 4 weeks, within 1 month, within 2 months, within 3 months, within 4 months, within 6 months, within 9 months, within 12 months, or within 2 years. In some embodiments, tumor shrinkage means reducing the size of the tumor by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, compared to the size of the tumor just before administration of the pharmaceutical composition. In some embodiments, tumor shrinkage means reducing the size of the tumor at least 30% compared to the size of the tumor just before administration of the pharmaceutical composition. [355] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising administering the LNP or the pharmaceutical composition thereof of the disclosure to the subject, wherein administration of the LNP to a subject bearing a tumor inhibits the metastasis of the cancer. [356] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject has a cancer, and wherein the method inhibits or slows the growth and/or metastasis of the cancer. [357] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising systemically administering the LNP or pharmaceutical composition thereof. In some embodiments, the administration is intravenous, intra-arterial, intraperitoneal, intramuscular, intradermal, subcutaneous, intranasal, oral, or a combination thereof. [358] In some embodiments, the disclosure provides methods of delivering an LNP to a subject, comprising locally administering the LNP or pharmaceutical composition thereof. In some embodiments, the administration is intratumoral. [359] In some embodiments, the cancer is a lung cancer, a liver cancer, a prostate cancer, a bladder cancer, a pancreatic cancer, a gastric cancer, a breast cancer, a neuroblastoma, a rhabdomyosarcoma, a medullablastoma, or a melanoma. In some embodiments, the cancer is a neuroendocrine cancer. [360] Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, leiomyosarcoma, chordoma, lymphangiosarcoma, lymphangioendotheliosarcoma, rhabdomyosarcoma, fibrosarcoma, myxosarcoma, chondrosarcoma), neuroendocrine tumors, mesothelioma, synovioma, schwannoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, small cell lung carcinoma, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, tumors of the biliary tract, Ewing's tumor, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic disease, heavy chain disease, neuroendocrine tumors, Schwannoma, and other carcinomas, as well as head and neck cancer. In some embodiments, the cancer is selected from small cell lung cancer (SCLC), small cell bladder cancer, large cell neuroendocrine carcinoma (LCNEC), castration- resistant small cell neuroendocrine prostate cancer (CRPC-NE), carcinoid (e.g., pulmonary carcinoid), and glioblastoma multiforme-IDH mutant (GBM-IDH mutant). Method of LNP Preparation [361] In some embodiments, the disclosure provides methods for preparing a composition of lipid nanoparticles (LNPs) containing a nucleic acid molecule, comprising the steps of: (a) diluting the nucleic acid molecule to a desired concentration in an aqueous solution; (b) mixing organic lipid phase comprising all lipid components of the LNPs with the aqueous phase containing the nucleic acid molecule using microfluidic flow to form the LNPs; (c) dialyzing the LNPs against a buffer to remove the organic solvent; (d) concentrating the LNPs to a target volume; and (e) optionally, filtered through a sterile filter. [362] In some embodiments, the organic lipid phase and the aqueous phase are mixed at a ratio of between 1:1 (v:v) and 1:10 (v:v). In some embodiments, the organic lipid phase and the aqueous phase are mixed at a ratio of 1:1 (v:v), 1:2 (v:v), 1:3 (v:v), 1:4 (v:v), 1:5 (v:v), 1:6 (v:v), 1:7 (v:v), 1:8 (v:v), 1:9 (v:v), or 1:10 (v:v). In some embodiments, the organic lipid phase and the aqueous phase are mixed at a ratio of between 1:1 (v:v) and 1:3 (v:v), between 1:2 (v:v) and 1:4 (v:v), between 1:3 (v:v) and 1:5 (v:v), between 1:4 (v:v) and 1:6 (v:v), between 1:5 (v:v) and 1:7 (v:v), between 1:6 (v:v) and 1:8 (v:v), between 1:7 (v:v) and 1:9 (v:v), or between 1:8 (v:v) and 1:10 (v:v). In some embodiments, the organic lipid phase and the aqueous phase are mixed at a ratio of between 1:3 (v:v) and 1:5 (v:v). In some embodiments, the organic lipid phase and the aqueous phase are mixed at a ratio of 1:3 (v:v). In some embodiments, the organic lipid phase and the aqueous phase are mixed at a ratio of 1:5 (v:v). [363] In some embodiments, the total flow rate of the microfluidic flow is 5-20 mL/min. In some embodiments, the total flow rate of the microfluidic flow is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mL/min. In some embodiments, the total flow rate of the microfluidic flow is 9-20 mL/min. In some embodiments, the total flow rate of the microfluidic flow is 11-13 mL/min. [364] In some embodiments, the solvent in the organic lipid phase in step (b) is ethanol. In some embodiments, heat is applied to the organic lipid phase in step (b). In some embodiments, about 40, 45, 50, 55, 60, 65, 70, 75, or 80 °C is applied to the organic lipid phase in step (b). In some embodiments, 60 °C heat is applied to the organic lipid phase in step (b). In some embodiments, no heat is applied to the organic lipid phase in step (b). [365] In some embodiments, the aqueous solution in step (a) has a pH of between 1 and 7. In some embodiments, the aqueous solution in step (a) has a pH of between 1 and 3, between 2 and 4, between 3 and 5, between 4 and 6, or between 5 and 7. In some embodiments, the aqueous solution in step (a) has a pH of 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7. In some embodiments, the aqueous solution in step (a) has a pH of 3. In some embodiments, the aqueous solution in step (a) has a pH of 5. [366] In some embodiments, the total lipid concentration is between 5 mM and 80 mM. In some embodiments, the total lipid concentration is about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 mM. In some embodiments, the total lipid concentration is about 20 mM. In some embodiments, the total lipid concentration is about 40 mM. [367] In some embodiments, the LNP generated by the method has a lipid-nitrogen-to- phosphate ratio (N:P) of between 1 to 25. In some embodiments, the N:P is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25. In some embodiments, the N:P is between 1 to 25, between 1 to 20, between 1 to 15, between 1 to 10, between 1 to 5, between 5 to 25, between 5 to 20, between 5 to 15, between 5 to 10, between 10 to 25, between 10 to 20, between 10 to 15, between 15 to 25, between 15 to 20, or between 20 to 25. In some embodiments, the LNP comprises a nucleic acid molecule and has a lipid-nitrogen-to- phosphate ratio (N:P) of 14. [368] In some embodiments, the buffer in step (c) has a neutral pH (e.g., 1x PBS, pH 7.2). In some embodiments, step (d) uses centrifugal filtration for concentrating. [369] In some embodiments, the encapsulation efficiency of the method of the disclosure is at least 70%, at least 75%, at least 75%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%. In some embodiments, the encapsulation efficiency of the method of the disclosure is at least 90%. In some embodiments, the encapsulation efficiency of the method of the disclosure is at least 95%. In some embodiments, the encapsulation efficiency is determined by RiboGreen. [370] In some embodiments, the LNPs produced by the method of the disclosure have an average size (i.e., average outer diameter) of about 50 nm to about 500 nm. In some embodiments, the LNPs have an average size of about 50 nm to about 200 nm, about 100 nm to about 200 nm, about 150 nm to about 200 nm, about 50 nm to about 100 nm, about 50 nm to about 150 nm, about 100 nm to about 150 nm, about 200 nm to about 250 nm, about 250 nm to about 300 nm, about 300 nm to about 400 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm. In some embodiments, the plurality of LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, about 120, or about 125 nm. In some embodiments, the plurality of LNPs have an average size of about 100 nm. In some embodiments, the plurality of LNPs have an average size of 50 nm to 150 nm. In some embodiments, the plurality of LNPs have an average size (average outer diameter) of 50 nm to 150 nm, 50 nm to 125 nm, 50 nm to 100 nm, 50 nm to 75 nm, 75 nm to 150 nm, 75 nm to 125 nm, 75 nm to 100 nm, 100 nm to 150 nm, 100 nm to 125 nm, or 125 nm to 150 nm. In some embodiments, the plurality of LNPs have an average size of 70 nm to 90 nm, 80 nm to 100 nm, 90 nm to 110 nm, 100 nm to 120 nm, 110 nm to 130 nm, 120 nm to 140 nm, or 130 nm to 150 nm. In some embodiments, the plurality of LNPs have an average size of 90 nm to 110 nm. [371] In some embodiments, the polydispersity index of the plurality of LNPs is between 0.01 and 0.3. In some embodiments, the polydispersity index of the plurality of LNPs is between 0.1 and 0.15. In some embodiments, the polydispersity index of the plurality of LNPs is about 0.01, about 0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, about 0.15, about 016, about 0.17, about 0.18, about 0.19, about 0.20, about 0.21, about 0.22, about 0.23, about 0.24, about 0.25, about 0.26, about 0.27, about 0.28, about 0.29, or about 0.30. In some embodiments, the polydispersity index of the plurality of LNPs is about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, or about 0.15. In some embodiments, the average diameter and/or the polydispersity is determined via dynamic light scattering. Exemplification Abbreviations: Bn: benzyl DCM: dichloromethane DMAP: 4-Dimethylaminopyridine EtOAc: ethyl acetate EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HPLC: high performance liquid chromatography LCMS: liquid chromatography-mass spectrometry Ns: nosylate TBAI: tetrabutylammonium iodide TEA: triethylamine (NEt 3 ) THF: tetrahydrofuran TFA: trifluoroacetic acid Ts: tosyl Pharmacokinetic parameters AUC (area under the curve): the integral of the concentration-time curve Cmax: the peak plasma concentration of a drug after administration C 0 : amount of drug in a given volume of plasma CL (clearance): the volume of plasma cleared of the drug per unit time t 1/2 (elimination half-life): the time required for the concentration of the drug to reach half of its original value t max : time to reach C max Vss (steady state volume of distribution): the apparent volume in which a drug is distributed at steady state Example 1: Synthesis of Ionizable Lipids Synthesis of intermediate A: Route 1 [372] Step 1: (2E,2'E)-diethyl 4,4'-(benzylazanediyl)bis(but-2-enoate) (2) [373] To a solution of phenylmethanamine (6.94 g, 64.75 mmol, 0.5 eq) in MeCN (300 mL) were added K 2 CO 3 (19.69 g, 142.46 mmol, 1.1 eq) and ethyl (E)-4-bromobut-2-enoate (25 g, 129.51 mmol, 1 eq). The mixture was stirred at 20 °C for 16 hr. The reaction mixture was filtered and the filter cake was washed with EtOAc (20 mL*2). The filtrate was concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, EtOAc/Petroleum Ether (PE): 0~10%) to give compound 2 (20.3 g, 56.17 mmol, 43.4% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 7.39 - 7.31 (m, 4H), 7.30 - 7.23 (m, 1H), 6.99 - 6.93 (m, 2H), 6.07 - 6.03 (m, 2H), 4.22 (q, J = 7.2, 4H), 3.63 (s, 2H), 3.24 - 3.23 (m, 4H), 1.32 (t, J = 7.2, 6H). [374] Step 2: diethyl 4,4'-((tert-butoxycarbonyl)azanediyl)dibutanoate (3) [375] To a solution of ethyl (E)-4-[benzyl-[(E)-4-ethoxy-4-oxo-but-2-enyl]amino]but-2- enoate (20 g, 60.35 mmol, 1 eq) in EtOH (400 mL) was added (Boc)2O (19.76 g, 90.52 mmol, 20.80 mL, 1.5 eq) and Pd/C (3 g, 60.35 mmol, 10% purity) under N 2 . The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (50 psi) at 35°C for 8 hours. The reaction mixture was filtered and the filter cake was washed with ethanol (80 mL*2). The filtrate was concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, EtOAc/Petroleum ether (PE): 0~15%) to give compound 3 (13.2 g, 38.21 mmol, 63.3% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 4.17 - 4.12 (m, 4H), 3.25 - 3.21 (m, 4H), 2.34 - 2.29 (m, 4H), 1.89 - 1.82 (m, 4H), 1.47 (s, 9H), 1.30 - 1.25 (m, 6H). [376] Step 3: 4,4'-((tert-butoxycarbonyl)azanediyl)dibutanoic acid (4) [377] To a solution of ethyl 4-[tert-butoxycarbonyl-(4-ethoxy-4-oxo-butyl)amino]butanoate (12.7 g, 36.77 mmol, 1 eq) in THF (150 mL) was added LiOHȈH2O (5.40 g, 128.68 mmol, 3.5 eq) in H2O (20 mL). The mixture was stirred at 30 °C for 16 hr. The reaction mixture was diluted with H 2 O (120 mL). The aqueous phase was extracted with EtOAc (50 mL*2). Then the aqueous phase was neutralized to pH = 4~5 with aq. HCl (1 N) and extracted with EtOAc (150 mL*3). The combined organic phase was washed with brine (120 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give compound 4 (8.5 g, 29.38 mmol, 79.9% yield) as a yellow oil. The crude product was used for next step without further purification. 1 H NMR (400 MHz, CDCl 3 ) δ = 11.88 - 9.58 (brs, 2H), 3.35 - 3.15 (m, 4H), 2.37 (t, J = 7.2 Hz, 4H), 1.90 - 1.83 (m, 4H), 1.46 (s, 9H). [378] Step 4: di(pentadecan-8-yl) 4,4'-((tert-butoxycarbonyl)azanediyl)dibutanoate (5) [379] A solution of 4-[tert-butoxycarbonyl(3-carboxypropyl)amino]butanoic acid (2 g, 6.91 mmol, 1.2 eq) dissolved in DCM (30 mL), EDCI (3.31 g, 17.28 mmol, 3 eq), TEA (2.91 g, 28.80 mmol, 4.01 mL, 5 eq) and DMAP (703.8 mg, 5.76 mmol, 1 eq) were added at 0 °C under N 2 . After addition, the mixture was stirred at 20 °C for 1 hr, and then pentadecan-8-ol (2.63 g, 11.52 mmol, 2 eq) in DCM (20 mL) was added dropwise. The resulting mixture was stirred at 20 °C for 15 hr. The reaction mixture was diluted with EtOAc (100 mL) and successively washed with saturated aqueous NaHCO3 (50 mL*2), brine (50 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, EtOAc/PE: 0~10%) to give compound 5 (1.5 g, 2.11 mmol, 36.7% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.87 (m, 2H), 3.24 - 3.21 (m, 4H), 2.30 -2.26 (m, 4H), 1.88 - 1.81 (m, 4H), 1.54 - 1.18 (m, 8H), 1.46 (s, 9H), 1.34 - 1.21 (m, 40H), 0.92 - 0.85 (m, 12H). [380] Step 5: di(pentadecan-8-yl) 4,4'-azanediyldibutanoate (A) [381] To a solution of 1-heptyloctyl 4-[tert-butoxycarbonyl-[4-(1-heptyloctoxy)-4-oxo- butyl]amino]butanoate (1.3 g, 1.83 mmol, 1 eq) in DCM (20 mL) was added TFA (3.08 g, 27.01 mmol, 2 mL) at 0 °C under N 2 . After addition, the mixture was stirred at 20 °C for 4 hr . Then, iced water (20 mL) was added and the mixture was neutralized to pH = 8~9 with saturated aqueous NaHCO3. The aqueous phase was extracted with EtOAc (50 mL*3). The combined organic phase was washed with brine (40 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give compound A (1.06 g, crude) as a yellow oil. The crude product was used for next step without further purification. 1H NMR (400 MHz, CDCl3) δ = 4.89 - 4.83 (m, 2H), 2.86 - 2.82 (m, 4H), 2.42 - 2.38 (m, 4H), 1.96 - 1.90 (m, 4H), 1.52 - 1.50 (m, 8H), 1.32 - 1.20 (m, 40H), 0.90 - 0.86 (m, 12H). Synthesis of intermediate A: Route 2 [382] Step 1: dimethyl 4,4'-(((4-nitrophenyl)sulfonyl)azanediyl)dibutanoate (7)) [383] To a solution of methyl 4-bromobutanoate (89.53 g, 494.59 mmol, 4 eq) and 4- nitrobenzenesulfonamide (25 g, 123.65 mmol, 1 eq) in MeCN (500 mL) were added Cs2CO3 (80.57 g, 247.30 mmol, 2 eq), KI (10.26 g, 61.82 mmol, 0.5 eq) and TBAI (456.72 mg, 1.24 mmol, 0.01 eq). The mixture was stirred at 90 °C for 12 hours. The reaction mixture was quenched with saturated aqueous NH4C1 (1000 mL) and then diluted with EtOAc (500 mL). The aqueous phase was extracted with EtOAc (1000 mL x 3). The combined organic phases were washed with brine (600 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue, it was purified by silica gel chromatography (PE/EtOAc = 10/1 to 3/1) to give compound methyl 4-[(4-methoxy-4-oxo-butyl)-(4-nitrophenyl)sulfonyl- amino]butanoate (48 g, 119.28 mmol, 96.47% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3) ¥ = 8.34 (d, J = 8.8 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H), 3.67 (s, 6H), 3.21 (t, J = 7.6 Hz, 4H), 2.34 (t, J = 7.2 Hz, 4H), 1.89-1.82 (m, 4H). [384] Step 2: 4,4'-(((4-nitrophenyl)sulfonyl)azanediyl)dibutanoic acid (8) [385] To a solution of methyl 4-[(4-methoxy-4-oxo-butyl)-(4-nitrophenyl)sulfonyl- amino]butanoate (48 g, 119.28 mmol, 1 eq) in THF (300 mL), MeOH (100 mL) and H 2 O (100 mL) were added LiOH^•H2O (25.03 g, 596.39 mmol, 5 eq). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was adjusted pH=6 with HCl (2N, aq.), then the solid was filtered and concentrated in vacuum to give compound 4-[3-carboxypropyl-(4- nitrophenyl)sulfonyl-amino]butanoic acid (42 g, 112.19 mmol, 94.06% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) ¥ = 8.41-8.36 (m, 2H), 8.10-8.01 (m, 2H), 3.18-3.12 (m, 4H), 2.24-2.18 (m, 4H), 1.75-1.68 (m, 4H). [386] Step 3: pentadecan-8-ol (A1) [387] To a solution of pentadecan-8-one (25 g, 110.43 mmol, 1 eq) in THF (300 mL) and MeOH (50 mL) was added NaBH 4 (12.53 g, 331.28 mmol, 3 eq) at 0 °C slowly. The mixture was stirred at 20 °C for 2 hours under N2. The reaction mixture was quenched with saturated aqueous NH 4 C1 (400 mL) and then diluted with EtOAc (500 mL). The aqueous phase was extracted with EtOAc (500 mL x 3). The combined organic phases were washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue, it was purified by silica gel chromatography (PE/EtOAc = 10/1 to 3/1) to give compound pentadecan-8-ol (23 g, 100.69 mmol, 91.19% yield) as a white solid. 1H NMR (400 MHz, CDCl 3 ) ¥ = 3.65-3.56 (m, 1H), 1.55-1.36 (m, 8H), 1.33-1.26 (m, 16H), 0.95-0.82 (m, 6H). [388] Step 4: di(pentadecan-8-yl) 4,4'-(((4-nitrophenyl)sulfonyl)azanediyl)dibutanoate (9) [389] To a solution of 4-[3-carboxypropyl-(4-nitrophenyl)sulfonyl-amino]butanoic acid (12 g, 32.05 mmol, 1 eq) and pentadecan-8-ol (14.64 g, 64.11 mmol, 2 eq) in CH2Cl2 (100 mL) were added EDCI (18.43 g, 96.16 mmol, 3 eq), DMAP (3.92 g, 32.05 mmol, 1 eq) and TEA (9.73 g, 96.16 mmol, 13.38 mL, 3 eq). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was quenched by the addition of saturated aqueous NH 4 C1 (300 mL) and then extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, it was purified by silica gel chromatography (PE/EtOAc = 10/1 to 3/1) to give compound 1- heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-(4-nitrophenyl)sulfonyl- amino]butanoate (9 g, 11.32 mmol, 35.31% yield) as a yellow oil. [390] Step 5: di(pentadecan-8-yl) 4,4'-azanediyldibutanoate (A): (EC1090-45) [391] A mixture of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-(4- nitrophenyl)sulfonyl-amino]butanoate (10 g, 12.58 mmol, 1 eq), benzenethiol (1.52 g, 13.83 mmol, 1.41 mL, 1.1 eq), Cs2CO3 (8.20 g, 25.15 mmol, 2 eq) in DMF (100 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 25 °C for 12 hours under N 2 atmosphere. The reaction mixture was quenched by the addition of water (500 mL) and then extracted with EtOAc (500 mL × 3). The combined organic layers were washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 10/1 to 3/1) to give compound 1- heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (5.6 g, 9.18 mmol, 73.00% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 4.88 - 4.85 (m, 2H), 2.73 - 2.70 (m, 4H), 2.38 - 2.35 (m, 4H), 1.87 - 1.84 (m, 4H), 1.52 - 1.50 (m, 8H), 1.32 - 1.20 (m, 40H), 0.90 - 0.86 (m, 12H). Example 1.1: Synthesis of CAT1 [392] Step 1: 3-(piperidin-1-yl)propyl carbamimidothioate hydrochloride (1-2): [393] To a solution of 1-(3-chloropropyl)piperidine (10 g, 50.47 mmol, 1 eq, HCl) in EtOH (120 mL) were added NaI (378.3 mg, 2.52 mmol, 0.05 eq) and thiourea (3.84 g, 50.47 mmol, 1 eq). The mixture was stirred at 75 °C for 16 hr. The reaction mixture was cooled to 10 °C and a precipitate formed. The reaction mixture was filtered and the filter cake was washed with EtOAc (30 mL*2). The filter cake and concentrated in vacuum to give compound 1-2 (10.4 g, crude, HCl) as a white solid. The crude product was used for next step without further purification. [394] Step 2: 3-(piperidin-1-yl)propane-1-thiol (1-3): [395] To a solution of 2-[3-(1-piperidyl)propyl]isothiourea (4 g, 16.82 mmol, 1 eq, HCl) in EtOH (40 mL) was added NaOH (1.01 g, 25.23 mmol, 1.5 eq) in H 2 O (5 mL). The mixture was stirred at 80 °C for 2 hr. The reaction mixture was diluted with EtOAc (150 mL). Solid Na2SO4 (10 g) was added the reaction mixture. The reaction mixture was filtered and the filter cake was washed with EtOAc (30 mL*2). The filtrate was washed with brine (30 mL*2), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give compound 1-3 (2.1 g, 13.18 mmol, 78.4% yield) as yellow oil. The crude product was used for the next step without further purification. 1 H NMR (400 MHz, CDCl3) δ = 2.71 (t, J = 7.6 Hz, 2H), 2.41 - 2.34 (m, 6H), 1.91 - 1.84 (m, 2H), 1.60 - 1.55 (m, 4H), 1.47 - 1.41 (m, 2H). [396] Step 3: di(pentadecan-8-yl) 4,4'-((((3-(piperidin-1-yl)propyl)thio)carbonyl)azanediyl) dibutanoate (CAT1): [397] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (700 mg, 1.15 mmol, 1 eq) dissolved in dry DCM (15 mL) were added TEA (348.4 mg, 3.44 mmol, 0.48 mL, 3 eq) and triphosgene (204.3 mg, 0.69 mmol, 0.6 eq) at 0° C under nitrogen atmosphere. The resulting solution was stirred at 20°C under nitrogen atmosphere for 1 hour. The resulting reaction mixture was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (321.29 mg, 8.03 mmol, 7 eq) was dissolved in dry THF (12 mL) at 0° C, and then 3-(1-piperidyl)propane-1-thiol (913.9 mg, 5.74 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride in THF (10 mL) was added via syringe slowly under nitrogen atmosphere at 0 °C. The resulting solution was stirred at 20° C for 15 hr. The reaction mixture was quenched by NH4Cl (50 mL) at 0 °C and then diluted with EtOAc (30 mL). The aqueous phase was extracted with EtOAc (40 mL*3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, DCM : MeOH: 0~17.5%, 2% NH 3 •H 2 O in MeOH) to give compound CAT1 (1.02 g, crude) as a yellow oil. Then, the crude product was purified again by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, PE : EtOAc: 0~12.5%, 5% NH 3 •H 2 O in EtOAc) to afford pure compound CAT1 (522 mg, 0.64 mmol, 50.2% yield, 98% purity) as a yellow oil. LCMS: [M+H] + : 796.5; 1H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 2H), 3.38 - 3.37 (m, 4H), 2.91 (t, J = 7.2 Hz, 2H), 2.45 - 2.22 (m, 10H), 1.94 - 1.86 (m, 4H), 1.84 - 1.77 (m, 2H), 1.63 - 1.47 (m, 12H), 1.46 - 1.38 (m, 2H), 1.34 - 1.21 (m, 40H), 0.89 (t, J = 7.2 Hz, 12H). Example 1.2: Synthesis of CAT6 [398] Step 1: 1-(azetidin-1-yl)-3-(tritylthio)propan-1-one (2-3) [399] A mixture of 3-tritylsulfanylpropanoic acid (20 g, 57.40 mmol, 1.23 mL, 1 eq), EDCI (16.50 g, 86.09 mmol, 1.5 eq), HOBt (11.63 g, 86.09 mmol, 1.5 eq) in DMF (100 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 20 °C for 1 hr under N2 atmosphere, and then azetidine (3.93 g, 68.88 mmol, 4.65 mL, 1.2 eq) in DMF (5 mL) was added dropwise at 0 °C. The resulting mixture was stirred at 20 °C for 15 hr. After completion, the reaction mixture was diluted with H2O (150 mL) and extracted with EtOAc (200 mL×3). The combined organic layers were washed with saturated brine (100 mL×2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, EtOAc/PE: 0~50%) to give compound 2-3 (15.1 g, 38.96 mmol, 67.9% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3 ) δ = 7.45 - 7.43 (m, 6H), 7.33 - 7.26 (m, 6H), 7.26 - 7.19 (m, 3H), 4.03 - 3.93 (m, 4H), 2.51 (t, J = 7.2 Hz, 2H), 2.26 - 2.18 (m, 2H), 1.98 - 1.95 (m, 2H). [400] Step 2: 1-(3-(tritylthio)propyl)azetidine (2-4) [401] To a solution of 1-(azetidin-1-yl)-3-tritylsulfanyl-propan-1-one (7 g, 18.06 mmol, 1 eq) in THF (120 mL) was added LAH (822.67 mg, 21.68 mmol, 1.2 eq) in portions at 0 °C under N 2 . After addition, the resulting mixture was stirred at 20 °C for 3 hr. After completion, the reaction mixture was diluted with THF (60 mL), then successively was added H2O (0.82 mL), aq.NaOH (0.82 mL, 4M), H 2 O (2.5 mL) and Na 2 SO 4 (25 g) at 0 °C under N 2 . The reaction mixture was filtered and the filtrate was concentrated in vacuum to give crude product. The crude product was triturated with MTBE (50 mL) at 20 o C for 30 min to give compound 2-4 (5.2 g, 13.92 mmol, 77.1% yield) as a light yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ = 7.33 - 7.29 (m, 12H), 7.26 - 7.23 (m, 3H), 2.91 (t, J = 6.8 Hz, 4H), 2.18 (t, J = 6.8 Hz, 2H), 2.10 (t, J = 7.6 Hz, 2H), 1.89 - 1.84 (m, 2H), 1.27 - 1.22 (m, 2H). Step 3: 3-(azetidin-1-yl)propane-1-thiol (2-5) [402] To a solution of 1-(3-tritylsulfanylpropyl)azetidine (4 g, 10.71 mmol, 1 eq) in DCM (30 mL) were added TFA (23.10 g, 202.59 mmol, 15 mL, 18.92 eq) and TIPS (4.20 g, 21.42 mmol, 2 eq) at 0 °C under N 2 . After addition, the resulting mixture was stirred at 20 °C for 3 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove TFA. The residue was diluted with MeOH (100 mL) and extracted with PE ( 50 mL×5). The MeOH layers was concentrated under reduced pressure to give compound 2-5 (2.4 g, crude, TFA) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ = 4.12 - 4.09 (m, 2H), 3.99 - 3.97 (m, 2H), 3.22 - 3.17 (m, 2H), 2.51 - 2.50 (m, 2H), 2.40 - 2.38 (m, 1H), 2.32 - 2.22 (m, 1H), 1.74 - 1.70 (m, 2H). [403] Step 4: di(pentadecan-8-yl) 4,4'-((((3-(azetidin-1- yl)propyl)thio)carbonyl)azanediyl)dibutanoate (CAT6) [404] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.50 g, 2.46 mmol, 1 eq) dissolved in dry dichlormethane (30.0 mL) were added triethylamine (746.48 mg, 7.38 mmol, 1.03 mL, 3 eq) and triphosgene (437.83 mg, 1.48 mmol, 0.6 eq) at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 20 °C for 1 hr. After that, the resulting reaction was concentrated under reduced pressure. At the same time, to a solution of 3-(azetidin-1-yl)propane-1-thiol (2.11 g, 8.61 mmol, 3.5 eq, TFA) dissolved in dry tetrahydrofuran (30.0 mL) was added NaOH (688.52 mg, 17.22 mmol, 7 eq) at 0 °C under nitrogen atmosphere. Then carbamoyl chloride, which was dissolved in tetrahydrofuran (15 mL), was added to this resulting solution via syringe slowly at 0 °C under nitrogen atmosphere. After that, the resulting solution was stirred at 20 °C for 15 hrs under nitrogen atmosphere. After completion, the reaction mixture was quenched by NH 4 Cl (60 mL) at 0 °C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (60 mL*3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by prep-HPLC (column: Welch Ultimate XB-SiOH 250*50*10um; mobile phase: [Hexane-EtOH];B%: 0%- 30%,10min) to give compound CAT6 (322 mg, 419.69 umol, 49.54% yield, 100% purity) as a light yellow oil. LCMS [M+1] + : 767.5; 1H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 2H), 3.42 -3.31 (m, 4H), 3.19 (t, J = 6.8 Hz, 4H), 2.90 (t, J = 7.2 Hz, 2H), 2.47 (t, J = 8.0 Hz, 2H), 2.36 - 2.26 (m, 4H), 2.08 - 2.05 (m, 2H), 1.95 - 1.85 (m, 4H), 1.67 - 1.65 (m, 2H), 1.52 - 1.50 (m, 8H), 1.30 - 1.26 (m, 40H), 0.90 - 0.86 (m, 12H). Example 1.3: Synthesis of CAT7
[405] Step 1: 1-methylpiperidin-4-yl carbamimidothioate (3-2) [406] To a solution of 4-chloro-1-methylpiperidine (20.0 g, 150 mmol, 1.00 eq.) and thiourea (28.5 g, 74.2 mmol, 2.50 eq.) in ethanol (100 mL) was added sodium iodide (2.24 g, 15.0 mmol, 0.10 eq.). The mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 80 °C for 24 hours under nitrogen atmosphere to give compound 3-2 (60.0 g, crude, hydrochloric acid salt) as a yellow gum. 1 H NMR (400 MHz, CDCl 3 ) δ = 3.06-3.02 (m, 1H), 2.70 (s, 3H), 2.67-2.54 (m, 4H), 1.91-1.73 (m, 4H) [407] Step 2: 1-methylpiperidine-4-thiol (3-3) [408] To a solution of 1-methylpiperidin-4-yl carbamimidothioate (16.0 g, 76.3 mmol, 1.00 eq., hydrochloric acid salt) in ethanol (80.0 mL) was added sodium hydroxide (18.3 g, 458 mmol, 6.00 eq.) which dissolved in water (10.0 mL). The mixture was degassed and purged with nitrogen three times, and then the mixture was stirred at 80 °C for 3 hours under nitrogen atmosphere. After completion, the mixture was concentrated and then extracted with ethyl acetate (200 mL × 3). The combined organic layers were dried with anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to compound 3-3 (4.20 g, crude) as a yellow gum. [409] Step 3: di(pentadecan-8-yl) 4,4'-((((1-methylpiperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT7) [410] To a solution of di(pentadecan-8-yl) 4,4'-azanediyldibutanoate (2.00 g, 3.28 mmol, 1.00 eq.) dissolved in dry dichloromethane (30.0 mL) were added triethylamine (995 mg, 9.84 mmol, 1.37 mL, 3.00 eq.) and triphosgene (584 mg, 1.97 mmol, 0.60 eq.) at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 20 °C for 1 hour. After that, the resulting reaction was concentrated under reduced pressure. At the same time, to a solution of 1- methylpiperidine-4-thiol (2.15 g, 16.4 mmol, 5.00 eq.) dissolved in dry tetrahydrofuran (20.0 mL) was added sodium hydroxide (918 mg, 23.0 mmol, 7.00 eq.) at 0 °C under nitrogen atmosphere. Finally, carbamoyl chloride, which was dissolved in tetrahydrofuran (20.0 mL), was added to this resulting solution via syringe slowly at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 20 °C for 15 hours under nitrogen atmosphere. After completion, the mixture was quenched by saturated ammonium chloride aqueous solution (200 mL) at 0 °C and then extracted with ethyl acetate (200 mL × 3), dried with anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate/NH3•H2O = 50/1/0.05 to 2/1/0.05) and prep-HPLC (neutral condition; column: Welch Ultimate XB-CN 250 * 50 * 10 μm; mobile phase: [Hexane-EtOH]; B%: 0% - 10%, 12 min) to give -CAT7 (350 mg, 452 umol, 51.7% yield, 99.6% purity) as a yellow oil. LCMS [M+1] + : 768.4; 1H NMR (400 MHz, CDCl 3 ) δ = 4.91-4.84 (m, 2H), 3.46-3.33 (m, 4H), 2.93-2.81 (m, 2H), 2.36 (s, 3H), 2.34-2.28 (m, 5H), 2.14-2.04 (m, 2H), 1.93-1.79 (m, 6H), 1.55-1.49 (m, 8H), 1.31-1.24 (m, 42H), 0.91-0.86 (m, 12H). Example 1.4: Synthesis of CAT8
[411] Step 1: 4,4'-(((4-nitrophenyl)sulfonyl)azanediyl)bis(N,N-dioctylbuta namide) (4-2) [412] To a solution of 4-[3-carboxypropyl-(4-nitrophenyl)sulfonyl-amino]butanoic acid (6.00 g, 16.0 mmol, 1 eq) in DCM (50 mL) were added EDCI (9.22 g, 48.1 mmol, 3 eq), TEA (4.87 g, 48.1 mmol, 6.69 mL, 3 eq) and DMAP (979 mg, 8.01 mmol, 0.5 eq) at 0 °C under N2. After addition, the mixture was stirred at 20 °C for 1 hour, and then a solution of N-octyloctan- 1-amine (8.13 g, 33.7 mmol, 2.1 eq) in DCM (10 mL) was added to dropwise. The resulting mixture was stirred at 20 °C for 6 hours. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Welch Ultimate XB- CN 250*50*10um; mobile phase: [Hexane-EtOH]; B%: 0%-15%, 12 min) to yield compound 4-2 (9.00 g, 11.0 mmol, 68% yield) as a yellow oil. LCMS: [M+H] + : 821.6. [413] Step 2: 4,4'-azanediylbis(N,N-dioctylbutanamide) (4-3) [414] To a solution of 4-[[4-(dioctylamino)-4-oxo-butyl]-(4-nitrophenyl)sulfonyl-am ino]- N,N-dioctyl-butanamide (8.00 g, 9.74 mmol, 1 eq) and benzenethiol (2.15 g, 19.5 mmol, 1.99 mL, 2 eq) in DMF (100 mL) was added Cs2CO3 (6.35 g, 19.5 mmol, 2.0 eq). The mixture was stirred at 20 °C for 12 hours under N 2. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (300 mL × 3). The combined organic layers were washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Welch Ultimate XB- CN 250*50*10um; mobile phase: [Hexane-EtOH]; B%: 5%-50%, 30 min) to yield compound 4-3 (2.90 g, 4.56 mmol, 47% yield) as a yellow oil. LCMS: [M+H] + : 637.4. [415] Step 3: S-(3-(dimethylamino)propyl) bis(4-(dioctylamino)-4-oxobutyl)carbamothioate (CAT8) [416] To a solution of 4-[[4-(dioctylamino)-4-oxo-butyl]amino]-N,N-dioctyl-butanami de (2.003.14 mmol, 1 eq) dissolved in dry DCM (20 mL) were added TEA (955mg, 9.43 mmol, 1.31 mL, 3 eq) and bis(trichloromethyl) carbonate (467mg, 1.57 mmol, 0.5 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure and kept under N 2 . To a solution of 3- (dimethylamino)propane-1-thiol (1.87 g, 15.7 mmol, 5 eq) in dry THF (20 mL) was added NaOH (880 mg, 22.0 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution, carbamoyl chloride was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched with saturated aqueous NH 4 C1 (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give residue. The residue was purified by column chromatography (SiO 2 , Dichloromethane / Methanol = 50/1 to 10/1). Compound S-[3-(dimethylamino)propyl] N,N-bis[4-(dioctylamino)-4-oxo- butyl]carbamothioate (4.10 g, crude) was obtained as a yellow oil. LCMS: [M+H] + : 756.1; 1H NMR (400 MHz, CDCl 3 ) δ : 4.82 - 4.77 (m, 2H), 3.39 - 3.29 (m, 4H), 2.84 (t, J = 7.2 Hz, 2H), 2.31 - 2.22 (m, 6H), 2.17 - 2.15 (m, 6H), 1.85 - 1.70 (m, 6H), 1.46-1.42 (m, 8H), 1.25 - 1.10 (m, 40H), 0.86 - 0.72 (m, 12H). Example 1.5: Synthesis of CAT3 [417] Step 1: 3-(pyrrolidin-1-yl)propyl carbamimidothioate hydrochloride (5-2): [418] To a solution of 1-(3-chloropropyl)pyrrolidine (25 g, 169.32 mmol, 1 eq, HCl) in EtOH (300 mL) were added NaI (1.27 g, 8.47 mmol, 0.05 eq) and thiourea (13.53 g, 177.79 mmol, 1.05 eq). The mixture was stirred at 75 °C for 16 hr . The reaction mixture was cooled to 0 °C and precipitate formed. The reaction mixture was filtered and the filter cake was washed with EtOAc (50 mL*3). The filter cake was concentrated in vacuum to give compound 5-2 (22.5 g, 100.55 mmol, 59.4% yield, HCl) as a white solid. The crude product was used for next step without further purification. 1 H NMR (400 MHz, DMSO-d6) δ = 11.24 (s, 1H), 9.37 (s, 3H), 3.52 - 3.44 (m, 2H), 3.33 - 3.31 (m, 2H), 3.22 - 3.14 (m, 2H), 3.02 - 2.92 (m, 2H), 2.09 - 2.00 (m, 2H), 2.00 - 1.92 (m, 2H), 1.91 - 1.82 (m, 2H). [419] Step 2: 3-(pyrrolidin-1-yl)propane-1-thiol (5-3): [420] To a solution of 2-(3-pyrrolidin-1-ylpropyl)isothiourea (5.2 g, 23.24 mmol, 1 eq, HCl) in EtOH (80 mL) was added NaOH (2.79 g, 69.72 mmol, 3 eq) in H2O (10 mL). The mixture was stirred at 80 °C for 16 hr . The reaction mixture was diluted with EtOAc (150 mL). Then, the mixture was washed with brine (30 mL*2), dried with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuum to give compound 5-3 (2.8 g, 19.28 mmol, 82.9% yield) as a yellow oil. The crude product was used for next step without further purification. 1 H NMR (400 MHz, CDCl3) δ = 2.73 (t, J = 7.2 Hz, 1H), 2.62 - 2.53 (m, 2H), 2.50 - 2.48 (m, 6H), 1.83 - 1.75 (m, 6H). [421] Step 3: di(pentadecan-8-yl) 4,4'-((((3-(pyrrolidin-1-yl)propyl)thio)carbonyl) azanediyl)dibutanoate (CAT3): [422] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.2 g, 1.97 mmol, 1 eq) in dry DCM (15 mL) were added TEA (597.2 mg, 5.90 mmol, 0.82 mL, 3 eq) and triphosgene (350.3 mg, 1.18 mmol, 0.6 eq) at 0° C under nitrogen atmosphere. The resulting solution was stirred at 20 °C under nitrogen atmosphere for 1 hour. The resulting reaction mixture was concentrated under reduced pressure and kept under nitrogen atmosphere. To a solution of 3-pyrrolidin-1-ylpropane-1-thiol (1.00 g, 6.89 mmol, 3.5 eq) in dry THF (12 mL) at 0° C under nitrogen atmosphere was added NaOH (550.8 mg, 13.77 mmol, 7 eq) under nitrogen atmosphere. A solution of carbamoyl chloride in THF (10 mL) was added via syringe slowly under nitrogen atmosphere at 0 °C to the resulting solution which was stirred at 20° C for 15 hr. The reaction mixture was quenched by NH 4 Cl (60 mL) at 0 °C and then diluted with EtOAc (40 mL). The aqueous phase was extracted with EtOAc (50 mL*3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, PE : EtOAc: 0~15%, 5% NH 3 •H 2 O in EtOAc) to give compound CAT3 (1.1 g, crude) as a yellow oil. Then the crude product was purified again by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~12%, 5% NH3•H2O in EtOAc) to afford pure compound CAT3 (395 mg, 0.50 mmol, 30.0% yield, 98.7% purity) as a yellow oil. LCMS: [M+H] + : 781.6; 1H NMR (400 MHz, CDCl 3 ) δ = 4.90 - 4.84 (m, 2H), 3.39 - 3.37 (m, 4H), 2.94 (t, J = 7.2 Hz, 2H), 2.56 - 2.44 (m, 6H), 2.33 -2.28 (m, 4H), 1.97 - 1.81 (m, 6H), 1.80 - 1.74 (m, 4H), 1.56 - 1.46 (m, 8H), 1.35 -1.24 (m, 40H), 0.88 (t, J = 7.2 Hz, 12H). Example 1.6: Synthesis of CAT4 [423] Step 1: 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride (6-2) [424] To a solution of 2-(1-methylpyrrolidin-2-yl)ethanol (2.00 g, 15.5 mmol, 2.10 mL, 1.00 eq.) in dichlormethane (20.0 mL) was added thionyl chloride (5.52 g, 46.4 mmol, 3.37 mL, 3.00 eq.) drop-wise. Then, the mixture was stirred at 40 °C for 2 hours. After completion, the reaction mixture was filtered and concentrated under reduced pressure to give compound 6-2 (2.20 g, crude) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ = 11.32 (s, 1H), 3.86-3.79 (m, 1H), 3.71-3.63 (m, 1H), 3.53-3.44 (m, 1H), 3.40-3.29 (m, 1H), 3.06-2.96 (m, 1H), 2.74 (d, J = 4.8 Hz, 3H), 2.40-2.31 (m, 1H), 2.26-2.10 (m, 2H), 2.02-1.83 (m, 2H), 1.74-1.63 (m, 1H). [425] Step 2: 2-(1-methylpyrrolidin-2-yl)ethyl carbamimidothioate hydrochloride (6-3) [426] A mixture of 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride (14.0 g, 76.0 mmol, 1.00 eq.), thiourea (5.90 g, 77.6 mmol, 1.02 eq.) and sodium iodide (2.28 g, 15.2 mmol, 0.20 eq.) in ethanol (100 mL) was degassed and purged with nitrogen three times, then the mixture was stirred at 80 °C for 12 hours under nitrogen atmosphere. After completion, the reaction mixture was cooled down to ambient temperature. Then ethyl acetate (100 mL) was added until permanent opalescence was detected and the mixture was maintained at 4 °C for 12 hours. After that, the mixture was filtered and concentrated under reduced pressure to compound 6-3 (16.0 g, 71.5 mmol, 94.0% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ = 10.99 (s, 1H), 9.32 (s, 3H), 3.50-3.39 (m, 2H), 3.35-3.29 (m, 2H), 3.08-2.98 (m, 1H), 2.77 (d, J = 4.8 Hz, 3H), 2.28-2.16 (m, 2H), 2.04-1.93 (m, 2H), 1.92-1.69 (m, 2H). [427] Step 3: 2-(1-methylpyrrolidin-2-yl)ethanethiol (6-4) [428] To a solution of 2-(1-methylpyrrolidin-2-yl)ethyl carbamimidothioate hydrochloride (10.0 g, 44.7 mmol, 1.00 eq.) in ethanol (80.0 mL) was added sodium hydroxide (5.36 g, 134 mmol, 3.00 eq.) which dissolved in water (20.0 mL). The mixture was stirred at 80 °C for 3 hours under nitrogen atmosphere. After completion, the mixture was concentrated and then extracted with ethyl acetate (200 mL × 3). The combined organic layers were dried with anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to compound 6-4 (2.40 g, crude) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 3.08-3.01 (m, 2H), 2.50-2.45 (m, 1H), 2.31 (s, 3H), 2.18-2.09 (m, 4H), 1.79-1.65 (m, 4H). [429] Step 4: di(pentadecan-8-yl) 4,4'-((((2-(1-methylpyrrolidin-2- yl)ethyl)thio)carbonyl)azanediyl)dibutanoate (CAT4) [430] To a solution of di(pentadecan-8-yl) 4,4'-azanediyldibutanoate (2.00 g, 3.28 mmol, 1.00 eq.) dissolved in dry dichlormethane (30.0 mL) were added triethylamine (995 mg, 9.84 mmol, 1.37 mL, 3.00 eq.) and triphosgene (584 mg, 1.97 mmol, 0.60 eq.) at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 20 °C for 1 hour. After that, the resulting reaction was concentrated under reduced pressure. At the same time, to a solution of 2-(1- methylpyrrolidin-2-yl)ethanethiol (2.38 g, 16.4 mmol, 5.00 eq.) dissolved in dry tetrahydrofuran (20.0 mL) was added sodium hydroxide (918 mg, 22.9 mmol, 7.00 eq.) at 0 °C under nitrogen atmosphere. Then, carbamoyl chloride, which was dissolved in tetrahydrofuran (20.0 mL), was added to this resulting solution via syringe slowly at 0 °C under nitrogen atmosphere. After that, the resulting solution was stirred at 20° C for 15 hours under nitrogen atmosphere. After completion, the mixture was quenched by ammonium chloride (200 mL) at 0 °C and then extracted with ethyl acetate (200 mL × 3), dried with anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate/NH3•H2O = 1/0/0.05 to 10/1/0.05) to give CAT4 (451 mg, 576 umol, 17.6% yield, 99.9% purity) as a yellow oil. LCMS [M+1] + : 781.5; 1 H NMR (400 MHz, CDCl 3 ) δ = 4.91-4.84 (m, 2H), 3.43-3.33 (m, 4H), 3.14-3.03 (m, 1H), 3.00-2.92 (m, 1H), 2.89-2.80 (m, 1H), 2.33 (s, 3H), 2.32-2.29 (m, 2H), 2.23-2.09 (m, 2H), 2.03- 1.86 (m, 6H), 1.80-1.67 (m, 2H), 1.58-1.47 (m, 10H), 1.33-1.22 (m, 42H), 0.92-0.85 (m, 12H). Example 1.7: Synthesis of 23 (CAT4)
[431] Step 1: 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride (20): [432] To a solution of 2-(1-methylpyrrolidin-2-yl)ethanol (2 g, 15.48 mmol, 2.10 mL, 1 eq) in CH2Cl2 (20 mL) was added SOCl2 (5.52 g, 46.44 mmol, 3.37 mL, 3 eq) dropwised slowly. The mixture was stirred at 45 °C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give compound 2-(2-chloroethyl)-1-methyl-pyrrolidine (2.2 g, 11.95 mmol, 77.19% yield, hydrochloride salt) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) ¥ = 11.32 (s, 1H), 3.88-3.80 (m, 1H), 3.75-3.66 (m, 1H), 3.55-3.45 (m, 1H), 3.43-3.35 (m, 1H),.3.08-2.97 (m, 1H), 2.75 (s, 3H), 2.48-2.31 (m, 1H), 2.28-2.10 (m, 2H), 2.04 -1.88 (m, 2H), 1.82-1.66 ppm (m, 1H). [ : [434] A mixture of 2-(2-chloroethyl)-1-methyl-pyrrolidine (14 g, 76.04 mmol, 1 eq, hydrochloride salt), thiourea (5.90 g, 77.56 mmol, 1.02 eq), NaI (2.28 g, 15.21 mmol, 0.2 eq) in EtOH (100 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 80 °C for 12 hours under N2 atmosphere. The reaction mixture was cooled to ambient temperature. EtOAc (100 mL) until permanent opalescence was obtained. Then the reaction mixture was stood at 4 °C for 12 hours. The mixture was then filtered and concentrated under reduced pressure to give compound 2-[2-(1-methylpyrrolidin-2-yl)ethyl]isothiourea (16 g, 71.50 mmol, 94.03% yield, hydrochloride salt) as a yellow solid. LCMS: [M+H] + : 188.1. [435] Step 3: 2-(1-methylpyrrolidin-2-yl)ethanethiol (22): [436] To a solution of 2-[2-(1-methylpyrrolidin-2-yl)ethyl]isothiourea (3 g, 13.41 mmol, 1 eq, hydrochloride salt) in H 2 O (1 mL) and EtOH (8 mL) was added NaOH (2.68 g, 67.03 mmol, 5 eq). The mixture was stirred at 90 °C for 2 hours. The mixture was filtered and concentrated under reduced pressure to give compound 2-(1-methylpyrrolidin-2-yl)ethanethiol (1.8 g, 12.39 mmol, 92.42% yield) as a yellow oil which was used next step without purification. [437] Step 4: di(pentadecan-8-yl) 4,4'-((((2-(1-methylpyrrolidin-2- yl)ethyl)thio)carbonyl)azanediyl) dibutanoate (23): [438] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.5 g, 2.46 mmol, 1 eq) dissolved in dry CH2Cl2 (15 mL) were added TEA (746.47 mg, 7.38 mmol, 1.03 mL, 3 eq) and triphosgen (364.85 mg, 1.23 mmol, 0.5 eq) at 0° C under nitrogen atmosphere. The resulting solution was stirred at 20 °C under nitrogen atmosphere for 1 hour. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (688.47 mg, 17.22 mmol, 7 eq) was dissolved in dry THF (20 mL) at 0° C under nitrogen atmosphere, then 2-(1-methylpyrrolidin-2-yl)ethanethiol (1.79 g, 12.30 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride dissolved in THF (10 mL) was added slowly under nitrogen atmosphere at 0°C. The mixture was stirred at 20° C for 12 hours. The reaction mixture was quenched by water (50 mL) and then diluted with EtOAc (50 mL), then extracted with EtOAc (50 mL × 3). The combined organic phase was washed with brine (20 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by silica gel chromatography (PE/EtOAc = 20/1 to 0/1, 6% NH 3 •H 2 O in EtOAc) to give compound CAT4 (551 mg, 695.39 umol, 28.27% yield, 98.6% purity) as a yellow oil. LCMS: [M+H] + : 781.9; 1 H NMR (400 MHz, CDCl3) ¥ = 4.95-4.78 (m, 2H), 3.51-3.40 (m, 4H), 3.12-3.03 (m, 1H), 3.01-2.94 (m, 1H), 2.91-2.83 (m, 1H), 2.32 (s, 3H), 2.31-2.26 (m, 2H), 2.22-2.10 (m, 2H), 2.04-1.94 (m, 6H), 1.85-1.62 (m, 4H), 1.59-1.52 (m, 8H), 1.37-1.18 (m, 42H), 0.88 (t, J = 6.8 Hz, 12H). Example 1.8: Synthesis of CAT5 [ [440] To a solution of cyclopropanecarbaldehyde (19.46 g, 277.70 mmol, 20.75 mL, 2 eq) and 3-chloro-N-methyl-propan-1-amine (20 g, 138.85 mmol, 1 eq, hydrochloride) in dichlormethane (200 mL) were added NaBH3CN (13.09 g, 208.27 mmol, 1.5 eq) and KOAc (40.88 g, 416.54 mmol, 3 eq). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was quenched with saturated aqueous NH4C1 (500 mL) and then diluted with ethyl acetate (300 mL). The aqueous phase was extracted with ethyl acetate (500 mL x 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate=10/1 to 3/1 and ethyl acetate/methanol=30/1 to 10/1) to give compound 8-6 (15 g, 92.78 mmol, 66.82% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 3.62-3.55 (m, 2H), 2.54-2.51 (m, 2H), 2.28-2.23 (m, 5H), 2.02-1.97 (m, 2H), 0.90-0.85 (m, 1H), 0.55-0.48 (m, 2H), 0.18-0.08 (m, 2H). [441] Step 2: 2-[3-[cyclopropylmethyl(methyl)amino]propyl]isothiourea hydrochloride (8-7) [442] To a solution of 3-chloro-N-(cyclopropylmethyl)-N-methyl-propan-1-amine (7 g, 43.30 mmol, 1 eq) and thiourea (3.96 g, 51.96 mmol, 1.2 eq) in ethanol (15 mL) was added NaI (649.01 mg, 4.33 mmol, 0.1 eq). The mixture was stirred at 90 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to give compound 8-7 (8 g, 33.64 mmol, 77.70% yield, hydrochloride) as a brown oil. 1 H NMR (400 MHz, DMSO-d6) δ = 7.03-6.95 (m, 4H), 3.28-3.24 (m, 1H), 2.91-2.85 (m, 2H), 2.70-2.66 (m, 2H), 2.53-2.48 (m, 3H), 2.38-2.32 (m, 2H), 1.72-1.58 (m, 2H), 0.98-0.90 (m, 1H), 0.48-0.41 (m, 2H), 0.26-0.12 (m, 2H). [443] Step 3: 3-[cyclopropylmethyl(methyl)amino]propane-1-thiol (8-8) [444] To a solution of 2-[3-[cyclopropylmethyl(methyl)amino]propyl]isothiourea (8 g, 39.74 mmol, 1 eq hydrochloride) in ethanol (16 mL) and water (4 mL) was added NaOH (9.54 g, 238.41 mmol, 6 eq). The mixture was stirred at 90 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to give compound 8-8 (2.4 g, 15.07 mmol, 37.92% yield) as a yellow oil. [445] Step 4: 1-heptyloctyl 4-[3-[cyclopropylmethyl(methyl)amino]propylsulfanylcarbonyl- [4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate [446] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2 g, 3.28 mmol, 1 eq) dissolved in dry dichlormethane (20 mL) were added TEA (995.30 mg, 9.84 mmol, 1.37 mL, 3 eq) and triphosgene (486.47 mg, 1.64 mmol, 0.5 eq) at 0° C under nitrogen atmosphere. The resulting solution was stirred at 20 °C under nitrogen atmosphere for 1 hour. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (917.96 mg, 22.95 mmol, 7 eq) was dissolved in dry THF (20 mL) at 0° C under nitrogen atmosphere, then 3-[cyclopropylmethyl(methyl)amino]propane-1-thiol (2.61 g, 16.39 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride dissolved in THF (10 mL) was added slowly under nitrogen atmosphere at 0°C. The mixture was stirred at 20° C for 12 hours. The reaction mixture was quenched with saturated aqueous NH4C1 (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate=10/1 to 1/1 and dichloromethane/methanol=30/1 to 10/1) to give compound CAT5 (1.0 g, 1.26 mmol, 38.31% yield, 99.9% purity) as a yellow oil. LCMS: [M+H] + : 796.2; 1 H NMR (400 MHz, CDCl3) δ = 4.87 - 4.85 (m, 2H), 3.49-3.35 (m, 4H), 2.92 (t, J = 7.2 Hz, 2H), 2.47 (t, J = 7.2 Hz, 2H), 2.42-2.30 (m, 7H), 2.24 (d, J = 6.4 Hz, 2H), 1.98-1.94 (m, 4H), 1.80-1.74 (m, 2H), 1.53-1.48 (m, 8H), 1.28-1.20 (m, 40H), 0.98-0.90 (m, 13H), 0.51 (d, J = 8.0 Hz, 2H), 0.11 - .010 (m, 2H). Example 1.9: Synthesis of CAT9 [447] Step 1: (1-methylpyrrolidin-3-yl)methanol (9-2) [448] To a solution of 1-tert-butoxycarbonylpyrrolidine-3-carboxylic acid (30 g, 139.38 mmol, 1 eq) in THF (600 mL) was added LAH (15.87 g, 418.13 mmol, 3 eq) in portions at 0°C under N2. After addition, the mixture was stirred at 20 °C for 3 hr. After completion, the reaction mixture was diluted with THF (350 mL), then successively was added H 2 O (16 mL), aq.NaOH (16 mL, 4M), H2O (20 mL) and Na2SO4 (100 g) at 0 °C under N2. The reaction mixture was filtered and the filtrate was concentrated in vacuum to give compound 9-2 (11.2 g, 97.25 mmol, 69.8% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 3.67 - 3.63 (m, 1H), 3.54 - 3.50 (m, 1H), 2.95 - 2.68 (m, 2H), 2.58 - 2.52 (m, 1H), 2.51 - 2.44 (m, 1H), 2.40 - 2.33 (m, 1H), 2.32 (s, 3H), 2.02 - 1.97 (m, 1H), 1.66 - 1.63 (m, 1H). [449] Step 2: (1-methylpyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (9-3) [450] To a solution of (1-methylpyrrolidin-3-yl)methanol (10 g, 86.83 mmol, 1 eq) in DCM (200 mL) were added TEA (17.57 g, 173.65 mmol, 24.17 mL, 2 eq), DMAP (1.06 g, 8.68 mmol, 0.1 eq) and TosCl (19.86 g, 104.19 mmol, 1.2 eq) at 0 °C under N 2 . The mixture was stirred at 20 °C for 16 hr. After completion, the reaction mixture was diluted with DCM (150 mL) and washed with brine (100 mL * 2), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, Methanol : Dichloromethane : 0~15%) to give compound 9-3 (10.8 g, 40.10 mmol, 46.2% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 7.79 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 3.93 (d, J = 7.2 Hz, 2H), 2.60 - 2.46 (m, 4H), 2.45 (s, 3H), 2.31 (s, 3H), 2.30 - 2.28 (m, 1H), 1.97 - 1.95 (m, 1H), 1.45 - 1.31 (m, 1H). [451] Step 3: S-((1-methylpyrrolidin-3-yl)methyl) ethanethioate (9-4) [452] To a solution of (1-methylpyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (10.7 g, 39.72 mmol, 1 eq) in DMF (100 mL) was added acetylsulfanylpotassium (5.44 g, 47.67 mmol, 1.2 eq) under N2. The mixture was stirred at 25 °C for 16 hr. After completion, The reaction mixture was cooled to 0 °C and quenched by the addition of H 2 O (150 mL). Then, the reaction was diluted with EtOAc (100 mL) and extracted with EtOAc (150 mL*3). The combined organic phase was washed with brine (150 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Dichloromethane : Methanol : 0~10%) to give compound 9- 4 (4.8 g, 27.70 mmol, 69.7% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 2.97 - 2.94 (m, 2H), 2.72 - 2.71 (m, 1H), 2.59 - 2.51 (m, 2H), 2.45 - 2.41 (m, 1H), 2.34 - 2.33 (m, 6H), 2.24 - 2.22 (m, 1H), 2.21 - 2.03 (m, 1H), 1.52 - 1.48 (m, 1H). [453] Step 4: (1-methylpyrrolidin-3-yl)methanethiol (9-5) [454] To a solution of S-[(1-methylpyrrolidin-3-yl)methyl] ethanethioate (1.7 g, 9.81 mmol, 1 eq) in MeOH (10 mL) was added NH3 (7 M in MeOH, 4.20 mL, 3 eq). The mixture was stirred at 20 °C for 3 hr under N 2 . After completion, the reaction mixture was concentrated under reduced pressure (air bath, water pump) to remove solvent to give compound 9-5 (1.2 g, crude) as a yellow oil. The crude product was used in the next step without further purification. 1 H NMR (400 MHz, CD3OD) δ = 2.86 - 2.81 (m, 1H), 2.69 - 2.64 (m, 1H), 2.59 - 2.56 (m, 3H), 2.48 - 2.41 (m, 1H), 2.38 (s, 3H), 2.34 - 2.32 (m, 1H), 2.11 - 2.07 (m, 1H), 1.60 - 1.57 (m, 1H). [455] Step 5: di(pentadecan-8-yl) 4,4'-(((((1-methylpyrrolidin-3- yl)methyl)thio)carbonyl)azanediyl)dibutanoate (CAT9) [456] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.5 g, 2.46 mmol, 1 eq) dissolved in dry DCM (25 mL) were added TEA (746.48 mg, 7.38 mmol, 1.03 mL, 3 eq) and triphosgene (437.83 mg, 1.48 mmol, 0.6 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure and kept under N2. To a solution of (1-methylpyrrolidin-3-yl)methanethiol (1.13 g, 8.61 mmol, 3.5 eq) dissolved in dry THF (30 mL) was added NaOH (688.52 mg, 17.21 mmol, 7 eq) at 0 °C under N2. To this resulting solution, carbamoyl chloride dissolved in THF (25 mL) was added via syringe slowly under N 2 at 0 °C. The resulting solution was stirred at 20 °C for 2 hr. After completion, the reaction mixture was quenched by NH4Cl (60 mL) at 0 °C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL * 3). The combined organic phase was washed with brine (60 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Ethyl acetate : Petroleum ether : 0~13%, 5% NH 3 •H 2 O in Ethyl acetate) to give 620 mg compound, and then the compound was purified by prep-HPLC (column: Welch Ultimate XB-SiOH 250*50*10um;mobile phase: [Hexane-EtOH];B%: 0%-30%,13min) to give compound CAT9 (325 mg, 0.42 mmol, 17.9% yield, 99.1% purity) as a light yellow oil. LCMS [M+1] + : 767.9; 1H NMR (400 MHz, CDCl3) δ = 4.91 - 4.84 (m, 2H), 3.41 - 3.36 (m, 4H), 3.05 - 2.98 (m, 2H), 2.81 -2.77 (m, 1H), 2.63 - 2.59 (m, 2H), 2.51 - 2.46 (m, 1H), 2.37 (s, 3H), 2.34 - 2.26 (m, 4H), 2.13 - 2.04 (m, 1H), 1.95 - 1.86 (m, 4H), 1.61 - 1.58 (m, 2H), 1.55 - 1.46 (m, 8H), 1.32 - 1.26 (m, 40H), 0.90 - 0.86 (m, 12H). [457] Step 1: 3-chloro-N-(cyclobutylmethyl)-N-methyl-propan-1-amine (10-2) [458] To a solution of cyclobutanecarbaldehyde (29.20 g, 347.12 mmol, 2 eq) and 3-chloro- N-methyl-propan-1-amine;hydrochloride (25 g, 173.56 mmol, 1 eq) in dichlormethane (100 mL) and MeOH (100 mL) were added NaBH 3 CN (16.36 g, 260.34 mmol, 1.5 eq) and KOAc (51.10 g, 520.68 mmol, 3 eq). The mixture was stirred at 35 °C for 12 hr. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=30/1 to 1/1 and Dichloromethane / Methanol=30/1 to 5/1) to give compound 10-2 (27 g, 153.67 mmol, 88.54% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 3.67 (t, J = 6.0 Hz, 2H), 3.26-3.20 (m, 2H), 3.12 (d, J = 7.2 Hz, 2H), 2.78-2.70 (m, 3H), 2.28-2.18 (m, 4H), 2.10-.2.05 (m, 1H), 1.90-1.80 (m, 4H). [459] Step 2: 2-[3-[cyclobutylmethyl(methyl)amino]propyl]isothiourea (10-3) [460] To a solution of 3-chloro-N-(cyclobutylmethyl)-N-methyl-propan-1-amine (10 g, 56.92 mmol, 1 eq) and thiourea (4.77 g, 62.61 mmol, 1.1 eq) in EtOH (100 mL) was added NaI (4.27 g, 28.46 mmol, 0.5 eq). The mixture was stirred at 90 °C for 12 hr under N2. The reaction mixture was filtered and concentrated under reduced pressure to give compound 10-3 (12 g, 47.65 mmol, 83.73% yield, hydrochloride) as a brown oil. [461] Step 3: 3-[cyclobutylmethyl(methyl)amino]propane-1-thiol (10-4) [462] To a solution of 2-[3-[cyclobutylmethyl(methyl)amino]propyl]isothiourea (6 g, 27.86 mmol, 1 eq) in EtOH (30 mL) and water (5 mL) was added NaOH (6.69 g, 167.16 mmol, 6 eq). The mixture was stirred at 90 °C for 6 hr. The reaction mixture was filtered and concentrated under reduced pressure to give compound 10-4 (2.8 g, 16.16 mmol, 57.99% yield) as a yellow oil. [463] Step 4: 1-heptyloctyl 4-[3-[cyclobutylmethyl(methyl)amino]propylsulfanylcarbonyl- [4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (CAT10) [464] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.8 g, 2.95 mmol, 1 eq) dissolved in dry dichlormethane (20 mL) were added TEA (895.77 mg, 8.85 mmol, 1.23 mL, 3 eq) and triphosgene (437.82 mg, 1.48 mmol, 0.5 eq) at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 25 °C under nitrogen atmosphere for 1 hr. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (826.17 mg, 20.66 mmol, 7 eq) was dissolved in dry THF (60 mL) at 0 °C under nitrogen atmosphere, then 3-[cyclobutylmethyl(methyl)amino]propane-1-thiol (2.56 g, 14.75 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride dissolved in THF (10 mL) was added slowly under nitrogen atmosphere at 0 °C. The mixture was stirred at 25 °C for 12 hr. until the reaction was completed. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 and Dichloromethane / Methanol=30/1 to 5/1) and MPLC (Welch Ultimate XB-SiOH 250*50*10um; mobile phase: [Hexane-EtOH]; B%: 0%-30%, 13min) to give compound CAT10 (238 mg, 292.02 umol, 11.82% yield, 99.3% purity) as a yellow oil. LCMS: [M+H] + : 810.0; 1H NMR (400 MHz, CDCl3) δ = 4.85-4.76 (m, 2H), 3.30-3.25 (m, 4H), 2.84 (t, J = 7.2 Hz, 2H), 2.52-2.32 (m, 4H), 2.28-2.12 (m, 7H), 2.05-1.98 (m, 2H), 1.88-1.60 (m, 8H), 1.60-1.52 (m, 3H), 1.48-1.32 (m, 8H), 1.25-1.10 (m, 40H), 0.85-0.78 (m, 12H). Example 1.11: Synthesis of CAT11
[465] Step 1: (1-methyl-3-piperidyl)methyl 4-methylbenzenesulfonate (11-2) [466] To a solution of (1-methyl-3-piperidyl)methanol (10 g, 77.40 mmol, 1 eq) in dichlormethane (100 mL) were added TosCl (14.76 g, 77.40 mmol, 1 eq) DMAP (945.58 mg, 7.74 mmol, 0.1 eq) and TEA (15.66 g, 154.80 mmol, 21.55 mL, 2 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 and Dichloromethane / Methanol=30/1 to 10/1) to give compound 11-2 as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.77 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 3.96-3.90 (m, 2H), 2.75-2.65 (m, 2H), 2.44 (s, 3H), 2.21 (s, 3H), 1.98-1.90 (m, 2H), 1.70-1.48 (m, 4H), 1.03-0.90 (m, 1H). [467] Step 2: 1-methyl-3-(tritylsulfanylmethyl)piperidine (11-3) [468] To a solution of (1-methyl-3-piperidyl)methyl 4-methylbenzenesulfonate (7.5 g, 26.47 mmol, 1 eq) and triphenylmethanethiol (8.78 g, 31.76 mmol, 1.2 eq) in DMF (80 mL) was added K2CO3 (10.97 g, 79.40 mmol, 3 eq). The mixture was stirred at 80 °C for 12 hr. The reaction mixture was quenched by the addition of water (200 mL), and then extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 and Dichloromethane / Methanol=30/1 to 10/1) to give compound 11-3 (7.5 g, 19.35 mmol, 73.12% yield) as a yellow oil. 1H NMR (400 MHz, CDCl 3 ) δ = 7.49-7.45 (m, 5H), 7.38-7.25 (m, 10H), 2.83-2.80 (m, 2H), 2.32-2.28 (m, 3H), 2.18-2.11 (m, 2H), 1.93-1.90 (m, 1H), 1.77-1.62 (m, 5H), 0.95-0.88 (m, 1H). [469] Step 3: (1-methyl-3-piperidyl)methanethiol (11-4) [470] To a solution of 1-methyl-3-(tritylsulfanylmethyl)piperidine (6.5 g, 16.77 mmol, 1 eq) in dichlormethane (50 mL) were added TFA (37.06 g, 325.00 mmol, 30 mL, 19.38 eq) and triisopropylsilane (5.31 g, 33.54 mmol, 6.89 mL, 2 eq) at 0 °C. The mixture was stirred at 25 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to remove TFA, it was diluted with MeOH (100 mL) and extracted with Petroleum ether (50 mL x 5). The MeOH layers was concentrated under reduced pressure to give compound 11-4 (2.2 g, 15.14 mmol, 90.30% yield) as a yellow oil. 1H NMR (400 MHz, CDCl 3 ) δ = 3.58-3.52 (m, 2H), 2.79 (s, 3H), 2.60-2.51 (m, 3H), 2.26-2.24 (m, 1H), 2.10-1.75 (m, 4H), 1.40-1.37 (m, 1H), 1.25-1.15 (m, 1H). [471] Step 4: 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-[(1-methyl-3- piperidyl)methylsulfanylcarbonyl]amino]butanoate (CAT11) [472] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.8 g, 2.95 mmol, 1 eq) dissolved in dry dichlormethane (20 mL) were added TEA (895.77 mg, 8.85 mmol, 1.23 mL, 3 eq) and triphosgene (437.82 mg, 1.48 mmol, 0.5 eq) at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 25 °C under nitrogen atmosphere for 1 hr. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (826.17 mg, 20.66 mmol, 7 eq) was dissolved in dry THF (30 mL) at 0 °C under nitrogen atmosphere, then (1-methyl-3-piperidyl)methanethiol (2.14 g, 14.75 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride dissolved in THF (10 mL) was added slowly under nitrogen atmosphere at 0 °C. The mixture was stirred at 25 ° C for 12 hr. The reaction mixture was quenched with saturated aqueous NH 4 C1 (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 and Dichloromethane / Methanol=30/1 to 10/1) and purified by column Welch Ultimate XB-SiOH 250*50*10um; mobile phase: [Hexane-EtOH]; B%: 0%-25%, 20 min to give compound CAT11 (300 mg, 383.61 umol, 16.65% yield, 99.9% purity) as a yellow oil . LCMS: [M+H] + : 782.1; 1H NMR (400 MHz, CDCl 3 ) δ = 4.90-4.85 (m, 2H), 3.48-3.40 (m, 4H), 3.10-2.82 (m, 4H), 2.40-2.28 (m, 6H), 2.10-1.70 (m, 8H), 1.60-1.48 (m, 12H), 1.33-1.20 (m, 40H), 0.90- 0.86 (m, 12H). Example 1.12: Synthesis of CAT12 [473] Step 1: 3-(tritylthio)propanal (12-2) [474] To a mixture of triphenylmethanethiol (10.0 g, 36.2 mmol, 1 eq) in DCM (100 mL) were added TEA (5.13 g, 50.7 mmol, 7.05 mL, 1.4 eq) and prop-2-enal (2.84 g, 50.7 mmol, 3.39 mL, 1.4 eq) successively, the reaction mixture was stirred at 20 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to yield compound 12-2 (12.4 g, crude) as an off-white solid. The reaction residue was used directly for the next step. [475] Step 2: 4-(3-(tritylthio)propyl)thiomorpholine (12-4) [476] To a mixture of 3-tritylsulfanylpropanal (7.40 g, 22.3 mmol, 1 eq) and thiomorpholine (2.53 g, 24.5 mmol, 2.32 mL, 1.1 eq) in MeOH (40 mL) and DCE (40 mL) were added AcOH (134 mg, 2.23 mmol, 0.127 mL, 0.1 eq) and NaBH3CN (2.80 g, 44.5 mmol, 2 eq) successively, the reaction mixture was stirred at 20 °C for 2 hours. The reaction mixture was quenched by the addition of saturated NH 4 Cl solution (50 mL) and extracted by dichloromethane (40 mL × 3), then the combined organic phase was dried by anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was triturated with Petroleum ether/Ethyl acetate = 10/1 at 20 o C for 10 min to give compound 12-4 (9.00 g, 21.5 mmol, 96% yield) as a white solid. LCMS: [M+H] + : 420.0; 1 H NMR (400 MHz, CDCl 3 ) δ : 7.44 - 7.28 (m, 12H), 7.24 - 7.20 (m, 3H), 2.68 - 2.53 (m, 8H), 2.37 - 2.25 (m, 2H), 2.19 (t, J = 7.2 Hz, 2H), 1.60 - 1.51 (m, 2H). [477] Step 3: 3-thiomorpholinopropane-1-thiol (12-5) [478] To a solution of 4-(3-tritylsulfanylpropyl)thiomorpholine (8.00 g, 19.1 mmol, 1 eq) in DCM (10 mL) were added TFA (30.8 g, 270 mmol, 20.0 mL, 14.2 eq) and triisopropylsilane (6.04 g, 38.1 mmol, 7.83 mL, 2 eq) at 0 °C. The mixture was stirred at 25 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtained a residue, then the reaction residue was added to MeOH (20 mL) and washed with petroleum ether (3 × 10 mL), dried by anhydrous Na2SO4, filtered and concentrated under vacuum to yield compound 12-5 as a yellow oil. The reaction residue was used directly for the next step. [479] Step 4: di(pentadecan-8-yl) 4,4'-((((3- thiomorpholinopropyl)thio)carbonyl)azanediyl)dibutanoate (CAT12)
[480] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.28 mmol, 1 eq) dissolved in dry DCM (30 mL) were added TEA (995 mg, 9.84 mmol, 1.37 mL, 3 eq) and bis(trichloromethyl) carbonate (486 mg, 1.64 mmol, 0.5 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure and kept under N 2 . To a solution of 3- thiomorpholinopropane-1-thiol (2.33 g, 13.1 mmol, 4 eq) in dry THF (30 mL) was added NaOH (918 mg, 23.0 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution, carbamoyl chloride was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 3 hours. The reaction mixture was quenched with saturated aqueous NH 4 C1 (60 mL) and then diluted with ethyl acetate (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO 2 , Petroleum ether/Ethyl acetate = 50/1 to 3/1). Compound CAT12 (1.50 g, 1.84 mmol, 56% yield) was obtained as a yellow oil. LCMS: [M+H] + : 813.6; 1 H NMR (400 MHz, CDCl3) δ : 4.89 - 4.86 (m, 2H), 3.40 - 3.36 (m, 4H), 2.91 (t, J = 7.2 Hz, 2H), 2.72 - 2.68 (m, 6H), 2.48 - 2.44 (m, 2H), 2.31 (m, 4H), 1.98 - 1.76 (m, 6H), 1.64 - 1.45 (m, 10H), 1.32 - 1.22 (m, 40H), 0.92 - 0.83 (m, 12H). Example 1.13: Synthesis of CAT13
[481] Step 1: undeca-1,10-dien-6-ol (13-2) [482] A suspension of Mg (24.61 g, 1.01 mol, 2.5 eq) and I2 (2.06 g, 8.10 mmol, 1.63 mL, 0.02 eq) in dry THF (1500 mL) (2mL/mmol of bromide) was prepared under nitrogen atmosphere. To this mixture, 5-bromopent-1-ene (150.88 g, 1.01 mol, 2.5 eq) was slowly added at 20 °C. While the addition, an increase in the temperature of the reaction mixture confirmed the initiation of the Grignard formation. Once the addition of the bromide was completed, the mixture was stirred at 20 °C for 1 hr, after which it was cooled down to 0 °C for the slow addition of ethyl formate (30 g, 404.98 mmol, 32.6 mL, 1 eq). After the addition, the cold bath was removed and the mixture was stirred at 20 °C for 15 hr. After completion, the reaction was cooled down to 0 °C for quenching by the addition of saturated solution NH4Cl (1000 mL) and stirred for 30 min. The aqueous phase was extracted with EtOAc (800 mL*3). The combined organic phase was washed with brine (400 mL * 2), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by MPLC (EtOAc : PE: 0~5%) to give compound 13-2 (53.2 g, 316.15 mmol, 81.9% yield) as a yellow liquid. 1H NMR (400 MHz, CDCl3) δ = 5.85 - 5.77 (m, 2H), 5.04 - 4.95 (m, 4H), 3.62 - 3.60 (m, 1H), 2.08 - 2.07 (m, 4H), 1.50 - 1.42 (m, 8H). [483] Step 2: N-methyl-4-nitro-N-(undeca-1,10-dien-6-yl)benzenesulfonamide (13-3) [484] A solution of undeca-1,10-dien-6-ol (20 g, 118.85 mmol, 1 eq), N-methyl-4-nitro- benzenesulfonamide (28.27 g, 130.74 mmol, 1.1 eq) and PPh3 (37.41 g, 142.62 mmol, 1.2 eq) was stirred in dry THF (200 mL) at 0 °C under N 2 . To this mixture was added dropwise DIAD (36.05 g, 178.28 mmol, 34.7 mL, 1.5 eq) in THF (30 mL) over a period of 0.5 hr. After addition, the resulting mixture was stirred at 20 °C 15.5 hr. After completion, the reaction mixture was quenched by H2O (150 mL) and then diluted with EtOAc (100 mL). The aqueous phase was extracted with EtOAc (150 mL * 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (330 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~10%) to give compound 13-3 (33.2 g, 90.59 mmol, 76.2% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 8.36 - 8.33 (m, 2H), 8.01 - 7.98 (m, 2H), 5.74 - 5.65 (m, 2H), 4.97 - 4.92 (m, 4H), 3.92 - 3.87 (m, 1H), 2.70 (s, 3H), 2.01 - 1.97 (m, 4H), 1.30 - 1.28 (m, 2H), 1.27 - 1.23 (m, 6H). [485] Step 3: 5-(N-methyl-4-nitrophenylsulfonamido)nonanedioic acid (13-4) [486] To a solution of N-methyl-4-nitro-N-(1-pent-4-enylhex-5-enyl)benzenesulfonami de (12.5 g, 34.11 mmol, 1 eq) in MeCN (150 mL) and CH2Cl2 (150 mL) was added RuCl3 (1.42 g, 6.82 mmol, 0.2 eq) at 20 °C. After addition, the mixture was stirred at this temperature for 0.5 hr, and then NaIO4 (36.48 g, 170.54 mmol, 5 eq) in H2O (200 mL) was added dropwise at 0 °C. The resulting mixture was stirred at 20 °C for 2.5 hr. After completion, the reaction mixture was neutralized to pH = 2~3 with aq.HCl (4 M). The aqueous phase was extracted with EtOAc (600 mL * 3). The combined organic phase successively was washed with saturated aqueous Na 2 S 2 O 3 (350 mL * 3) and saturated brine (350 mL * 2), dried over Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~50%, 2% AcOH in EtOAc) and prep-HPLC (column: YMC Triart C18250 * 50mm * 7um; mobile phase: [water (0.05%HCl)-ACN]; B%: 25%-55%, 18min) to give compound 13-4 (5.2 g, 12.92 mmol, 20.8% yield) as a light yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 11.98 (s, 2H), 8.41 - 8.38 (m, 2H), 8.07 - 8.05 (m, 2H), 3.76 - 3.74 (m, 1H), 2.67 (s, 3H), 2.16 - 2.11 (m, 4H), 1.35 - 1.22 (m, 8H). [487] Step 4: di(pentadecan-8-yl) 5-(N-methyl-4-nitrophenylsulfonamido)nonanedioate (13- 5) [488] A solution of 5-[methyl-(4-nitrophenyl)sulfonyl-amino]nonanedioic acid (5 g, 12.42 mmol, 1 eq) dissolved in CH2Cl2 (80 mL) were added EDCI (7.15 g, 37.27 mmol, 3 eq), TEA (3.77 g, 37.27 mmol, 5.2 mL, 3 eq) and DMAP (1.52 g, 12.42 mmol, 1 eq) at 0 °C under N 2 . After addition, the mixture was stirred at 25 °C for 1hr, and then pentadecan-8-ol (5.96 g, 26.09 mmol, 2.1 eq) in CH 2 Cl 2 (50 mL) was added dropwise. The resulting mixture was stirred at 25 °C for 15 hr. After completion, The reaction mixture was quenched by H2O (100 mL) and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (80 mL * 3). The combined organic phase was washed with brine (60 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~10% to give compound 13-5 (4.9 g, 5.89 mmol, 47.4% yield, 99% purity) as a yellow oil. LCMS [M+Na] + : 845.5; 1 H NMR (400 MHz, CDCl3) δ = 8.36 (d, J = 8.8 Hz, 2H), 8.01 (d, J = 8.8 Hz, 2H), 4.86 - 4.80 (m, 2H), 3.96 - 3.91 (m, 1H), 2.72 (s, 3H), 2.31 - 2.19 (m, 4H), 1.50 - 1.45 (m, 14H), 1.28 - 1.26 (m, 42H), 0.90 - 0.87 (m, 12H). [489] Step 5: di(pentadecan-8-yl) 5-(methylamino)nonanedioate (13-6) [490] To a solution of bis(1-heptyloctyl) 5-[methyl-(4-nitrophenyl)sulfonyl- amino]nonanedioate (4.9 g, 5.95 mmol, 1 eq) in DMF (40 mL) were added Cs2CO3 (3.88 g, 11.90 mmol, 2 eq) and benzenethiol (1.94 g, 17.61 mmol, 1.8 mL, 2.96 eq). The mixture was stirred at 25 °C for 5 hr. After completion, the reaction mixture was quenched by the addition of water (80 mL), and then extracted with EtOAc (100 mL * 3). The combined organic layers were washed with brine (60 mL * 3), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~60%) to give compound 13-6 (2.6 g, 4.07 mmol, 68.5% yield) as a yellow oil. 1H NMR (400 MHz, CDCl 3 ) δ = 4.90 - 4.84 (m, 2H), 2.47 - 2.45 (m, 1H), 2.40 (s, 3H), 2.32 - 2.29 (m, 4H), 1.67 - 1.63 (m, 4H), 1.51 - 1.45 (m, 12H), 1.43 - 1.27 (m, 40H), 0.90 - 0.87 (m, 12H). Step6: di(pentadecan-8-yl) 5-((((3- (dimethylamino)propyl)thio)carbonyl)(methyl)amino)nonanedioa te (CAT13) [491] To a solution of bis(1-heptyloctyl) 5-(methylamino)nonanedioate (1.5 g, 2.35 mmol, 1 eq) dissolved in dry CH2Cl2 (30 mL) were added TEA (713.7 mg, 7.05 mmol, 0.98 mL, 3 eq) and triphosgene (418.6 mg, 1.41 mmol, 0.6 eq) at 0 °C under N 2 . The resulting solution was stirred at 20 °C for 1 hr. The resulting reaction was concentrated under reduced pressure and kept under N 2 . To a solution of 3-(dimethylamino)propane-1-thiol (981.0 mg, 8.23 mmol, 3.5 eq) dissolved in dry THF (30 mL) was added NaOH (658.3 mg, 16.46 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution, carbamoyl chloride, dissolved in THF (20 mL), was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 2 hr. After completion, the reaction mixture was quenched by NH 4 Cl (60 mL) at 0°C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (60 mL * 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~12%, 5% NH 3 •H 2 O in Ethyl acetate) to afford compound CAT13 (1.05 g, 1.32 mmol, 56.2% yield, 98.5% purity) as a light yellow oil. LCMS [M+H] + : 783.6 1H NMR (400 MHz, CDCl 3 ) δ = 4.86 - 4.82 (m, 2H), 4.55 - 3.84 (m, 1H), 2.93 - 2.92 (m, 2H), 2.80 - 2.78 (m, 3H), 2.36 - 2.30 (m, 6H), 2.23 (s, 6H), 1.81 - 1.77 (m, 3H), 1.50 - 1.45 (m, 16H), 1.32 - 1.26 (m, 40H), 0.90 - 0.87 (m, 12H). Example 1.14: Synthesis of CAT14 [492] Step 1: N,N-bis(but-3-enyl)-4-nitro-benzenesulfonamide (14-2) [493] To a solution of 4-nitrobenzenesulfonamide (25 g, 123.65 mmol, 1 eq) and 4-bromobut- 1-ene (83.46 g, 618.24 mmol, 62.75 mL, 5 eq) in ACN (50 mL) were added Cs2CO3 (80.57 g, 247.30 mmol, 2 eq), TBAI (456.71 mg, 1.24 mmol, 0.01 eq) and KI (10.26 g, 61.82 mmol, 0.5 eq). The mixture was stirred at 90 °C for 12 hr. The reaction mixture was quenched by the addition of water (300 mL), and then extracted with EtOAc (500 mL × 3). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1) to give compound 14-2 (37 g, 119.21 mmol, 96.4% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 8.37-8.34 (m, 2H), 8.03-7.99 (m, 2H), 5.73-5.64 (m, 2H), 5.10-5.04 (m, 4H), 3.30-3.25 (m, 4H), 2.35-2.30 (m, 4H) [494] Step 2: N-but-3-enylbut-3-en-1-amine: (14-3) [495] To a solution of N,N-bis(but-3-enyl)-4-nitro-benzenesulfonamide (74 g, 238.43 mmol, 1 eq) and benzenethiol (52.54 g, 476.85 mmol, 48.65 mL, 2 eq) in DMF (200 mL) was added Cs 2 CO 3 (155.37 g, 476.85 mmol, 2 eq). The mixture was stirred at 25 °C for 12 hr under N 2 . The reaction mixture was quenched by the addition of water (1000 mL), and then extracted with EtOAc (1000 mL × 3). The combined organic layers were washed with brine (2000 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1) to give compound 14-3 (44 g, crude) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ =5.81-5.73 (m, 2H), 5.08-4.99 (m, 4H), 2.66 (t, J = 6.8 Hz, 4H), 2.26-2.20 (m, 4H), 1.39-1.36 (m, 1H) [496] Step 3: 3-(tritylthio)propanal: (14-4) [497] To a solution of triphenylmethanethiol (50 g, 180.90 mmol, 1 eq) in CH2Cl2 (300 mL) were added TEA (27.46 g, 271.35 mmol, 37.77 mL, 1.5 eq) and prop-2-enal (15.21 g, 271.35 mmol, 18.0 mL, 1.5 eq). The mixture was stirred at 20 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to give compound 3-tritylsulfanylpropanal (60 g, 180.47 mmol, 99.76% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ = 9.46 (s, 1H), 7.40-7.20 (m, 15H), 2.46-2.41 (m, 2H), 2.35- 2.29 (m, 2H) [498] Step 4: N-but-3-enyl-N-(3-tritylsulfanylpropyl)but-3-en-1-amine: ^14-5 ^ [499] To a solution of N-but-3-enylbut-3-en-1-amine (30 g, 239.60 mmol, 1 eq) and 3- tritylsulfanylpropanal (79.66 g, 239.60 mmol, 1 eq) in CH2Cl2 (100 mL) and MeOH (100 mL) were added NaBH 3 CN (30.11 g, 479.19 mmol, 2 eq) and AcOH (1.44 g, 23.96 mmol, 1.37 mL, 0.1 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched by the addition of water (300 mL), and then extracted with EtOAC (500 mL × 3). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1) to give compound N-but-3-enyl-N-(3- tritylsulfanylpropyl)but-3-en-1-amine (46 g, 104.15 mmol, 43.47% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.51-7.29 (m,15H), 5.86-5.79 (m, 2H), 5.12-5.03 (m, 4H), 2.53-2.45 (m, 6H), 2.28-2.20 (m, 6H), 1.63-1.57 (m, 2H) [500] Step 5: N-but-3-enyl-N-(3-tritylsulfanylpropyl)but-3-en-1-amine: (14-6) [501] To a solution of N-but-3-enyl-N-(3-tritylsulfanylpropyl)but-3-en-1-amine (30 g, 67.92 mmol, 1 eq) in CH 2 Cl 2 (100 mL) were added TFA (231.00 g, 2.03 mol, 150.00 mL, 29.83 eq) and triisopropylsilane (21.51 g, 135.85 mmol, 27.90 mL, 2 eq). The mixture was stirred at 25 °C for 6 hr. The reaction mixture was concentrated under reduced pressure to remove TFA. The residue was diluted with MeOH (100 mL) and extracted with PE ( 50 mL x 5). The MeOH layers was concentrated under reduced pressure to give crude product 14-6 (9.8 g, 49.16 mmol, 72.37% yield) as a yellow oil. [502] Step 6: 1-heptyloctyl 4-[3-[bis(but-3-enyl)amino]propylsulfanylcarbonyl-[4-(1- heptyloctoxy)-4-oxo-butyl]amino]butanoate: (CAT 14) [503] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (6 g, 9.84 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (50 mL) were added TEA (2.99 g, 29.51 mmol, 4.11 mL, 3 eq) and triphosgene (1.46 g, 4.92 mmol, 0.5 eq) at 0 °C under nitrogen atmosphere. The resulting solution was stirred at 20 °C under nitrogen atmosphere for 1 hr. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (2.75 g, 68.85 mmol, 7 eq) was dissolved in dry THF (100 mL) at 0 °C under nitrogen atmosphere, then 3-[bis(but-3-enyl)amino]propane-1-thiol (9.80 g, 49.18 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution,carbamoyl chloride dissolved in THF (50 mL) was added slowly under nitrogen atmosphere at 0 °C. The mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched with saturated aqueous NH 4 C1 (200 mL) and then diluted with EtOAC (300 mL). The aqueous phase was extracted with EtOAC (200 mL x 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 ) and Phenomenex Luna C8250*50mm*10um; mobile phase: [water (HCl)-MeOH]; B%: 80%-100%,10min to give compound CAT14 (240 mg, 284.46 umol, 23.76% yield, 99.01% purity) as a yellow oil. LCMS: [M+H] + : 836.2; 1H NMR (400 MHz, CDCl3) δ = 5.83-5.76 (m, 2H), 5.09-5.02 (m, 4H), 4.99-4.86 (m, 2H), 3.40-3.38 (m, 4H), 2.92 ( t, J = 7.2 Hz, 2H), 2.53-2.31 (m, 6H), 2.30-2.21 (m, 6H), 1.90-1.78 (m, 6H), 1.58-1.51 (m, 10H), 1.32-1.27 (m, 40H), 0.90-0.87 (m, 12H). Example 1.15: Synthesis of CAT15 [504] Step 1: 1-heptyloctyl 4-[3-[bis(3-hydroxypropyl)amino]propylsulfanylcarbonyl-[4-(1 - heptyloctoxy)-4-oxo-butyl]amino]butanoate: (CAT15) [505] A solution of 1-heptyloctyl 4-[3-[bis(but-3-enyl)amino]propylsulfanylcarbonyl-[4-(1- heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.8 g, 3.35 mmol, 1 eq) in CH2Cl2 (50 mL) and MeOH (50 mL) was cooled to −78 °C, and a stream of O 3 (15 psi) was bubbled into the reaction mixture until a light blue color became evident. Oxygen was then bubbled through the reaction mixture until the blue color disappeared, after 0.5 hr, the NaBH 4 (253.60 mg, 6.70 mmol, 2 eq) was added at 0 °C. Then, the mixture was stirred at 25 °C for 2 hr. The reaction mixture was quenched with saturated aqueous NH4C1 (100 mL) and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL x 3). The combined organic phase was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue, and was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1) and purified by column: Welch Ultimate XB-SiOH 250*50*10um; mobile phase: [Hexane-EtOH]; B%: 0%-20%, 20 min to give CAT15 (141 mg, 166.19 umol, 77.86% yield, 99.4% purity) as a yellow oil. LCMS: [M+H] + : 843.7; 1 H NMR (400 MHz, CDCl3) δ = 4.90-4.65 (m, 2H), 3.82-3.65 (m, 4H), 3.45-3.25 (m, 4H), 3.00-2.90 (m, 6H), 2.38-2.20 (m, 4H), 2.00-1.75 (m, 10H), 1.70-1.55 (m, 10H), 1.30-1.15 (m, 40H), 0.96-0.86 (m, 12H). Example 1.16: Synthesis of CAT16
[506] Step 1: methyl 3-(tosyloxy)cyclobutanecarboxylate (16-2) [507] To a solution of methyl 3-hydroxycyclobutanecarboxylate (15.0 g, 115 mmol, 1 eq) in DCM (250 mL) were added TEA (23.3 g, 231 mmol, 32.1 mL, 2 eq), DMAP (704 mg, 5.76 mmol, 0.05 eq) and TosCl (26.4 g, 138 mmol, 1.2 eq) at 0 °C under N2. The mixture was stirred at 20 °C for 16 hours. The reaction mixture was diluted with DCM (100 mL) and washed with brine (80 mL × 3), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Ethyl acetate : Petroleum ether: 0 ~ 25%). Compound 16-2 (22.3 g, 78.4 mmol, 68% yield) was obtained as a light yellow oil. [508] Step 2: methyl 3-(tritylthio)cyclobutanecarboxylate (16-3) [509] To a solution of methyl 3-(p-tolylsulfonyloxy)cyclobutanecarboxylate (26.0 g, 91.4 mmol, 1 eq) in DMF (300 mL) were added triphenylmethanethiol (37.9 g, 137 mmol, 1.5 eq) and Cs 2 CO 3 (59.6 g, 183 mmol, 2 eq). The mixture was stirred at 20 °C for 12 hours. The reaction mixture was quenched by H2O (100 mL) and then diluted with ethyl acetate (200 mL). The aqueous phase was extracted with ethyl acetate (200 mL × 2). The combined organic phase was washed with brine (200 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated under vacuum to give a crude product. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~15% Ethyl acetate/Petroleum ethergradient @ 40 mL/min). Compound 16-3 (35.0 g, 90.1 mmol, 98% yield) was obtained as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ : 7.28 - 7.17 (m, 15H), 3.59 (s, 3H), 3.35 - 3.30 (m, 1H), 3.00 - 2.93 (m, 1H), 2.19 - 2.13 (m, 2H), 2.04 - 1.99 (m, 2H). [510] Step 3: 3-(tritylthio)cyclobutanecarboxylic acid (16-4) To a mixtuire of methyl 3-tritylsulfanylcyclobutanecarboxylate (25.0 g, 64.4 mmol, 1 eq) in THF (200 mL) was added LiOH·H 2 O (8.10 g, 193.1 mmol, 3 eq), the reaction mixture was stirred at 40 °C for 12 hours. The reaction mixture was adjusted to pH 5 with 4 M HCl, then the reaction mixture was extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (200 mL × 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 50% Ethyl acetate/Petroleum ethergradient @ 40 mL/min). Compound 16-4 (17.8 g, 47.5 mmol, 74% yield) was obtained as a yellow solid. [511] 1 H NMR (400 MHz, DMSO-d 6 ) δ: 12.07 (s, 1H), 7.38 - 7.27 (m, 12H), 7.26 - 7.19 (m, 3H), 3.21 - 3.13 (m, 1H), 2.87 - 2.80 (m, 1H), 2.02 - 1.81 (m, 4H). [512] Step 4: 1,3-bis(3-(tritylthio)cyclobutyl)urea (16-5) [513] To a mixture of 3-tritylsulfanylcyclobutanecarboxylic acid (10.0 g, 26.7 mmol, 1 eq) and TEA (4.05 g, 40.1 mmol, 5.57 mL, 1.5 eq) in toluene (100 mL) was added DPPA (8.82 g, 32.0 mmol, 6.94 mL, 1.2 eq) at 20 °C, then the reaction mixture was heated to 100 °C and stirred for 4 hours. The reaction mixture was quenched by the addition of 10% NaOH solution, then the reaction mixture was filtered and the cake filter was concentrated under vacuum to give crude product. The reaction residue was used directly for the next step. Compound 16-5 (14.0 g, crude) was obtained as a white solid. LCMS: [M+H] + : 717.3 [514] Step 5: 3-(tritylthio)cyclobutanamine (16-6) [515] 1,3-bis(3-tritylsulfanylcyclobutyl)urea (2.00 g, 2.79 mmol, 1 eq), KOH (313 mg, 5.58 mmol, 2 eq) were taken up into a microwave tube in ethylene glycol (10 mL). The sealed tube was heated at 150 °C for 1 hour under microwave. The reaction mixture was quenched by H2O (30 mL) and extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give a crude product. The reaction residue was used directly for the next step. Compound 16- 6 (10.0 g, crude) was obtained as a brown oil. LCMS: [M+H] + : 346.1 [516] Step 6: N,N-dimethyl-3-(tritylthio)cyclobutanamine (16-7) [517] To a mixture of 3-tritylsulfanylcyclobutanamine (10.0 g, 28.9 mmol, 1 eq) in MeOH (10 mL) were added (HCHO)n (10.0 g, 145 mmol, 5 eq), AcOH (3.48 g, 57.9 mmol, 3.31 mL, 2 eq), NaBH 3 CN (3.64 g, 57.9 mmol, 2 eq) successively at 0 °C, then the reaction mixture was stirred at 25 °C for 3 hours. The reaction mixture was quenched by the addition of saturated NH 4 Cl solution (20 mL) and extracted by ethyl acetate (30 mL × 3), then the combined organic phase was dried by anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The reaction residue was used directly for the next step. Compound 16-7 (6.00 g, crude) was obtained as a yellow oil. LCMS: [M+H] + : 374.3 [518] Step 7: 3-(dimethylamino)cyclobutanethiol (16-8) [519] To a solution of N,N-dimethyl-3-tritylsulfanyl-cyclobutanamine (6.00 g, 16.1 mmol, 1 eq) in DCM (20 mL) were added triisopropylsilane (5.09 g, 32.1 mmol, 6.60 mL, 2 eq) and TFA (4.62 g, 40.5 mmol, 3 mL, 2.52 eq) at 0 °C. The mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to obtained a residue, then the reaction residue was added to MeOH (20 mL) and washed with Petroleum ether (3 × 10 mL), concentrated under vacuum. The reaction residue was used directly for the next step. Compound 16-8 (1.40 g, crude) was obtained as a yellow oil. [520] Step 8: di(pentadecan-8-yl) 4,4'-((((3- (dimethylamino)cyclobutyl)thio)carbonyl)azanediyl)dibutanoat e (CAT16) [521] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.28 mmol, 1 eq) dissolved in dry DCM (30 mL) were added TEA (995 mg, 9.84 mmol, 1.37 mL, 3 eq) and bis(trichloromethyl) carbonate (486 mg, 1.64 mmol, 0.5 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction mixture was concentrated under reduced pressure and kept under N 2 . To a solution of 3- (dimethylamino)cyclobutanethiol (1.72 g, 13.1 mmol, 4 eq) in dry THF (30 mL) was added NaOH (918 mg, 22.9 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution was added carbamoyl chloride via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 1 hour. The reaction mixture was quenched with saturated aqueous NH 4 C1 (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give residue. The residue was purified by column chromatography (SiO 2 , Petroleum ether/Ethyl acetate = 50/1 to 3/1). Compound CAT16 (1.60 g, 2.09 mmol, 64% yield) was obtained as a yellow oil. LCMS: [M+H] + : 767.6 1H NMR (400 MHz, CDCl3) δ : 4.93 - 4.83 (m, 2H), 3.86 - 3.82 (m, 1H), 3.34 - 3.32 (m, 4H), 3.00 -2.90 (m, 1H), 2.54 - 2.42 (m, 2H), 2.33 - 2.30 (m, 4H), 2.13 (s, 6H), 1.93 - 1.80 (m, 6H), 1.60 - 1.44 (m, 8H), 1.30 - 1.20 (m, 40H), 0.98 - 0.78 (m, 12H). Example 1.17: Synthesis of CAT17 [522] Step 1: (1-methylpyrrolidin-3-yl) 4-methylbenzenesulfonate (17-2) [523] To a solution of 1-methylpyrrolidin-3-ol (20 g, 197.73 mmol, 1 eq) in CH 2 Cl 2 (300 mL) was added TosCl (45.24 g, 237.28 mmol, 1.2 eq), TEA (60.03 g, 593.20 mmol, 82.57 mL, 3 eq) and DMAP (12.08 g, 98.87 mmol, 0.5 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched with saturated aqueous water (300 mL) and then diluted with CH 2 Cl 2 (100 mL). The aqueous phase was extracted with CH 2 Cl 2 (100 mL x 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1) to give compound 17-2 (39 g, 152.74 mmol, 77.25% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.79 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 5.10-4.96 (m, 1H), 2.70-2.58 (m, 2H), 2.44 (s, 3H), 2.38-2.32 (m, 2H), 2.31 (s, 3H), 2.18-2.12 (m, 1H), 1.95-1.90 (m, 1H) [524] Step 2: 1-methyl-3-tritylsulfanyl-pyrrolidine: (17-3) [525] To a solution of (1-methylpyrrolidin-3-yl) 4-methylbenzenesulfonate (15 g, 58.75 mmol, 1 eq) and triphenylmethanethiol (19.48 g, 70.50 mmol, 1.2 eq) in DMF (100 mL) was added K 2 CO 3 (24.36 g, 176.24 mmol, 3 eq). The mixture was stirred at 80 °C for 6 hr. The reaction mixture was quenched with saturated aqueous NH4C1 (100 mL) and then diluted with EtOAc (300 mL). The aqueous phase was extracted with EtOAc (100 mL x 3). The combined organic phase was washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 0/1) to give compound 17-3(20 g, 55.63 mmol, 94.69% yield) as a yellow oil 1 H NMR (400 MHz, CDCl 3 ) δ = 7.60-7.30 (m, 15H), 2.65-2.48 (m, 4H), 2.40-2.35 (m, 3H), 2.28-1.60 (m, 3H) [526] Step 3: 1-methylpyrrolidine-3-thiol: (17-4) [527] To a solution of 1-methyl-3-tritylsulfanyl-pyrrolidine (20 g, 55.63 mmol, 1 eq) in CH2Cl2 (300 mL) were added TFA (46.20 g, 405.18 mmol, 30.00 mL, 7.28 eq) and triisopropylsilane (26.43 g, 166.89 mmol, 34.28 mL, 3 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to remove TFA. The residue was diluted with MeOH (100 mL) and extracted with PE ( 50 mL x 5). The MeOH layers was concentrated under reduced pressure to give compound 17-4 (5.4 g, 46.07 mmol, 82.82% yield) as a yellow oil. [528] Step 4: 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-(1-methylpyrrolidin-3- yl)sulfanylcarbonyl-amino]butanoate: (CAT17) [529] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.5 g, 2.46 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (40 mL) were added TEA (746.47 mg, 7.38 mmol, 1.03 mL, 3 eq) and bis(trichloromethyl) carbonate (364.85 mg, 1.23 mmol, 0.5 eq) at 0 ° C under nitrogen atmosphere. The resulting solution was stirred at 20 °C under nitrogen atmosphere for 1 hr. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (688.47 mg, 17.21 mmol, 7 eq) was dissolved in THF (50 mL) at 0 °C under nitrogen atmosphere, then 1-methylpyrrolidine-3-thiol (1.44 g, 12.30 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride dissolved in THF (10 mL) was added slowly under nitrogen atmosphere at 0 °C. The mixture was stirred at 25 °C for 0.5 hr. The reaction mixture was quenched with saturated aqueous NH 4 C1 (100 mL) and then diluted with EtOAc (200 mL). The aqueous phase was extracted with EtOAc (100 mL x 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 0/1 and purified by column: Welch Ultimate XB-SiOH 250*50*10 μm; mobile phase: [Hexane-EtOH]; B%: 0%-13%,10 min to give CAT17 (395 mg, 516.03 μmol, 64.78% yield, 98.4% purity) as a yellow oil. LCMS: [M+H] + : 753.8 1 H NMR (400 MHz, CDCl 3 ) δ = 4.90-4.80 (m, 2H), 4.00-3.90 (m, 1H), 3.50-3.38 (m, 4H), 3.05-2.90 (m, 1H), 2.82-2.75 (m, 1H), 2.68-2.60 (m, 1H), 2.48-2.40 (m, 2H), 2.37 (s, 3H), 2.30 (t, J = 7.2 Hz, 4H), 1.98-1.70 (m, 5H), 1.52-1.48 (m, 8H), 1.32-1.24 (m, 40H), 0.92-0.86 (m, 12H) Example 1.18: Synthesis of CAT18
[530] Step 1: 4-(4-nitro-N-(4-oxo-4-(pentadecan-8-yloxy)butyl)phenylsulfon amido)butanoic acid (18-2) [531] A mixture of 4-[3-carboxypropyl-(4-nitrophenyl)sulfonyl-amino]butanoic acid (25 g, 66.78 mmol, 1.04 eq) , pentadecan-8-ol (8.09 g, 35.40 mmol, 0.55 eq), EDCI (6.79 g, 35.40 mmol, 0.55 eq), DMAP (786.38 mg, 6.44 mmol, 0.1 eq) and DIPEA (4.99 g, 38.62 mmol, 6.7 mL, 0.6 eq) in CH 2 Cl 2 (200 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 25 °C for 16 hr under N2 atmosphere. After completion, the reaction mixture was quenched by H 2 O (150 mL) and then diluted with EtOAc (150 mL). The aqueous phase was extracted with EtOAc (150 mL * 3). The combined organic phase was washed with brine (200 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, EtOAc/PE: 0~10%) to give compound 18-2 (12.8 g, 21.89 mmol, 34.0% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ = 8.37 - 8.35 (m, 2H), 8.02 - 7.99 (m, 2H), 4.90 - 4.84 (m, 1H), 3.27 - 3.23 (m, 4H), 2.43 (t, J = 7.2 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 1.91 - 1.86 (m, 4H), 1.52 - 1.50 (m, 4H), 1.27 - 1.25 (m, 20H), 0.89 - 0.86 (m, 6H). [532] Step 2: tert-butyl 4-(4-nitro-N-(4-oxo-4-(pentadecan-8- yloxy)butyl)phenylsulfonamido)butanoate (18-3) [533] To a solution of 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-(4-nitrophenyl)sulfonyl- amino]butanoic acid (12.5 g, 21.38 mmol, 1 eq) in THF (150 mL) was added dropwise 2-tert- butyl-1,3-diisopropyl-isourea (12.85 g, 64.13 mmol, 3 eq) at 25 °C under N 2 . After addition, the mixture was stirred at 50 °C for 16 hr. After addition, the reaction mixture was concentrated under reduced pressure to remove solvent to give a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, EtOAc/PE: 0~10%) to give compound 3 (11.6 g, 18.10 mmol, 84.7% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.37 - 8.34 (m, 2H), 8.02 - 7.99 (m, 2H), 4.88 - 4.85 (m, 1H), 3.26 - 3.21 (m, 4H), 2.32 (t, J = 7.2 Hz, 2H), 2.26 (t, J = 7.2 Hz, 2H), 1.91 - 1.79 (m, 4H), 1.52 - 1.50 (m, 4H), 1.45 (s, 9H), 1.30 - 1.25 (m, 20H), 0.90 - 0.86 (m, 6H). [534] Step 3: tert-butyl 4-((4-oxo-4-(pentadecan-8-yloxy)butyl)amino)butanoate (18-4) [535] To a solution of 1-heptyloctyl 4-[(4-tert-butoxy-4-oxo-butyl)-(4-nitrophenyl)sulfonyl- amino]butanoate (8 g, 12.48 mmol, 1 eq) in DMF (50 mL) were added Cs 2 CO 3 (8.13 g, 24.97 mmol, 2 eq) and benzenethiol (3.73 g, 33.85 mmol, 3.45 mL, 2.71 eq). The mixture was stirred at 25 °C for 16 hr under N2. After completion, the reaction mixture was quenched by the addition of H 2 O (120 mL), and then extracted with EtOAc (150 mL * 3). The combined organic layers were washed with brine (60 mL * 3), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, EtOAc/PE: 0~35%) to give compound 18-4 (4.1 g, 9.00 mmol, 72.1% yield) as yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 1H), 2.65 - 2.61 (m, 4H), 2.35 (t, J = 7.2 Hz, 2H), 2.27 (t, J = 7.2 Hz, 2H), 1.80 - 1.76 (m, 4H), 1.52 - 1.48 (m, 4H), 1.44 (s, 9H), 1.30 - 1.26 (m, 20H), 0.90 - 0.86 (m, 6H). [536] Step 4: tert-butyl 4-((4-oxo-4-(pentadecan-8-yloxy)butyl)(((3-(pyrrolidin-1- yl)propyl)thio)carbonyl)amino)butanoate (18-5) [537] To a solution of 1-heptyloctyl 4-[(4-tert-butoxy-4-oxo-butyl)amino]butanoate (1.5 g, 3.29 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (30 mL) were added TEA (999.2 mg, 9.87 mmol, 1.4 mL, 3 eq) and triphosgene (586.1 mg, 1.97 mmol, 0.6 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure and kept under N2. To a solution of 3-pyrrolidin-1-ylpropane-1-thiol (2.99 g, 11.52 mmol, 3.5 eq, TFA) dissolved in dry THF (30 mL) was added NaOH (921.63 mg, 23.04 mmol, 7 eq) at 0 °C under N2. To this resulting solution,carbamoyl chloride, dissolved in THF (20 mL), was added via syringe slowly under N 2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hr. After completion, the reaction mixture was quenched by NH4Cl (60 mL) at 0 °C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (60 mL * 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~13%, 5% NH3•H2O in EtOAc) to give compound 18-5 (1.05 g, 1.26 mmol, 41.5% yield, 75% purity) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ = 4.89 - 4.86 (m, 1H), 2.96 - 2.92 (m, 2H), 2.55 - 2.51 (m, 8H), 2.32 -2.30 (m, 2H), 2.26 - 2.23 (m, 2H), 1.86 - 1.82 (m, 6H), 1.80 - 1.78 (m, 4H), 1.53 - 1.50 (m, 4H), 1.45 (s, 9H), 1.30 - 1.26 (m, 20H), 1.18 - 1.16 (m, 2H), 0.90 - 0.86 (m, 6H). [538] Step 5: 4-((4-oxo-4-(pentadecan-8-yloxy)butyl)(((3-(pyrrolidin-1- yl)propyl)thio)carbonyl)amino)butanoic acid (18-6) [539] To a solution of 1-heptyloctyl 4-[(4-tert-butoxy-4-oxo-butyl)-(3-pyrrolidin-1- ylpropylsulfanylcarbonyl)amino]butanoate (950 mg, 1.52 mmol, 1 eq) in CH 2 Cl 2 (10 mL) was added TFA (3.44 g, 30.19 mmol, 2.5 mL) under N2. The mixture was stirred at 25 °C for 16 hr . After completion, the reaction mixture was concentrated under reduced pressure to remove solvent to give compound 18-6 (1.02 g, crude, TFA) as a yellow oil. The crude product was used in the next step without further purification. [540] Step 6: (Z)-non-2-en-1-yl 4-((4-oxo-4-(pentadecan-8-yloxy)butyl)(((3-(pyrrolidin-1- yl)propyl)thio)carbonyl)amino)butanoate ( CAT18) [541] A mixture of 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-(3-pyrrolidin-1- ylpropylsulfanylcarbonyl)amino]butanoic acid (1.0 g, 1.46 mmol, 1 eq, TFA) , (Z)-non-2-en- 1-ol (415.4 mg, 2.92 mmol, 2 eq) , EDCI (419.9 mg, 2.19 mmol, 1.5 eq) , DMAP (17.8 mg, 0.15 mmol, 0.1 eq) and DIPEA (566.1 mg, 4.38 mmol, 0.76 mL, 3 eq) in CH2Cl2 (20 mL) was degassed and purged with N23 times, and then the mixture was stirred at 25 °C for 3 hr under N2 atmosphere. After completion, the reaction mixture was quenched with H2O (60 mL) and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL * 3). The combined organic phase was washed with brine (60 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~13%, 5% NH 3 •H 2 O in EtOAc) to yield compound CAT18 (413 mg, 0.58 mmol, 40.5% yield, 98.1% purity) as a light yellow oil. LCMS [M+H] + : 695.5 1 H NMR (400 MHz, CDCl3) δ = 5.68 - 5.62 (m, 1H), 5.54 - 5.51 (m, 1H), 4.89 - 4.86 (m, 1H), 4.64 (d, J = 6.8 Hz, 2H), 3.39 - 3.37 (m, 4H), 2.94 (t, J = 7.2 Hz, 2H), 2.52 - 2.50 (m, 6H), 2.36 - 2.34 (m, 4H), 2.12- 2.09 (m, 2H), 1.84 - 1.79 (m, 6H), 1.78 - 1.76 (m, 4H), 1.52 - 1.50 (m, 4H), 1.40 - 1.35 (m, 2H), 1.30 - 1.25 (m, 26H), 0.90 - 0.87 (m, 9H). Example 1.19: Synthesis of CAT19 [542] Step 1: tert-butyl 4-hydroxyazepane-1-carboxylate (19-2) [543] To a mixture of tert-butyl 4-oxoazepane-1-carboxylate (30.0 g, 141 mmol, 1 eq) in THF (300 mL) was added LiAlH 4 (5.87 g, 155 mmol, 1.1 eq) in potrions at 0 °C, then the reaction mixture was stirred at the same temperature for 2 h. The reaction mixture was quenched with H 2 O (5.8 mL), aq.NaOH (17.4 mL, 4M), H 2 O (5.8 mL) successively at 0 °C. Then, anhydrous Na2SO4 (20.0 g) was added to the mixture which was stirred at the same temperature for 0.5 h. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give a crude product. The reaction residue was used directly for the next step. Compound 19-2 (30.0 g, crude) was obtained as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ : 4.50 (t, J = 4.0 Hz, 1H), 3.69 - 3.55 (m, 1H), 3.31 - 3.05 (m, 4H), 1.84 - 1.70 (m, 2H), 1.70 - 1.41 (m, 2H), 1.39 (s, 9H). [544] Step 2: tert-butyl 4-(tosyloxy)azepane-1-carboxylate (19-3) [545] To a solution of tert-butyl 4-hydroxyazepane-1-carboxylate (30.0 g, 139 mmol, 1 eq) in DCM (500 mL) were added TEA (42.3 g, 418 mmol, 58.2 mL, 3 eq), DMAP (8.51 g, 69.7 mmol, 0.5 eq) and TosCl (39.9 g, 209 mmol, 1.5 eq) successively, then the mixture was stirred at 25 °C for 5 h. The reaction mixture was quenched by the addition of water (100 mL) and extracted with DCM (100 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated under vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate/Petroleum ethergradient @ 100 mL/min). Compound 19-3(43.0 g, 116 mmol, 84% yield) was obtained as a brown oil. LCMS: [M-Boc] + : 270.0; 1 H NMR (400 MHz, CDCl3) δ : 7.80 - 7.75 (m, 2H), 7.35 - 7.32 (m, 2H), 4.75 - 4.59 (m, 1H), 3.60 - 3.36 (m, 2H), 3.31 - 3.23 (m, 2H), 2.45 (s, 3H), 1.93 - 1.81 (m, 4H), 1.78 - 1.65 (m, 2H), 1.43 (s, 9H). [546] Step 3: tert-butyl 4-(tritylthio)azepane-1-carboxylate (19-4) [547] To a solution of tert-butyl 4-(p-tolylsulfonyloxy)azepane-1-carboxylate (21.0 g, 56.8 mmol, 1 eq) and triphenylmethanethiol (20.4 g, 73.9 mmol, 1.3 eq) in DMF (200 mL) was added Cs2CO3 (37.0 g, 114 mmol, 2 eq). The mixture was stirred at 80 °C for 6 h. The reaction mixture was quenched by the addition of water (100 mL) and extracted with ethyl acetate (150 mL × 3). The combined organic phase was washed with brine (200 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated under vacuum to give residue. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 30% Ethyl acetate/Petroleum ethergradient @ 100 mL/min). Compound 19-4(21.0 g, 44.3 mmol, 39% yield) was obtained as a yellow oil. LCMS: [M+Na] + : 496.2 [548] Step 4: 4-(tritylthio)azepane (19-5) [549] To a solution of tert-butyl 4-tritylsulfanylazepane-1-carboxylate (20.0 g, 42.2 mmol, 1 eq) in DCM (200 mL) was added TFA (61.6 g, 540 mmol, 40.0 mL, 12.8 eq), the reaction mixture was stirred at 20 °C for 3 h. The reaction mixture was concentrated under vacuum to obtain a brown oil. The reaction residue was used directly for the next step. Compound 19-5 (27.0 g, crude, TFA) was obtained as a brown oil. LCMS: [M+H] + : 374.1; [550] Step 5: 3-(tritylthio)cyclobutanamine (19-6) [551] To a mixture of 4-tritylsulfanylazepane (10.0 g, 20.5 mmol, 1 eq, TFA) in MeOH (60 mL) were added (HCHO)n (10.0 g, 20.5 mmol, 1 eq), KOAc (3.02 g, 30.8 mmol, 1.5 eq) and NaBH3CN (2.58 g, 41.0 mmol, 2 eq) at 0 °C successively, then the reaction was stirred at 20 °C for 3 h. The reaction mixture was quenched by the addition of saturated NH 4 Cl solution (20 mL) and extracted by ethyl acetate (30 mL × 3), then the combined organic phase was dried by anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 20% Dichloromethane : Methanol gradient @ 80 mL/min). Compound 19-6 (4.30 g, 11.1 mmol, 54% yield) was obtained as a yellow oil. LCMS: [M+H] + : 388.2; [552] Step 6: 1-methylazepane-4-thiol (19-7) [553] To a solution of 1-methyl-4-tritylsulfanyl-azepane (4.30 g, 11.1 mmol, 1 eq) in DCM (40 mL) were added triisopropylsilane (3.51 g, 22.2 mmol, 4.56 mL, 2 eq) and TFA (9.93 g, 87.1 mmol, 6.45 mL, 7.85 eq) at 0 °C. The mixture was stirred at 25 °C for 5 h. The reaction mixture was concentrated under reduced pressure to obtaine a residue, then the reaction residue was added to MeOH (20 mL) and washed with Petroleum ether three times (3 × 10 mL), concentrated under vacuum. The reaction residue was used directly for the next step. Compound 19-7 (2.10 g, crude) was obtained as a brown oil. [554] Step 7: di(pentadecan-8-yl) 4,4'-((((1-methylazepan-4- yl)thio)carbonyl)azanediyl)dibutanoate ( CAT19) [555] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.50 g, 2.46 mmol, 1 eq) dissolved in dry DCM (30 mL) were added TEA (a746 mg, 7.38 mmol, 1.03 mL, 3 eq) and bis(trichloromethyl) carbonate (320 mg, 1.08 mmol, 4.39e-1 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 h. The resulting reaction was concentrated under reduced pressure and kept under N 2 . To a solution of 1-methylazepane-4- thiol (1.43 g, 9.84 mmol, 4 eq) in dry THF (30 mL) was added NaOH (688 mg, 17.2 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution was added carbamoyl chloride via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 1 h. The reaction mixture was quenched with saturated aqueous NH 4 C1 (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated under vacuum to give residue. The residue was purified by column chromatography (SiO 2 , Petroleum ether/Ethyl acetate = 10/1 to 2/1). Compound CAT19 (700 mg, 0.896 mmol, 36% yield) was obtained as a yellow oil. LCMS: [M+H] + : 781.5; 1H NMR (400 MHz, CDCl3) δ: 4.90 - 4.84 (m, 2H), 3.79 - 3.62 (m, 1H), 3.46 - 3.27 (m, 4H), 2.77 - 2.48 (m, 4H), 2.36 (s, 3H), 2.33 - 2.29 (m, 4H), 2.20 - 2.06 (m, 2H), 1.94 - 1.86 (m, 4H), 1.82 - 1.74 (m, 2H), 1.68 - 1.63 (m, 2H), 1.53 - 1.50 (m, 8H), 1.33 - 1.22 (m, 40H), 0.95 - 0.86 (m, 12H). Example 1.20: Synthesis of CAT20
[556] Step 1: 1-ethyl-4-(tritylthio)azepane (20-2) [557] To a mixture of 4-tritylsulfanylazepane (10.0 g, 20.5 mmol, 1 eq, TFA) in MeOH (10 mL) were added KOAc (3.02 g, 30.8 mmol, 1.5 eq), MeCHO (4.52 g, 41.0 mmol, 5.75 mL, 40% purity, 2 eq) and NaBH3CN (2.58 g, 41.0 mmol, 2 eq) successively, then the reaction mixture was stirred at 20 °C for 3 hours. The reaction mixture was quenched by the addition of saturated NH4Cl solution (20 mL) and extracted by ethyl acetate (30 mL × 3), then the combined organic phase was dried by anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 10/1 to 2/1). Compound 20-2(8.00 g, crude) was obtained as a yellow oil. LCMS: [M+H] + : 402.2 [558] Step 2: 1-ethylazepane-4-thiol (20-3) [559] To a solution of 1-ethyl-4-tritylsulfanyl-azepane (8.00 g, 19.9 mmol, 1 eq) in DCM (40 mL) were added triisopropylsilane (6.31 g, 39.8 mmol, 8.18 mL, 2 eq) and TFA (17.8 g, 156 mmol, 11.6 mL, 7.85 eq) at 0 °C. The mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to obtained a residue, then the reaction residue was added to MeOH (20 mL) and washed with Petroleum ether three times (3 × 10 mL), and concentrated under vacuum. The reaction residue was used directly for the next step. Compound 20-3 (2.30 g, crude) was obtained as a brown oil. [560] Step 3: di(pentadecan-8-yl) 4,4'-((((1-ethylazepan-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT20) [561] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.28 mmol, 1 eq) dissolved in dry DCM (30 mL) were added TEA (995 mg, 9.84 mmol, 1.37 mL, 3 eq) and bis(trichloromethyl) carbonate (300 mg, 1.01 mmol, 3.08e-1 eq) at 0 °C under N 2 . The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure and kept under N2. To a solution of 1-ethylazepane- 4-thiol (2.09 g, 13.1 mmol, 4 eq) in dry THF (30 mL) was added NaOH (918 mg, 23.0 mmol, 7 eq) at 0 °C under N2. To this resulting solution was added carbamoyl chloride via syringe slowly under N 2 at 0 °C. The resulting solution was stirred at 20 °C for 1 hour. The reaction mixture was quenched with saturated aqueous NH4C1 (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 10/1 to 2/1). Compound CAT20 (1.80 g, 2.26 mmol, 69% yield) was obtained as a yellow oil. LCMS: [M+H] + : 796.4; 1H NMR (400 MHz, CDCl 3 ) δ : 4.90 - 4.84 (m, 2H), 3.70 - 3.63 (m, 1H), 3.44 – 3.29 (m, 4H), 2.84 - 2.70 (m, 2H), 2.62 - 2.52 (m, 2H), 2.34 - 2.27 (m, 4H), 2.18 - 2.07 (m, 2H), 1.96 - 1.73 (m, 10H), 1.53 - 1.50 (m, 8H), 1.32 - 1.25 (m, 40H), 1.08 (t, J = 7.2 Hz, 3H), 0.91 - 0.86 (m, 12H). Example 1.21: Synthesis of CAT21
[562] Step 1: tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (21-2) [563] To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (50 g, 248.43 mmol, 1 eq) in CH 2 Cl 2 (500 mL) were added TEA (50.28 g, 496.86 mmol, 69.2 mL, 2 eq), DMAP (1.52 g, 12.42 mmol, 0.05 eq) and TosCl (71.04 g, 372.65 mmol, 1.5 eq) at 0 °C under N2. The mixture was stirred at 20 °C for 16 hr. After completion, the reaction mixture was diluted with CH2Cl2 (300 mL) and washed with brine (300 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (220 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~25%) to give compound 21-2 (82.6 g, 232.38 mmol, 91.8% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ = 7.80 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.70 - 4.65 (m, 1H), 3.59 - 3.57 (m, 2H), 3.28 - 3.23 (m, 2H), 2.45 (s, 3H), 1.77 - 1.74 (m, 2H), 1.70 - 1.67 (m, 2H), 1.43 (s, 9H). [564] Step 2: tert-butyl 4-(tritylthio)piperidine-1-carboxylate (21-3) [565] A mixture of tert-butyl 4-(p-tolylsulfonyloxy)piperidine-1-carboxylate (40 g, 112.53 mmol, 1 eq), triphenylmethanethiol (37.32 g, 135.04 mmol, 1.2 eq), NaI (843.39 mg, 5.63 mmol, 0.05 eq), Cs 2 CO 3 (55.00 g, 168.80 mmol, 1.5 eq) in DMF (300 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 50 °C for 3 hr under N2 atmosphere. After the addition, the reaction mixture was quenched with H 2 O (600 mL) and then diluted with EtOAc (500 mL). The aqueous phase was extracted with EtOAc (500 mL * 3). The combined organic phase was washed with brine (500 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a crude product. The crude product was purified by flash silica gel chromatography (330 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~5%) to give compound 21-3 (75.8 g, 164.91 mmol, 75.1% yield) as a yellow oil. 1 H NMR (400 MHz, CD3OD-d4) δ = 7.33 - 7.31 (m, 5H), 7.29 - 7.26 (m, 10H), 3.70 - 3.67 (m, 2H), 2.69 - 2.64 (m, 2H), 2.40 - 2.35 (m, 1H), 1.57 - 1.48 (m, 2H), 1.45 (s, 9H), 1.42 -1.34 (m, 2H). [566] Step 3: 4-(tritylthio)piperidine (21-4) [567] To a solution of tert-butyl 4-tritylsulfanylpiperidine-1-carboxylate (75 g, 163.17 mmol, 1 eq) in DCM (500 mL) was added TFA (154.00 g, 1.35 mol, 100 mL, 8.28 eq) at 25 °C under N2. After addition, the mixture was stirred at 25 °C for 5 hr. After completion, the mixture was concentrated in vacuo. Most of the TFA was removed by rotary evaporation, and the residual TFA was co‐evaporated with MeOH. The residue was triturated with PE (500 mL) at 25 o C for 0.5 hr. The residue mixture was filtered and the filter cake was washed with PE (100 mL*2). The filter cake was concentrated in vacuum to give compound 21-4 (56.8 g, crude, TFA) as a white solid. 1 H NMR (400 MHz, CDCl3) δ = 9.00 - 8.85 (m, 1H), 7.41 - 7.38 (m, 6H), 7.23 - 7.20 (m, 6H), 7.19 - 7.13 (m, 3H), 3.05 - 3.03 (m, 2H), 2.64 - 2.63 (m, 2H), 2.36 - 2.32 (m, 1H), 1.54 - 1.42 (m, 4H). [568] Step 4: 1-isopropyl-4-(tritylthio)piperidine (21-5) [569] To a solution of 4-tritylsulfanylpiperidine (15 g, 31.68 mmol, 1 eq, TFA) in MeCN (150 mL) were added K2CO3 (13.13 g, 95.03 mmol, 3 eq) and 2-iodopropane (5.92 g, 34.84 mmol, 3.48 mL, 1.1 eq). The mixture was stirred at 60 °C for 16 hr. After completion, the reaction mixture was filtered and the filtrate was concentrated in a vacumu to give a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, MeOH/EtOAc: 0~5%) to give compound 21-5 (8.2 g, 20.42 mmol, 64.46% yield) as a yellow oil. 1H NMR (400 MHz, CDCl 3 ) δ = 7.55 - 7.50 (m, 6H), 7.32 - 7.27 (m, 6H), 7.24 - 7.18 (m, 3H), 2.67 - 2.61 (m, 2H), 2.61 - 2.53 (m, 1H), 2.25 - 2.15 (m, 1H), 1.94 (t, J = 9.0 Hz, 2H), 1.50 - 1.40 (m, 4H), 0.96 (d, J = 6.4 Hz, 6H). [570] Step 5: 1-isopropylpiperidine-4-thiol (21-6) [571] To a solution of 1-isopropyl-4-tritylsulfanyl-piperidine (8.1 g, 20.17 mmol, 1 eq) in CH2Cl2 (80 mL) were added TFA (30.80 g, 270.13 mmol, 20 mL, 13.39 eq) and TIPS (7.91 g, 40.34 mmol, 2 eq) at 0 °C under N 2 . After addition, the resulting mixture was stirred at 20 °C for 16 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with MeOH (150 mL) and extracted with PE ( 50 mL * 5). The MeOH layers was concentrated under reduced pressure to give compound 21-6 (5.6 g, crude, TFA) as a yellow oil. The crude product was used in the next step without further purification. [572] Step6: ddi(pentadecan-8-yl) 4,4'-((((1-isopropylpiperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate ( CAT21) [573] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2 g, 3.28 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (25 mL) were added TEA (995.31 mg, 9.84 mmol, 1.37 mL, 3 eq) and triphosgene (583.8 mg, 1.97 mmol, 0.6 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hr. The resulting reaction was concentrated under reduced pressure. To a solution of 1-isopropylpiperidine-4-thiol (3.14 g, 11.48 mmol, 3.5 eq, TFA) dissolved in dry THF (30 mL) was added NaOH (918.03 mg, 22.95 mmol, 7 eq) at 0 °C under N2. To this resulting solution, carbamoyl chloride, dissolved in THF (20 mL) was added via syringe slowly under N 2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hr. After completion, the reaction mixture was quenched by NH4Cl (60 mL) at 0°C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (60 mL * 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~12%, 5% NH3•H2O in Ethyl acetate) and purified by positive prep-HPLC (column: Welch Ultimate XB-NH2 250*50*10um;mobile phase: [Hexane-EtOH];B%: 0%-20%,15min) to afford CAT21 (428 mg, 0.52 mmol, 57.7% yield, 97% purity) as a yellow oil. LCMS [M+H] + : 795.6; 1 H NMR (400 MHz, CDCl3) δ = 4.90 – 4.84 (m, 2H), 3.40 - 3.37 (m, 4H), 2.82 - 2.79 (m, 2H), 2.70 - 2.67 (m, 1H), 2.35 - 2.30 (m, 6H), 2.04 - 2.01 (m, 2H), 1.95 - 1.85 (m, 4H), 1.72 - 1.66 (m, 3H), 1.52- 1.50 (m, 8H), 1.32 - 1.26 (m, 40H), 1.03 (d, J = 6.4 Hz 6H), 0.90 - 0.86 (m, 12H). Example 1.22: Synthesis of CAT22 [574] Step 1: 1-ethyl-4-(tritylthio)piperidine (22-5) [575] To a solution of 4-tritylsulfanylpiperidine (15.0 g, 31.9 mmol, 1.00 eq, TFA) in DMF (100 mL) were added K 2 CO 3 (13.1 g, 95.0 mmol, 3.00 eq) and iodoethane (4.45 g, 28.5 mmol, 2.28 mL, 0.90 eq). The mixture was stirred at 25 °C for 16 hours. The reaction mixture was quenched by water (150 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (150 mL × 3). The combined organic phase was washed with brine (100 mL × 3), dried with anhydroussodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Ethyl acetate : Petroleumether : 0 ~ 40%), then the residue was purified by inverted MPLC (MeCN : H 2 O: 0 ~ 40%) to give compound 22-5 (8.60 g, 22.0 mmol, 78.8% yield, 99% purity) as a yellow oil. 1 H NMR (400 MHz, MeOD-d 4 ) δ = 7.53-7.50 (m, 6H), 7.35-7.31 (m, 6H), 7.28-7.23 (m, 3H), 3.39-3.32 (m, 2H), 3.16-3.00 (m, 3H), 2.70-2.63 (m, 2H), 2.48-2.40 (m, 1H), 1.87-1.63 (m, 2H), 1.57-1.47 (m, 2H), 1.33-1.24 (m, 3H). [576] Step 2: 1-ethylpiperidine-4-thiol (22-6) [577] A mixture of 1-ethyl-4-tritylsulfanyl-piperidine (4.50 g, 11.6 mmol, 1.00 eq) in TFA (15.0 mL) and dichlormethane (50.0 mL), the mixture was degassed and purged with nitrogen atmosphere three times, then triisopropylsilane (3.68 g, 23.2 mmol, 4.77 mL, 2.00 eq) was added slowly at 0 °C, and then the mixture was stirred at 20 °C for 3 hours under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with methyl alcohol (50.0 mL) and extracted with petroleum ether ( 50.0 mL × 5). The methyl alcohol layers was concentrated under reduced pressure to give a crude product to yield compound 22-6 (3.01 g, crude, TFA salt) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ = 3.43-3.40 (m, 2H), 3.18-3.10 (m, 1H), 3.08-2.97 (m, 2H), 2.94-2.87 (m, 2H), 2.08 (d, J = 14 Hz, 2H), 1.84-1.73 (m, 2H), 1.24-1.18 (m, 3H). [578] Step 3: di(pentadecan-8-yl) 4,4'-((((1-ethylpiperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT22) [579] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.30 mmol, 1.00 eq) dissolved in dry dichloromethane (25.0 mL) were added TEA (995 mg, 9.80 mmol, 1.37 mL, 3.00 eq) and triphosgene (540 mg, 1.80 mmol, 0.50 eq) at 0 °C under N 2 . The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. To 1-ethylpiperidine-4-thiol (2.98 g, 11.5 mmol, 3.50 eq, TFA salt) dissolved in dry THF (30.0 mL) was added NaOH (918 mg, 23.0 mmol, 7.00 eq) at 0 °C under nitrogen atmosphere. To this resulting solution, carbamoyl chloride, dissolved in THF (25.0 mL) was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched by NH 4 Cl (60.0 mL) at 0 °C and then diluted with ethyl acetate (60.0 mL). The aqueous phase was extracted with ethyl acetate (60.0 mL × 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 50% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) to give compound CAT22 (268 mg, 0.34 mmol, 10.3% yield, 98.8% purity) as a light yellow oil. LCMS [M+1] + : 781.7; 1H NMR (400 MHz, CDCl 3 ) δ = 4.92-4.86 (m, 2H), 3.46-3.32 (m, 4H), 2.87-2.84 (m, 2H), 2.45-2.40 (m, 2H), 2.36-2.31 (m, 4H), 2.16 ( t, J = 9.6 Hz, 2H), 2.07-2.04 (m, 2H), 1.91 (s, 4H), 1.77-1.68 (m, 2H), 1.63-1.62 (m, 1H), 1.54-1.53 (m, 8H), 1.34-1.28 (m, 40H), 1.10 (t, J = 7.2 Hz, 3H), 0.92-0.88 (m, 12H). Example 1.22: Synthesis of CAT23
[580] Step 1: tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (23-8) [581] To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (70 g, 347.81 mmol, 1 eq) in CH 2 Cl 2 (750 mL) were added TEA (70.39 g, 695.61 mmol, 96.82 mL, 2 eq) and DMAP (2.12 g, 17.39 mmol, 0.05 eq) at 20 °C under N2. After addition, the mixture was stirred at 20 °C for 0.5 hr, and then was added TosCl (79.57 g, 417.37 mmol, 1.2 eq) in portions at 0 °C under N2. The resulting mixture was stirred at 20 °C for 16 hr. After completion, the reaction mixture was diluted with CH 2 Cl 2 (800 mL) and washed with H 2 O (500 mL * 3), brine (500 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a crude product. The crude product was triturated with (PE/EtOAc = 10/1, 500 mL * 2) at 25 °C for 1 hr to give compound 23-8 (230.6 g, 648.76 mmol, 93.3% yield) as a light yellow solid. 1 H NMR (400 MHz, CDCl3) δ = 7.82 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 4.72 - 4.66 (m, 1H), 3.64 - 3.57 (m, 2H), 3.32 - 3.24 (m, 2H), 2.47 (s, 3H), 1.82 - 1.75 (m, 2H), 1.74 - 1.68 (m, 2H), 1.45 (s, 9H). [582] Step 2: tert-butyl 4-(tritylthio)piperidine-1-carboxylate (23-9) [583] A mixture of tert-butyl 4-(p-tolylsulfonyloxy)piperidine-1-carboxylate (115 g, 323.54 mmol, 1 eq) , triphenylmethanethiol (107.31 g, 388.24 mmol, 1.2 eq), NaI (2.42 g, 16.18 mmol, 0.05 eq), Cs2CO3 (158.12 g, 485.30 mmol, 1.5 eq) in DMF (700 mL) was degassed and purged with N23 times, and then the mixture was stirred at 50 °C for 3 hr under N2 atmosphere. After completion, the reaction mixture was quenched by H2O (1000 mL) and then diluted with EtOAc (800 mL). The aqueous phase was extracted with EtOAc (800 mL * 3). The combined organic phase was washed with brine (600 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, PE/EtOAc = 20/1 to 5/1) to give compound 23-9 (178.8 g, 389.00 mmol, 66.7% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.43 - 7.40 (m, 6H), 7.21 - 7.17 (m, 6H), 7.13 - 7.11 (m, 3H), 3.62 -3.60 (m, 2H), 2.60 - 2.53 (m, 2H), 2.42 - 2.31 (m, 1H), 2.26 - 2.14 (m, 1H), 2.10 - 2.01 (m, 1H), 1.48 - 1.43 (m, 2H), 1.32 (s, 9H). [584] Step 3: 1-methyl-4-(tritylthio)piperidine (23-10) [585] To a solution of tert-butyl 4-tritylsulfanylpiperidine-1-carboxylate (75 g, 163.17 mmol, 1 eq) in THF (1000 mL) was added LAH (9.29 g, 244.76 mmol, 1.5 eq) in portions at 0 °C under N2 . After addition, the mixture was stirred at 70 °C for 16 hr. After completion, the reaction mixture was diluted with THF (500 mL), then successively was added H 2 O (9.3 mL), aq.NaOH (9.3 mL, 4M), H2O (28 mL) and Na2SO4 (100 g) at 0 °C under N2. The reaction mixture was filtered and the filtrate was concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (330 g SepaFlash® Silica Flash Column, MeOH/CH2Cl2: 0~5%, 1% NH3 in MeOH) to give compound 23-10 (47.8 g, 120.28 mmol, 44.1% yield, 94% purity) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.43 - 7.41 (m, 6H), 7.21 - 7.17 (m, 6H), 7.13 - 7.09 (m, 3H), 2.49 - 2.45 (m, 2H), 2.12 - 2.07 (m, 1H), 2.05 (s, 3H), 1.76 - 1.71 (m, 2H), 1.41 - 1.33 (m, 4H). [586] Step 4: 1-methylpiperidine-4-thiol (23-3) [587] To a solution of 1-methyl-4-tritylsulfanyl-piperidine (7 g, 18.74 mmol, 1 eq) in CH2Cl2 (60 mL) were added TFA (30.80 g, 270.13 mmol, 20 mL, 14.42 eq) and TIPS (7.34 g, 37.48 mmol, 2 eq) at 0 °C under N 2 . After addition, the resulting mixture was stirred at 20 °C for 16 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with MeOH (100 mL) and extracted with PE ( 50 mL * 5). The MeOH layers was concentrated under reduced pressure to give compound 23-3 (4.5 g, crude, TFA) as a yellow oil. The crude product was used in the next step without further purification. 1 H NMR (400 MHz, CDCl 3 ) δ = 3.74 - 3.71 (m, 2H), 3.51 - 3.48 (m, 1H), 3.33 - 3.27 (m, 1H), 2.89 - 2.85 (m, 3H), 2.01 - 2.76 (m, 1H), 2.51 - 2.39 (m, 1H), 2.28 - 2.25 (m, 1H), 2.08 - 1.96 (m, 1H), 1.91 - 1.87 (m, 1H). [588] Step 5: tert-butyl 4-((4-oxo-4-(pentadecan-8-yloxy)butyl)amino)butanoate (23-2) [589] To a solution of 1-heptyloctyl 4-[(4-tert-butoxy-4-oxo-butyl)-(4-nitrophenyl)sulfonyl- amino]butanoate (15.6 g, 24.34 mmol, 1 eq) in DMF (100 mL) were added Cs2CO3 (15.86 g, 48.68 mmol, 2 eq) and benzenethiol (6.18 g, 56.09 mmol, 5.72 mL, 2.30 eq). The mixture was stirred at 25 °C for 16 hr under N2. After completion, the reaction mixture was quenched by the addition of a solution of NaOH (150 mL, 1M), and then extracted with EtOAc (150 mL * 3). The combined organic layers were washed with brine (60 mL * 3), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~35%) to give compound 23-2 (8.7 g, 19.09 mmol, 78.4% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 1H), 2.64 - 2.61 (m, 4H), 2.33 (t, J = 7.6 Hz, 2H), 2.25 (t, J = 7.6 Hz, 2H), 1.80 - 1.76 (m, 4H), 1.53 - 1.48 (m, 4H), 1.45 (s, 9H), 1.30 - 1.26 (m, 20H), 0.90 - 0.86 (m, 6H). [590] Step 6: tert-butyl 4-((((1-methylpiperidin-4-yl)thio)carbonyl)(4-oxo-4-(pentade can-8- yloxy)butyl)amino)butanoate (23-4) [591] To a solution of 1-heptyloctyl 4-[(4-tert-butoxy-4-oxo-butyl)amino]butanoate (2 g, 4.39 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (30 mL) were added Et 3 N (1.33 g, 13.17 mmol, 1.8 mL, 3 eq) and triphosgene (781.41 mg, 2.63 mmol, 0.6 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hr. The resulting reaction was concentrated under reduced pressure and kept under N2. To a solution of 1-methylpiperidine-4-thiol (3.77 g, 15.36 mmol, 3.5 eq, TFA) dissolved in dry THF (40 mL) was added NaOH (1.23 g, 30.72 mmol, 7 eq) at 0 °C under N2. To this resulting solution, carbamoyl chloride, dissolved in THF (20 mL) was added via syringe slowly under N 2 at 0 °C. The resulting solution was stirred at 20° C for 15 hr. After completion, the reaction mixture was quenched by NH4Cl (60 mL) at 0°C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (60 mL * 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, EtOAc : PE: 0~25%) to give compound 23-4 (1.5 g, 1.81 mmol, 42.7% yield, 74% purity) as a yellow oil. LCMS [M+H] + : 613.3 [592] Step 7: 4-((((1-methylpiperidin-4-yl)thio)carbonyl)(4-oxo-4-(tetrade can-7- yloxy)butyl)amino)butanoic acid (23-5) [593] To a solution of 1-heptyloctyl 4-[(4-tert-butoxy-4-oxo-butyl)-[(1-methyl-4- piperidyl)sulfanylcarbonyl]amino]butanoate (1.5 g, 2.45 mmol, 1 eq) in CH 2 Cl 2 (15 mL) was added TFA (7.70 g, 67.53 mmol, 5 mL) under N2. The mixture was stirred at 25 °C for 3 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove solvent to give compound 23-5 (1.6 g, crude, TFA) as a yellow oil. The crude product was used directly in the next step without further purification. [594] Step 8: (Z)-non-2-en-1-yl 4-((((1-methylpiperidin-4-yl)thio)carbonyl)(4-oxo-4- (pentadecan-8-yloxy)butyl)amino)butanoate ( CAT23) [595] To a solution of 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-[(1-methyl-4- piperidyl)sulfanylcarbonyl]amino]butanoic acid (1.4 g, 2.09 mmol, 1 eq, TFA) in CH2Cl2 (20 mL) were added EDCI (1.20 g, 6.26 mmol, 3 eq), HOBt (845.9 mg, 6.26 mmol, 3 eq) and DIPEA (809.1 mg, 6.26 mmol, 1.1 mL, 3 eq) at 0 °C under N 2 . After addition, the mixture was stirred at this temperature for 0.5 hr, and then (Z)-non-2-en-1-ol (890.5 mg, 6.26 mmol, 3 eq) was added dropwise. The resulting mixture was stirred at 20 °C for 15.5 hr. After completion, the reaction mixture was quenched by H2O (60 mL) and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL * 3). The combined organic phase was washed with brine (60 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by positive prep-HPLC (column: Welch Ultimate XB-CN 250*50*10um;mobile phase: [Hexane-EtOH]; B%: 0%-15%,8min) to give CAT23 (682 mg, 0.98 mmol, 47.7% yield, 98% purity) as a light yellow oil. LCMS [M+H] + : 682.3 1 H NMR (400 MHz, CDCl 3 ) δ = 5.66 - 5.61 (m, 1H), 5.55 - 5.50 (m, 1H), 4.88 - 4.85 (m, 1H), 4.63 (br d, J = 6.4 Hz, 2H), 3.45 - 3.32 (m, 5H), 2.78 -2.72 (m, 2H), 2.33 - 2.30 (m, 4H), 2.26 (s, 3H), 2.16 - 2.08 (m, 4H), 2.03 - 1.99 (m, 2H), 1.92 - 1.85 (m, 4H), 1.73 - 1.65 (m, 2H), 1.55 - 1.48 (m, 4H), 1.37 - 1.34 (m, 2H), 1.30 - 1.22 (m, 26H), 0.89 - 0.86 (m, 9H). Example 1.24: Synthesis of CAT24
[ [597] To a solution of 2-(1-piperidyl)ethanol (5.00 g, 38.7 mmol, 5.14 mL, 1 eq) in dichloromethane (50.0 mL) was added SOCl 2 (13.8 g, 116 mmol, 8.42 mL, 3.00 eq), dropwise, slowly at 0 °C. Then the mixture was stirred at 40 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give compound 24-2 (7.17 g, crude, HCl salt) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ = 11.0 (s, 1H), 4.06 (t, J = 6.8 Hz, 2H), 3.42-3.40 (m, 4H), 2.95 -2.89 (m, 2H), 1.86 - 1.78 (m, 4H), 1.70 - 1.67 (m, 1H), 1.41-1.31 (m, 1H). [598] Step 2: 1-(2-(tritylthio)ethyl)piperidine (24-3) [599] A mixture of 1-(2-chloroethyl)piperidine (5.00 g, 33.9 mmol, 1.00 eq), triphenylmethanethiol (11.2 g, 40.6 mmol, 1.20 eq), potassium carbonate (18.7 g, 135 mmol, 4.00 eq), potassium iodide (562 mg, 3.39 mmol, 0.10 eq) in DMF (50.0 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 50 °C for 3 hours under N 2 atmosphere. The reaction mixture was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic phase was separated, washed with brine (60.0 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 10% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) to give compound 24-3 (5.70 g, 13.7 mmol, 40.6% yield, 93.4% purity) and (2.20 g, 4.92 mmol, 14.5% yield, 86.7% purity) as a white solid. LCMS [M+1] + : 388.2 1 H NMR (400 MHz, CDCl3-d) δ = 7.44 - 7.42 (m, 6H), 7.31 - 7.27 (m, 6H), 7.25 - 7.20 (m, 3H), 2.39 - 2.34 (m, 2H), 2.31 - 2.26 (m, 2H), 2.22 (s, 4H), 1.54 - 1.49 (m, 4H), 1.40 - 1.37 (m, 2H). [600] Step 3: 2-(piperidin-1-yl)ethanethiol (24-4) [601] A mixture of 1-(2-tritylsulfanylethyl)piperidine (6.50 g, 16.8 mmol, 1.00 eq) in TFA (20.0 mL) and dichloromethane (60.0 mL), the mixture was degassed and purged with N 2 3 times, then triisopropylsilane (5.31 g, 33.5 mmol, 6.89 mL, 2 eq) was added slowly at 0 °C, and then the mixture was stirred at 20 °C for 3 hours under N 2 atmosphere. The reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with methanol (150 mL) and extracted with petroleum ether (50.0 mL × 5). The methanol layers were concentrated under reduced pressure to give a crude product to give compound 24-4 (4.30 g, 16.6 mmol, 98.9% yield, TFA salt) as a light yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ = 3.45-3.42 (m, 2H), 3.19 - 3.12 (m, 2H), 2.89 - 2.80 (m, 5H), 1.80 - 1.77 (m, 2H), 1.66 - 1.63 (m, 3H), 1.38 - 1.35 (m, 1H). [602] Step 4: 2-(piperidin-1-yl)ethanethiol (CAT24) [603] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.28 mmol, 1.00 eq) dissolved in dry dichloromethane (20.0 mL) were added TEA (995 mg, 9.84 mmol, 1.37 mL, 3.00 eq) and triphosgene (876 mg, 2.95 mmol, 0.90 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. To a 2-(1-piperidyl)ethanethiol (2.98 g, 11.5 mmol, 3.50 eq, TFA salt) dissolved in dry THF (25.0 mL) was added NaOH (1.97 g, 49.2 mmol, 15.0 eq) at 0 °C under nitrogen atmosphere,. To this resulting solution, carbamoyl chloride, dissolved in THF (20.0 mL), was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched by ammonium chloride (20.0 mL) at 0 °C and then diluted with ethyl acetate (60.0 mL). The aqueous phase was extracted with ethyl acetate (50.0 mL × 3). The combined organic phase was washed with brine (60.0 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 50% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) to give compound CAT24 (1.09 g, 1.38 mmol, 43.3% yield, 99.2% purity) as a light yellow oil. LCMS [M+1] + : 782.4 1H NMR (400 MHz, CDCl3-d) δ = 4.90 - 4.84 (m, 2H), 3.38 (s, 4H), 3.05 - 3.01 (m, 2H), 2.57 - 2.53 (m, 2H), 2.46 (s, 4H), 2.31 (s, 4H), 1.90 (s, 4H), 1.61 - 1.56 (m, 4H), 1.52 - 1.51 (m, 8H), 1.46 - 1.43 (m, 2H), 1.32 - 1.27 (m, 40H), 0.90 - 0.87 (m, 12H). Example 1.25: Synthesis of CAT25 [604] Step 1: tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (25-2) [605] To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (50.0 g, 248 mmol, 1 eq.) in CH 2 Cl 2 (1000 mL) were added TEA (50.3 g, 497 mmol, 69.2 mL, 2 eq.), DMAP (1.52 g, 12.4 mmol, 0.05 eq.) and 4-methylbenzenesulfonyl chloride (71.0 g, 373 mmol, 1.5 eq.) under N 2 at 0 °C. The mixture was stirred at 25 °C for 12 hours. The reaction mixture was diluted with CH2Cl2 (500 mL), and extracted with water (500 mL × 3) and brine (500 mL ), dried with anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with petroleum ether : ethyl acetate (10 : 1, 500 mL) at 25 ℃ for 10 min to give compound 25-2 (320 g, 900 mmol, 91% yield) as a white solid. 1H NMR (400 MHz, CDCl 3 ) δ = 7.79 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.75 - 4.60 (m, 1H), 3.65 - 3.52 (m, 2H), 3.32 - 3.19 (m, 2H), 2.45 (s, 3H), 1.83 - 1.72 (m, 2H), 1.71 - 1.62 (m, 2H), 1.43 (s, 9H) Step 2: tert-butyl 4-(tritylthio)piperidine-1-carboxylate (25-3) [606] A mixture of tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (160 g, 450 mmol, 1 eq.), triphenylmethanethiol (149 g, 540 mmol, 1.2 eq.), NaI (3.37 g, 22.5 mmol, 0.05 eq.) ,Cs2CO3 (219 g, 675 mmol, 1.5 eq.) in DMF (1600 mL) was degassed and purged with N23 times, and then the mixture was stirred at 50 °C for 12 hours under N2 atmosphere. The reaction mixture was filtered, and the filtrate was extracted with ethyl acetate (1000 mL × 3) and water (1000 mL), The combined organic layers were washed with brine (1000 mL × 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give compound 25-3 (410 g, crude) as a yellow solid. Step 3: 4-(tritylthio)piperidine (25-4) [607] To a solution of tert-butyl 4-(tritylthio)piperidine-1-carboxylate (100 g, 218 mmol, 1 eq.) in CH2Cl2 (1000 mL) was added TFA (308 g, 2.70 mol, 200 mL, 12.4 eq.). The mixture was stirred at 25 °C for 3 hours. The reaction was washed and concentrated with CH2Cl2 (500 mL) for 4 times. The residue was triturated with MTBE at 25 ℃ for 1 hour to give compound 25-4 (75.0 g, 121 mmol, 48.2% yield, 57.8% purity) as a white solid. 1 H NMR (400 MHz, CDCl 3 ) δ = 9.06 - 8.93 (m, 1H), 7.45 - 7.34 (m, 6H), 7.26 - 7.17 (m, 7H), 7.16 -7.09 (m, 2H), 3.05 (s, 2H), 2.63 (s, 2H), 2.51 - 2.39 (m, 1H), 2.38 - 2.28 (m, 1H), 1.71 - 1.61 (m, 1H), 1.49 - 1.33 (m, 2H). [608] Step 4: 1-propyl-4-(tritylthio)piperidine (25-5) [609] To a solution of 4-(tritylthio)piperidine (15 g, 41.7 mmol, 1 eq.) and 1-bromopropane (4.62 g, 37.6 mmol, 3.42 mL, 0.9 eq.) in DMF (150 mL) were added K2CO3 (28.83g, 209 mmol, 5 eq.) and KI (693 mg, 4.17 mmol, 0.1 eq.). The mixture was stirred at 25 °C for 10 hours. The reaction mixture was quenched by the addition of 300 mL at 25 °C, and extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate/Petroleum ether gradient @ 100 mL/min). The residue was purified by MPLC(Column I.D.100mm * H300 mm Welch Ultimate XB_C1820-40 μm; 120 A; Flow rate 200 ml/min; Mobile phase H2O + ACN; Gradient B% 10-45% 20 min; 45% 5 min ) to give compound 25-5(6.58 g, 12.5 mmol, 29.9% yield, 98% purity, TFA) as a white solid. LCMS [M+1] + : 402.3 1 H NMR (400 MHz, CDCl3) δ = 12.69 - 11.85 (m, 1H), 7.60 - 7.35 (m, 6H), 7.27 - 7.18 (m, 6H), 7.16 – 7.03 (m, 3H), 3.41 - 3.13 (m, 2H), 2.88 - 2.60 (m, 4H), 2.24 - 1.82 (m, 3H), 1.77 - 1.53 (m, 2H), 1.42 - 1.14 (m, 2H), 0.94 - 0.74 (m, 3H). [610] Step 5: 1-propylpiperidine-4-thiol (25-6) [611] To a solution of 1-propyl-4-(tritylthio)piperidine (6.50 g, 16.2 mmol, 1 eq.) in TFA (20.0 mL) and CH 2 Cl 2 (60.0 mL) was added triisopropylsilane (5.13 g, 32.4 mmol, 6.65 mL, 2 eq.). The mixture was stirred at 25 °C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue.The residue was dissolved in methanol (10.0 mL), and extrated with petroleum ether (10.0 mL × 5), The combined methanol layers was concentrated under reduced pressure to give 1-propylpiperidine-4-thiol (4.42 g, crude, TFA) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ = 3.50 - 3.13 (m, 3H), 3.10 - 2.83 (m, 5H), 2.20 - 2.03 (m, 2H), 1.86 - 1.55 (m, 4H), 0.95 - 0.85 (m, 3H). [612] Step 6: di(pentadecan-8-yl) 4,4'-((((1-propylpiperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT25) [613] To a solution of di(pentadecan-8-yl) 4,4'-azanediyldibutanoate (2.80 g, 4.59 mmol, 1 eq.) dissolved in dry CH 2 Cl 2 (40.0 mL) were added TEA (1.39 g, 13.8 mmol, 1.92 mL, 3 eq.) and triphosgene (1.24 g, 4.18 mmol, 0.91 eq.) at 0 ℃ under N2. The resulting solution was stirred at 20°C for 1 hour. To a 1-propylpiperidine-4-thiol (4.39 g, 16.1 mmol, 3.50 eq., TFA) dissolved in dry THF (40.0 mL) at 0 ℃ under nitrogen atmosphere, was added NaOH (1.84 g, 45.9 mmol, 10.0 eq.) under nitrogen atmosphere. To this resulting solution, carbamoyl chloride, dissolved in THF (10.0 mL), was added via syringe slowly under N2 at 0 ℃. The resulting solution was stirred at 20 ℃ for 11 hours. The reaction mixture was quenched by NH 4 Cl (50.0 mL) at 0 ℃ and then diluted with ethyl acetate (50.0 mL). The aqueous phase was extracted with ethyl acetate (50.0 mL × 3). The combined organic phase was washed with brine (30.0 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~35% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to give CAT25 (0.85 g, 1.06 mmol, 23.1% yield, 99.1% purity) as a yellow oil. LCMS [M+1] + : 796.4 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.80 (m, 2H), 3.37 (s, 5H), 2.83 (d, J = 9.2, 2H), 2.40 - 2.23 (m, 6H), 2.21 - 2.08 (m, 2H), 2.06 - 1.97 (m, 2H), 1.90 (s, 4H), 1.76 - 1.67 (m, 2H), 1.52 (s, 10H), 1.27 (s, 40H), 0.98 - 0.76 (m, 15H). Example 1.26: Synthesis of CAT26
[614] Step 1: tert-butyl 2-(2-hydroxyethyl)pyrrolidine-1-carboxylate (26-2) [615] To a solution of 2-(1-tert-butoxycarbonylpyrrolidin-2-yl)acetic acid (50.0 g, 218 mmol, 1.00 eq) in THF (600 mL) was added BH3-Me2S (10.0 M, 32.7 mL, 1.50 eq) at 0 °C via Syringe dropwise over 30 min under a nitrogen atmosphere, then the mixture was stirred at 20 °C for 9.5 h under nitrogen atmosphere. The reaction was quenched by methanol (100 mL) and concentrated, then the residue was diluted with ethyl acetate (300 mL) and H 2 O (350 mL), extracted with ethyl acetate (200 mL × 3),washed by brine (500 mL),dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The aqueous phase quenched by sodium hypochlorite solution and discarded. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=50/1 to 3/1) to give compound 2 (30.0 g, 132 mmol, 60.7% yield, 95.0% purity) as a colorless oil. LCMS [M+23] + : 238.1 1H NMR (400 MHz, DMSO-d 6 ) δ = 4.37 (t, J = 5.2 Hz, 1H), 3.73 (s, 1H), 3.42 - 3.38 (m, 2H), 3.23 - 3.19 (m, 2H), 1.83 - 1.66 (m, 6H), 1.39 (s, 9H). [616] Step 2: tert-butyl 2-[2-(p-tolylsulfonyloxy)ethyl]pyrrolidine-1-carboxylate (26-3) [617] A mixture of tert-butyl 2-(2-hydroxyethyl)pyrrolidine-1-carboxylate (27.0 g, 125 mmol, 1.00 eq), TEA (25.4 g, 251 mmol, 34.9 mL, 2.00 eq) and DMAP (766 mg, 6.27 mmol, 0.05 eq) in dichloromethane (450 mL) was degassed and purged with N23 times, then TosCl (35.9 g, 188 mmol, 1.50 eq) was added slowly at 0 °C, and then the mixture was stirred at 25 °C for 3 hours under N2 atmosphere. The residue was diluted with dichloromethane (200 mL), the combined organic layers were washed with H 2 O (450 mL) and brine (450 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , Petroleum ether/Ethyl acetate=50/1 to 3/1)to give compound 26-3 (23.2 g, 49.5 mmol, 39.5% yield, 78.9% purity) as a yellow oil. LCMS [M-100+1] + : 270.1 1 H NMR (400 MHz, MeOD-d 4 ) δ = 7.80 (d, J = 2.0 Hz, 1H) 7.81 - 7.79 (m, 1H), 7.72 (s, 1H), 7.46 (s, 1H), 7.25 (s, 1H), 4.09 - 4.03 (m, 2H), 3.79 - 3.77 (m, 1H), 3.49-3.43 (m, 2H), 2.37 (s, 3H), 2.00 - 1.95 (m, 2H), 1.66 - 1.49 (m, 4H), 1.42 (s, 9H). [618] Step 3: tert-butyl 2-(2-tritylsulfanylethyl)pyrrolidine-1-carboxylate (26-4) [619] A mixture of tert-butyl 2-[2-(p-tolylsulfonyloxy)ethyl]pyrrolidine-1-carboxylate (23.0 g, 62.3 mmol, 1 eq), triphenylmethanethiol (20.7 g, 74.7 mmol, 1.20 eq), Cs2CO3 (30.4 g, 93.4 mmol, 1.5 eq), NaI (933 mg, 6.23 mmol, 0.10 eq) in DMF (200 mL) was degassed and purged with N23 times, and then the mixture was stirred at 50 °C for 3 hours under N2 atmosphere. The reaction mixture was partitioned between ethyl acetate (1500 mL) and H 2 O (1000 mL). The organic phase was separated, washed with brine (300 mL × 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 5/1) to give compound 26-4 (20.6 g, 39.3 mmol, 63.2% yield, 90.6% purity) as a yellow oil. 1 H NMR (400 MHz, CDCl3-d) δ = 7.46 - 7.41 (m, 6H), 7.33 - 7.27 (m, 6H), 7.25 - 7.20 (m, 3H), 3.68 (s, 1H), 3.31 (s, 1H), 3.20 (s, 1H), 2.15 (s, 2H), 1.76 - 1.65 (m, 4H), 1.43 (s, 9H), 1.39 - 1.34 (m, 2H) [620] Step 4: 2-(2-tritylsulfanylethyl)pyrrolidine (26-5) [621] To a solution of tert-butyl 2-(2-tritylsulfanylethyl)pyrrolidine-1-carboxylate (20.6 g, 43.4 mmol, 1 eq) in dichloromethane (200 mL) was added TFA (61.6 g, 540 mmol, 40.0 mL, 12.5 eq). The mixture was stirred at 25 °C for 10 hours. The reaction mixture was concentrated under reduced pressure to remove dichloromethane and TFA. The residue was purified by prep- MPLC (MeCN : H2O : 0 ~ 45%) to give compound 26-5 (16.2 g, 32.2 mmol, 74.3% yield, 97.0% purity, TFA salt) as a yellow solid. LCMS [M+1] + : 374.1 1 H NMR (400 MHz, CDCl 3 -d) δ = 7.32 - 7.30 (m, 6H), 7.21 - 7.17 (m, 6H), 7.14 - 7.13 (m, 3H), 3.31 (s, 1H), 3.11 (s, 2H), 2.20 - 2.12 (m, 2H), 1.84 - 1.79 (m, 3H), 1.50 - 1.43 (m, 1H), 1.33 - 1.31 (m, 1H), 1.20 - 1.16 (m, 1H). [622] Step 5: 1-isopropyl-2-(2-tritylsulfanylethyl)pyrrolidine (26-6) [623] To a solution of 2-(2-tritylsulfanylethyl)pyrrolidine (8.00 g, 16.4 mmol, 1.00 eq, TFA) and 2-iodopropane (3.07 g, 18.1 mmol, 1.80 mL, 1.10 eq) in MeCN (80.0 mL) was added K 2 CO 3 (6.80 g, 49.2 mmol, 3.00 eq). The mixture was stirred at 70 °C for 10 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 10% Methanol/Dichloromethanegradient @ 100 mL/min) to give compound 26-6 (4.60 g, 11.1 mmol, 67.7% yield) as a brown red solid. LCMS [M+1] + : 416.5 1 H NMR (400 MHz, CDCl 3 -d) δ = 7.40 - 7.37 (m, 6H), 7.27 - 7.22 (m, 6H), 7.20 - 7.16 (m, 3H), 3.01 - 2.92 (m, 2H), 2.79 - 2.75 (m, 1H), 2.53 - 2.47 (m, 1H), 2.29 - 2.23 (m, 1H), 2.12 – 2.05 (m, 1H), 1.75 - 1.61 (m, 4H), 1.56 - 1.49 (m, 1H), 1.38 - 1.30 (m, 1H), 1.14 (d, J = 6.4 Hz, 3H), 0.97 (d, J = 6.4 Hz, 3H) [624] Step 6: 2-(1-isopropylpyrrolidin-2-yl)ethanethiol (26-9) [625] A mixture of 1-isopropyl-2-(2-tritylsulfanylethyl)pyrrolidine (4.10 g, 9.86 mmol, 1.00 eq) in TFA (14.0 mL) and dichloromethane (42.0 mL), the mixture was degassed and purged with N 2 3 times, then triisopropylsilane (3.12 g, 19.7 mmol, 4.05 mL, 2.00 eq) was added slowly at 0 °C, and then the mixture was stirred at 20 °C for 3 hours under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with methanol (70.0 mL) and extracted with petroleum ether (50.0 mL × 5). The methanol layers was concentrated under reduced pressure to give compound 26-9 (2.69 g, crude, TFA) as a yellow oil. 1H NMR (400 MHz, CDCl3-d) δ = 3.76 - 3.69 (m, 3H), 3.09 – 3.00 (m, 1H), 2.92 - 2.84 (m, 1H), 2.46 - 2.41 (m, 1H), 2.27 - 2.12 (m, 5H), 2.04 - 1.88 (m, 2H), 1.47 (d, J = 6.4 Hz, 3H), 1.36 (d, J = 6.8 Hz, 3H) [626] Step 7: 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-[2-(1-isopropylpyrrolidi n-2- yl)ethylsulfanylcarbonyl]amino]butanoate (ONC-SM-027-NX-1): (EC1092-33/34) [627] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.90 g, 3.11 mmol, 1.00 eq) dissolved in dry dichloromethane (20.0 mL) were added TEA (946 mg, 9.34 mmol, 1.30 mL, 3.00 eq) and triphosgene (760 mg, 2.56 mmol, 0.82 eq) at 0 °C under N 2 . The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. To 2-(1-isopropylpyrrolidin-2-yl)ethanethiol (2.68 g, 9.34 mmol, 3.00 eq, TFA) dissolved in dry THF (25.0 mL) was added NaOH (1.87 g, 46.7 mmol, 15.0 eq) at 0 °C under nitrogen atmosphere. To this resulting solution, carbamoyl chloride, dissolved in THF, (20.0 mL) was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched by NH 4 Cl (50.0 mL) at 0 °C and then diluted with ethyl acetate (60.0 mL). The aqueous phase was extracted with ethyl acetate (60.0 mL × 3). The combined organic phase was washed with brine (50.0 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 50% Ethyl acetate/Petroleum ethergradient @100 mL/min) to give compound CAT26 (610 mg, 0.742 mmol, 21.3% yield, 98.4% purity) as a yellow oil. LCMS [M+1] + : 810.6 1H NMR (400 MHz, CDCl 3 -d) δ = 4.90 - 4.84 (m, 2H), 3.38 (s, 4H), 2.99 - 2.92 (m, 2H), 2.90 - 2.80 (m, 2H), 2.79 - 2.75 (m, 1H), 2.52 - 2.46 (m, 1H), 2.31 (s, 4H), 1.89 (d, J = 4.8 Hz, 6H), 1.79 - 1.67 (m, 4H), 1.52 (d, J = 5.2 Hz, 8H), 1.27 (s, 40H), 1.12 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.4 Hz, 3H), 0.88 (t, J = 6.8 Hz, 12H). Example 1.27: Synthesis of CAT27 [628] Step 1: 1-(but-3-en-1-yl)-4-(tritylthio)piperidine (27-2) [629] To a solution of 4-tritylsulfanylpiperidine (20 g, 42.23 mmol, 1 eq, TFA) in DMF (120 mL) were added K2CO3 (17.51 g, 126.70 mmol, 3 eq) and 4-bromobut-1-ene (5.13 g, 38.01 mmol, 3.86 mL, 0.9 eq). The mixture was stirred at 25 °C for 16 hr. After completion, the reaction mixture was quenched by H2O (150 mL) and then diluted with EtOAc (100 mL). The aqueous phase was extracted with EtOAc (150 mL * 3). The combined organic phase was washed with brine (100 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~20%, 1% NH3•H2O in EtOAc) and inverted MPLC (MeCN : H 2 O: 0~45%) to give compound 27-2 (9.6 g, 22.51 mmol, 65.6% yield, 97% purity) as a yellow solid. LCMS [M+H] + : 414.6 1 H NMR (400 MHz, CDCl3) δ = 12.27 - 12.21 (m, 1H), 7.42 - 7.36 (m, 6H), 7.23 - 7.18 (m, 6H), 7.16 - 7.10 (m, 3H), 5.64 - 5.55 (m, 1H), 5.09 - 5.00 (m, 2H), 3.40 - 3.25 (m, 3H), 2.87 - 2.79 (m, 4H), 2.42 - 2.36 (m, 2H), 2.21 - 2.16 (m, 1H), 2.07 - 1.99 (m, 2H), 1.25 - 1.18 (m, 1H). [630] Step 2: 1-(but-3-en-1-yl)piperidine-4-thiol (27-3) [631] To a solution of 1-but-3-enyl-4-tritylsulfanyl-piperidine (9.5 g, 22.97 mmol, 1 eq) in CH2Cl2 (80 mL) were added TFA (36.58 g, 320.78 mmol, 23.8 mL, 13.97 eq) and TIPS (9.00 g, 45.94 mmol, 2 eq) at 0 °C under N 2 . After addition, the resulting mixture was stirred at 20 °C for 4 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with MeOH (150 mL) and extracted with PE ( 50 mL * 5). The MeOH layers was concentrated under reduced pressure to give compound 27-3 (6.4 g, crude, TFA) as a yellow oil. The crude product was used in the next step without further purification. [632] Step 6: di(pentadecan-8-yl) 4,4'-((((1-(but-3-en-1-yl)piperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT27) [633] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (4.5 g, 7.38 mmol, 1 eq) dissolved in dry CH2Cl2 (50 mL)were added TEA (2.24 g, 22.13 mmol, 3.1 mL, 3 eq) and triphosgene (1.31 g, 4.43 mmol, 0.6 eq) at 0 °C under N 2 . The resulting solution was stirred at 20 °C for 1 hr. The resulting reaction was concentrated under reduced pressure. To a solution of 1-but-3-enylpiperidine-4-thiol (6.31 g, 22.13 mmol, 3 eq, TFA) dissolved in dry THF (35 mL) was added NaOH (2.07 g, 51.64 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution, carbamoyl chloride, dissolved in THF (30 mL), was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hr. After completion, the reaction mixture was quenched by NH 4 Cl (100 mL) at 0 °C and then diluted with EtOAc (100 mL). The aqueous phase was extracted with EtOAc (100 mL * 3). The combined organic phase was washed with brine (120 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~40%) and positive prep-HPLC (column: Welch Ultimate XB-CN 250 * 50 * 10 um; mobile phase: [Neu- ETOH];B%: 0%-10%, 8min) to afford CAT27 (488 mg, 0.59 mmol, 59.9% yield, 98.2% purity) as a light yellow oil. LCMS [M+H] + : 808.3 1 H NMR (400 MHz, CD3OD-d4) δ = 5.86 - 5.79 (m, 1H), 5.13 - 5.01(m, 2H), 4.93 - 4.89 (m, 2H), 3.48 - 3.38 (m, 5H), 2.89 -2.86 (m, 2H), 2.48 - 2.43 (m, 2H), 2.35 - 2.23 (m, 8H), 2.08 - 2.03 (m, 2H), 1.93 - 1.88 (m, 4H), 1.76 - 1.67 (m, 2H), 1.61 - 1.56 (m, 8H), 1.35 - 1.25 (m, 40H), 0.94 - 0.90 (m, 12H). Example 1.28: Synthesis of CAT28 [634] Step 1: 4-((bis(4-oxo-4-(pentadecan-8-yloxy)butyl)carbamoyl)thio)-1- (3- hydroxypropyl)piperidine 1-oxide (28-2) [635] To a solution of 1-heptyloctyl 4-[(1-but-3-enyl-4-piperidyl)sulfanylcarbonyl-[4-(1- heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.2 g, 1.49 mmol, 1 eq) in CH2Cl2 (20 mL) and MeOH (10 mL) was cooled to -78 °C, and a stream of Ozone (71.35 mg, 1.49 mmol, 1 eq) (15 Psi) was bubbled into the reaction mixture until a light blue color became evident. O2 was then bubbled through the reaction mixture until the blue color disappeared and then was added NaBH4 (112.47 mg, 2.97 mmol, 2 eq). The reaction mixture was stirred at 20 °C for 2 hr. After completion, the reaction mixture gave compound 28-2 (1.23 g, crude) as a yellow liquid. The reaction mixture was used directly in the next step without further purification. [636] Step 2: di(pentadecan-8-yl) 4,4'-((((1-(3-hydroxypropyl)piperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT28) [637] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-[1-(3- hydroxypropyl)-1-oxido-piperidin-1-ium-4-yl]sulfanylcarbonyl -amino]butanoate (1.23 g, 1.49 mmol, 1 eq) in CH 2 Cl 2 (10 mL) was added BPD (755.11 mg, 2.97 mmol, 2 eq). The mixture was stirred at 25 °C for 1 hr . After completion, the reaction mixture was quenched by H2O (60 mL) and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL * 3). The combined organic phase was washed with brine (60 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Ethyl acetate : Petroleum ether : 0~20%) and positive prep-HPLC (column: Welch Ultimate XB-CN 250 * 50 * 10um; mobile phase: [Hexane-EtOH]; B%: 0%-30%, 10min) to afford CAT28 (248 mg, 296.82 umol, 20.07% yield, 97.1% purity) as a yellow oil. LCMS [M+H] + : 811.6 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 m, 2H), 3.80 (t, J = 5.2 Hz, 2H), 3.38 - 3.34 (m, 5H), 2.95 - 2.90 (m, 2H), 2.60 (t, J = 5.6 Hz, 2H), 2.33 - 2.27 (m, 4H), 2.23 - 2.16 (m, 2H), 2.08 - 2.01 (m, 2H), 1.93 - 1.85 (m, 4H), 1.74 - 1.62 (m, 4H), 1.55 - 1.48 (br s, 8H), 1.33 - 1.25 (m, 40H), 0.91 - 0.86 (m, 12H). Example 1.29: Synthesis of CAT29 [638] Step 1: undeca-1,10-dien-6-ol (29-2) [639] A suspension of I2 (3.43 g, 13.50 mmol, 2.72 mL, 0.02 eq) and Mg (41.83 g, 1.72 mol, 2.55 eq) in dry THF (1500 mL) was prepared under nitrogen atmosphere. To this mixture, 5- bromopent-1-ene (251.47 g, 1.69 mol, 2.5 eq) was added slowly at 25 °C. During the addition, an increase in the temperature of the reaction mixture confirmed the initiation of the Grignard formation. Once the addition of the bromide was completed, the mixture was stirred at 25 °C for 1 hr, after which it was cooled down to 0 °C for the slow addition of ethyl formate (50 g, 674.96 mmol, 54.29 mL, 1 eq). After the addition, the cold bath was removed and the mixture was stirred at 25 °C for 15 hr. The reaction was cooled down to 0 °C for quenching by the addition of saturated solution NH4Cl (1000 mL) and stirred for 30 minutes. The aqueous phase was extracted with EtOAc (1000 mL x 3). The combined organic phase was washed with brine (400 x 2 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a crude product. The crude product was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=30/1 to 5/1) to give compound 29-2 (105 g, 623.98 mmol, 92.45% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 5.82-5.76 (m, 2H), 5.01-4.92 (m, 4H), 3.58 – 3.57 (m, 1H), 2.06-2.02 (m, 4H), 1.53-1.50 (m, 1H), 1.48-1.41 (m, 8H). [640] Step 2: 2-(1-pent-4-enylhex-5-enyl)isoindoline-1,3-dione (29-3) [641] To a solution of undeca-1,10-dien-6-ol (66 g, 392.21 mmol, 1 eq) and isoindoline-1,3- dione (69.25 g, 470.66 mmol, 1.2 eq) in THF (800 mL) was added PPh3 (154.31 g, 588.32 mmol, 1.5 eq), then DIAD (237.93 g, 1.18 mol, 228.78 mL, 3 eq) was added, dropwise, at 0 °C. The mixture was stirred at 25 °C for 12 hr. The reaction was quenched by the addition of saturated solution NH 4 Cl (1000 mL) and the aqueous phase was extracted with EtOAc (1000 mL x 3). The combined organic phase was washed with brine (500 x 2 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a crude product. The crude product was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=30/1 to 5/1) to give compound 29-3 (100 g, 336.26 mmol, 85.73% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.84-7.82 (m, 2H), 7.73-7.71 (m, 2H), 5.78-5.71 (m, 2H), 5.31-5.23 (m, 4H), 4.24-4.14 (m, 1H), 2.15-2.05 (m, 4H), 1.76-1.70 (m, 2H), 1.33-1.28 (m, 6H). [642] Step 3: undeca-1,10-dien-6-amine (29-4) [643] To a solution of 2-(1-pent-4-enylhex-5-enyl)isoindoline-1,3-dione (250 g, 840.65 mmol, 1 eq) in EtOH (1000 mL) was added N 2 H 4 •H 2 O (85.88 g, 1.68 mol, 83.38 mL, 98% purity, 2 eq). The mixture was stirred at 95 °C for 2 hr. The reaction mixture was filtered three times and the filtrate was concentrated. The crude was dissolved in EtOAc (500 mL) and the organic phase was washed with water (500 mL x 3), dried over Na2SO4, filtered and concentrated in vacuum to give compound 29-4 (130 g, 777.09 mmol, 92.44% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ = 5.83-5.76 (m, 2H), 5.01-4.92 (m, 4H), 2.71-2.68 (m, 1H), 2.05-2.02 (m, 4H), 1.45-1.27 (m, 8H). [644] Step 4: 4-nitro-N-(1-pent-4-enylhex-5-enyl)benzenesulfonamide (29-5) [645] To a solution of undeca-1,10-dien-6-amine (60 g, 358.66 mmol, 1 eq) and 4- nitrobenzenesulfonyl chloride (87.43 g, 394.52 mmol, 1.1 eq) in CH 2 Cl 2 (500 mL) was added TEA (72.58 g, 717.32 mmol, 99.84 mL, 2 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched by the addition of water (500 mL) and then extracted with CH2Cl2 (1000 mL × 3). The combined organic layers were washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residuewas purified by silica gel chromatography (Petroleum ether / Ethyl acetate=20/1 to 3/1) to give compound 29-5 (60 g, 170.24 mmol, 47.47% yield) as a yellow oil . 1 H NMR (400 MHz, CDCl3) δ = 8.37 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 5.71-5.62 (m, 2H), 4.93-4.89 (m, 4H), 3.35-3.30 (m, 1H), 1.97-1.91 (m, 4H), 1.33-1.25 (m, 8H). [646] Step 5: 5-[(4-nitrophenyl)sulfonylamino]nonanedioic acid (29-6) [647] First, a solution of 4-nitro-N-(1-pent-4-enylhex-5-enyl)benzenesulfonamide (20 g, 56.75 mmol, 1 eq) in CH2Cl2 (200 mL) and MeOH (200 mL) was cooled to -70 °C, and OZONE (136.19 mg, 2.84 mmol) was bubbled into the reaction mixture until a light blue color became evident. N2 was then bubbled through the reaction mixture until the blue color disappeared. Then PPh 3 (44.65 g, 170.24 mmol, 3 eq) was added, the reaction was stirred at 20 °C for 12 hr. The reaction mixture was concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=20/1 to 1/1) to give compound 4-nitro-N-[5-oxo-1-(4-oxobutyl)pentyl]benzenesulfonamide (12.6 g, 35.35 mmol, 62.30% yield) as a yellow oil. Second, to a solution of 4-nitro-N-[5-oxo-1-(4-oxobutyl)pentyl]benzenesulfonamide (12 g, 33.67 mmol, 1 eq) in ACN (150 mL) were added benzene-1,3-diol (18.54 g, 168.35 mmol, 28.09 mL, 5 eq) and sodium; dihydrogen phosphate (1 M, 101.01 mL, 3 eq), then sodium chlorite (1 M, 168.35 mL, 5 eq) in water (150 mL) was added dropwise at 0 °C. The mixture was stirred at 25 °C for 12 hr. The reaction mixture was neutralized to pH =2~3 with aq.HCl (4 M). The aqueous phase was extracted with EtOAc (500 mL x 3). The combined organic phase successively was washed with saturated aqueous Na2SO3 (200 mL x 3) and brine (100 mL x 2), dried over Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=20/1 to 0/1) to give compound 29-6 (5.8 g, 14.93 mmol, 44.35% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ = 11.94 (s, 2H), 8.39 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 7.95 (d, J = 8.0 Hz, 1H), 3.15 - 3.14 (m, 1H), 2.03 (t, J = 5.6 Hz, 4H), 1.33-1.23 (m, 8H). [648] Step 6: bis(1-heptyloctyl) 5-[(4-nitrophenyl)sulfonylamino]nonanedioate (29-7) [649] First, to a solution of 5-[(4-nitrophenyl)sulfonylamino]nonanedioic acid (2 g, 5.15 mmol, 1 eq) in CH 2 Cl 2 (20 mL) were added oxalyl dichloride (1.96 g, 15.45 mmol, 1.35 mL, 3 eq) and DMF (3.76 mg, 51.49 umol, 3.96 uL, 0.01 eq). The mixture was stirred at 0 °C for 2 hr. The reaction mixture was concentrated under reduced pressure to give compound 5-[(4- nitrophenyl)sulfonylamino]nonanedioyl dichloride (2 g, 4.70 mmol, 91.33% yield) as a yellow oil. Second, to a solution of pentadecan-8-ol (2.15 g, 9.41 mmol, 2 eq) in CH 2 Cl 2 (30 mL) was added 5-[(4-nitrophenyl)sulfonylamino]nonanedioyl dichloride (2 g, 4.70 mmol, 1 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=20/1 to 1/1) to give compound 29-7 (2.5 g, 3.09 mmol, 65.70% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 8.36 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 4.87-4.82 (m, 2H), 3.31 – 3.30 (m, 1H), 2.21 (t, J = 6.0 Hz, 4H), 1.50-1.41 (m, 16H), 1.32-1.26 (m, 40H), 0.90-0.87(m, 12H). [650] Step 7: bis(1-heptyloctyl) 5-[(4-nitrophenyl)sulfonyl-propyl-amino]nonanedioate (29- 8) [651] To a solution of bis(1-heptyloctyl) 5-[(4-nitrophenyl)sulfonylamino]nonanedioate (5 g, 6.18 mmol, 1 eq) and 1-iodopropane (3.15 g, 18.54 mmol, 1.81 mL, 3 eq) in DMF (80 mL) were added Cs 2 CO 3 (6.04 g, 18.54 mmol, 3 eq), KI (512.86 mg, 3.09 mmol, 0.5 eq) and TBAI (1.14 g, 3.09 mmol, 0.5 eq). The mixture was stirred at 120 °C for 12 hr. The reaction mixture was quenched with saturated aqueous water (200 mL) and then diluted with EtOAC (200 mL). The aqueous phase was extracted with EtOAC (200 mL x 3). The combined organic phase was washed with brine (300 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=40/1 to 5/1) to give compound 29-8 (5 g, 5.87 mmol, 95.06% yield) as a yellow oil. LCMS: [M+Na] + : 873.6; [652] Step 8: bis(1-heptyloctyl) 5-(propylamino)nonanedioate (29-9) [653] To a solution of bis(1-heptyloctyl) 5-[(4-nitrophenyl)sulfonyl-propyl- amino]nonanedioate (5 g, 5.87 mmol, 1 eq) in DMF (100 mL) was added Cs2CO3 (3.83 g, 11.74 mmol, 2 eq), then benzenethiol (1.86 g, 16.88 mmol, 1.72 mL, 2.88 eq) was added dropwise. The mixture was stirred at 25 °C for 12 hr under N2. The reaction mixture was quenched by the addition of water (400 mL), and then extracted with EtOAC (500 mL x 2). The combined organic layers were washed with brine (300 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 0/1) to give compound 29-9 (1.7 g, 2.55 mmol, 43.48% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 4.91-4.84 (m, 2H), 2.56-2.54 (m, 2H), 2.30 (t, J = 7.6 Hz, 4H), 1.66-1.51 (m, 4H), 1.48-1.46 (m, 16H), 1.30-1.26 (m, 40H), 0.94-0.87 (m, 15H). [654] Step 9: bis(1-heptyloctyl) 5-[2-(1-methylpyrrolidin-2-yl)ethylsulfanylcarbonyl-propyl- amino]nonanedioate (CAT29) [655] To a solution of bis(1-heptyloctyl) 5-(propylamino)nonanedioate (1.5 g, 2.25 mmol, 1 eq) in dry CH 2 Cl 2 (20 mL) were added TEA (683.60 mg, 6.76 mmol, 940.30 uL, 3 eq) and bis(trichloromethyl) carbonate (334.12 mg, 1.13 mmol, 0.5 eq) at 0 °C under N2 atmosphere. The resulting solution was stirred at 20 °C for 1 hr. The reaction was concentrated under reduced pressure and kept under N2 atmosphere. NaOH (630.48 mg, 15.76 mmol, 7 eq) was dissolved in dry THF (50 mL) at 0 °C, then 2-(1-methylpyrrolidin-2-yl)ethanethiol (1.64 g, 11.26 mmol, 5 eq) was added under N2 atmosphere. To this resulting solution, carbamoyl chloride in THF (50 mL) was added slowly at 0 °C. The mixture was stirred at 25 °C for 2 hr. The reaction mixture was quenched with saturated aqueous NH4C1 (100 mL) and then diluted with EtOAC (100 mL). The aqueous phase was extracted with EtOAC (100 mL x 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/2) to give compound CAT29 (530 mg, 630.40 umol, 35.19% yield, 99.6% purity) as a yellow oil. LCMS: [M+H] + : 838.3; 1 H NMR (400 MHz, CDCl3) δ = 4.88-4.83 (m, 2H), 4.25-3.81 (m, 1H), 3.11-2.86 (m, 5H), 2.33-2.30 (m, 6H), 2.10-1.97 (m, 4H), 1.58-1.50 (m, 23H), 1.32-1.22 (m, 40 H), 0.90-0.87 (m, 15H). Example 1.30: Synthesis of CAT30
[656] Step 1: 1-(cyclopropylmethyl)-4-(tritylthio)piperidine (30-2) [657] A mixture of 4-tritylsulfanylpiperidine (15 g, 31.68 mmol, 1 eq, TFA), cyclopropanecarbaldehyde (16.65 g, 95.03 mmol, 17.8 mL, 40% purity, 3 eq), HOAc (3.80 g, 63.35 mmol, 3.6 mL, 2 eq), KOAc (6.22 g, 63.35 mmol, 2 eq) in MeOH (50 mL) was degassed and purged with N 2 3 times, the mixture was stirred at 20 °C for 2 hr under N 2 atmosphere. Then, NaBH(OAc)3 (13.43 g, 63.35 mmol, 2 eq) was added. The resulting mixture was stirred at 20 °C for 14 hr. After completion, iced water (50 mL) was added and the mixture was neutralized to pH 8~9 with saturated NaHCO3 solution. The aqueous phase was extracted with EtOAc (150 mL * 3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a crude product. The residue was purified by inverted MPLC (MeCN : H2O: 0~45%) to give compound 29-2 (7.2 g, 15.67 mmol, 50.1% yield, 90% purity) as a yellow solid. LCMS [M+H] + : 414.5 1H NMR (400 MHz, CDCl 3 ) δ = 7.56 - 7.39 (m, 6H), 7.38 - 7.30 (m, 9H), 3.65 - 3.48 (m, 2H), 3.02 - 2.79 (m, 4H), 2.47 - 2.31 (m, 3H), 2.28 - 2.17 (m, 2H), 1.43 - 1.37 (m, 1H), 1.25 - 1.01 (m, 1H), 0.83 - 0.76 (m, 2H), 0.45 - 0.35 (m, 2H). [658] Step 2: 1-(cyclopropylmethyl)piperidine-4-thiol (29-3) [659] To a solution of 1-(cyclopropylmethyl)-4-tritylsulfanyl-piperidine (6 g, 14.51 mmol, 1 eq) in DCM (80 mL) were added TFA (30.80 g, 270.13 mmol, 20 mL, 18.62 eq) and TIPS (5.69 g, 29.01 mmol, 2 eq) at 0 °C under N2. After addition, the resulting mixture was stirred at 20 °C for 4 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove TFA and filtered. The filtrate was diluted with MeOH (150 mL) and extracted with PE ( 50 mL * 5). The MeOH layers was concentrated under reduced pressure to give compound 30-3 (4.1 g, crude, TFA) as a yellow oil. The crude product was used in the next step without further purification. [660] Step 3: di(pentadecan-8-yl) 4,4'-((((1-(cyclopropylmethyl)piperidin-4- yl)thio)carbonyl)azanediyl)dibutanoate (CAT30) [661] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (1.8 g, 2.95 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (30 mL) were added TEA (895.78 mg, 8.85 mmol, 1.23 mL, 3 eq) and triphosgene (525.39 mg, 1.77 mmol, 0.6 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hr. The resulting reaction was concentrated under reduced pressure. To a solution of 1-(cyclopropylmethyl)piperidine-4-thiol (2.53 g, 8.85 mmol, 3 eq, TFA) dissolved in dry THF (25 mL) was added NaOH (826.22 mg, 20.66 mmol, 7 eq) at 0 °C under N 2 . To this resulting solution, carbamoyl chloride, dissolved in THF (20 mL), was added via syringe slowly under N2 at 0 °C. The resulting solution was stirred at 20 °C for 15 hr. After completion, the reaction mixture was quenched by NH 4 Cl (80 mL) at 0 °C and then diluted with EtOAc (50 mL). The aqueous phase was extracted with EtOAc (60 mL * 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, EtOAc : PE : 0~20%) and positive prep-HPLC (column: Welch Ultimate XB-SiOH 250 * 50 * 10um;mobile phase: [Hexane-EtOH]; B%: 0%-20%, 10min) to yield CAT30 (235 mg, 0.28 mmol, 44.3% yield, 98% purity) as a light yellow oil. LCMS [M+H] + : 808.4 1 H NMR (400 MHz, CDCl 3 ) δ = 4.89 - 4.85 (m, 2H), 3.48 - 3.31 (m, 5H), 2.97 - 2.93 (m, 2H), 2.33 - 2.28 (m, 4H), 2.25 - 2.18 (m, 4H), 2.08 - 2.01 (m, 2H), 1.91 - 1.87 (m, 4H), 1.77 - 1.68 (m, 3H), 1.55 - 1.18 (m, 8H), 1.32 - 1.26 (m, 40H), 0.91 - 0.86 (m, 12H), 0.53 - 0.50 (m, 2H), 0.11 - 0.08 (m, 2H). Example 1.31: Synthesis of CAT31 [662] Step 1: 4-chloro-1-(pyrrolidin-1-yl)butan-1-one (31-3) [663] To a solution of pyrrolidine (5.00 g, 70.3 mmol, 5.87 mL, 1.00 eq) in THF (120 mL) was added TEA (14.2 g, 141 mmol, 19.6 mL, 2.00 eq), then 4-chlorobutanoyl chloride (11.9 g, 84.4 mmol, 9.44 mL, 1.20 eq) was added slowly. The mixture was stirred at 25 °C for 5 hours. The reaction mixture was quenched by the addition of water (100 mL) at 25 °C, and then extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (100 mL × 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/EtOAc=1/0 to 3/1). Compound 31-3 (5.60 g, 28.3 mmol, 40.2% yield, 88.8% purity) was obtained as a yellow oil. LCMS [M+1] + : 175.9. 1 H NMR (400 MHz, CDCl3) δ = 3.64 (t, J = 6.0 Hz, 2H), 3.46 -3.40 (m, 4H), 2.43 (t, J = 6.8 Hz, 2H), 2.115 -2.09 (m, 2H), 1.98 - 1.91 (m, 2H), 1.88 - 1.81 (m, 2H). [664] Step 2: 1-(pyrrolidin-1-yl)-4-(tritylthio)butan-1-one (31-4) [665] A mixture of 4-chloro-1-pyrrolidin-1-yl-butan-1-one (5.00 g, 28.5 mmol, 1.00 eq), triphenylmethanethiol (9.44 g, 34.2 mmol, 1.20 eq), K2CO3 (15.7 g, 114 mmol, 4.00 eq), KI (473 mg, 2.85 mmol, 0.10 eq) in DMF (50 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 50 °C for 10 hours under N2 atmosphere. The reaction mixture was partitioned between EtOAc (100 mL) and H 2 O (100 mL). The organic phase was separated, washed with brine (60 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 10% EtOAc/Petroleum ethergradient @ 100 mL/min). Compound 31-4 (9.32 g, 17.7 mmol, 62.2% yield, 79.0% purity) was obtained as a white solid. LCMS [2M+1] + : 831.4. 1 H NMR (400 MHz, CDCl3) δ = 7.37 - 7.32 (m, 6H), 7.23 - 7.18 (m, 6H), 7.16 - 7.11 (m, 3H), 3.33 (t, J = 6.8 Hz, 2H), 3.25 (t, J = 6.8 Hz, 2H), 2.18 (t, J = 6.8 Hz, 2H), 2.13 (t, J = 7.6 Hz, 2H), 1.87 - 1.81 (m, 2H), 1.78 - 1.73 (m, 2H), 1.67 (t, J = 7.6 Hz, 2H). [666] Step 3: 1-(4-(tritylthio)butyl)pyrrolidine (31-5) [667] To a solution of 1-pyrrolidin-1-yl-4-tritylsulfanyl-butan-1-one (9.00 g, 21.7 mmol, 1.00 eq) in THF (120 mL) was added BH 3 -Me 2 S (10.0 M, 10.8 mL, 5.00 eq) at 0 °C via syringe, dropwise, under N2 atmosphere, then the mixture was stirred at 20 °C for 10 hours under N2 atmosphere. The reaction was quenched by methanol (100 mL) and concentrated. Then the residue was diluted with EtOAc (100 mL) and H 2 O (100 mL), extracted with EtOAc (100 mL × 3), washed by brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The aqueous phase was quenched by sodium hypochlorite solution and discarded. Compound 31-5 (7.60 g, 12.5 mmol, 57.7% yield, 66.0% purity) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.39 - 7.37 (m, 6H), 7.27 - 7.23 (m, 6H), 7.20 - 7.16 (m, 3H), 3.13- 3.08 (m, 2H), 2.63 - 2.51 (m, 4H), 2.17 - 2.10 (m, 4H), 1.82 - 1.79 (m, 2H), 1.75 - 1.69 (m, 2H), 1.33 - 1.25 (m, 2H). [668] Step 4: 4-(pyrrolidin-1-yl)butane-1-thiol (31-6) [669] A mixture of 1-(4-tritylsulfanylbutyl)pyrrolidine (5.00 g, 12.5 mmol, 1.00 eq) in TFA (16.0 mL) and DCM (52.0 mL) was degassed and purged with N 2 3 times, then triisopropylsilane (3.94 g, 24.9 mmol, 5.11 mL, 2.00 eq) was added slowly at 0 °C. The mixture was stirred at 20 °C for 3 hours under N 2 atmosphere. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with methanol (50 mL) and washed with petroleum ether ( 60 mL × 5). The methanol layer was concentrated under reduced pressure to give compound 31-6 (3.40 g, crude, TFA salt) as a yellow oil. 1H NMR (400 MHz, CDCl 3 ) δ = 3.34 - 3.28 (m, 1H), 3.15 - 3.10 (m, 1H), 2.95 - 2.82 (m, 4H), 2.60 - 2.54 (m, 2H), 2.13 - 2.08 (m, 2H), 1.94 - 1.78 (m, 3H), 1.72 - 1.62 (m, 2H), 1.41 - 1.35 (m, 1H). [670] Step 5: di(pentadecan-8-yl) 4,4'-((((4-(pyrrolidin-1- yl)butyl)thio)carbonyl)azanediyl)dibutanoate (CAT31) [671] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.28 mmol, 1.00 eq) in dry dichloromethane (25.0 mL) were added TEA (995 mg, 9.84 mmol, 1.37 mL, 3.00 eq) and triphosgene (920 mg, 3.10 mmol, 0.90 eq) at 0 °C under N 2 atmosphere. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. To a solution of 4-pyrrolidin-1-ylbutane-1-thiol (3.14 g, 11.5 mmol, 3.50 eq, TFA salt) in dry THF (25.0 mL) was added NaOH (1.31 g, 32.8 mmol, 10.0 eq) at 0 °C under N 2 atmosphere. To this resulting solution was added carbamoyl chloride in THF (15.0 mL) at 0 °C under N2 atmosphere. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched by NH 4 Cl (60.0 mL) at 0 °C and then diluted with EtOAc (60.0 mL). The aqueous phase was extracted with EtOAc (60.0 mL × 3). The combined organic phase was washed with brine (70.0 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 50% EtOAc/Petroleum ethergradient @ 100 mL/min), then was purified by positive prep- HPLC(column: Welch Ultimate XB - CN 250 * 50 * 10 um; mobile phase: [Hexane - EtOH]; B%: 0% - 35%, 20 min). Compound CAT31 (260 mg, 0.322 mmol, 10.2% yield, 98.5% purity) was obtained as a yellow oil. LCMS [M+1] + : 796.1. 1H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 2H), 3.58 - 3.53 (m, 1H), 3.38 - 3.34 (m, 4H), 3.26 - 3.20 (m, 1H), 2.95 - 2.89 (m, 2H), 2.53 – 2.52 (m, 2H), 2.49 - 2.46 (m, 2H), 2.33 - 2.29 (m, 4H), 2.14 - 2.07 (m, 1H), 2.00 - 1.97 (m, 1H), 1.89 – 1.87 (m, 4H), 1.80 - 1.77 (m, 2H), 1.65 - 1.63 (m, 2H), 1.52 - 1.51 (m, 8H), 1.32 - 1.27 (m, 42H), 0.88 (t, J = 6.4 Hz, 12H). Example 1.32: Synthesis of CAT32 [672] Step 1: di(pentadecan-8-yl) 5-(N-ethyl-4-nitrophenylsulfonamido)nonanedioate (32- 10) [673] To a solution of di(pentadecan-8-yl) 5-(4-nitrophenylsulfonamido)nonanedioate (5.00 g, 6.18 mmol, 1 eq) and iodoethane (1.16 g, 7.41 mmol, 0.593 mL, 1.2 eq) in MeCN (50 mL) were added Cs 2 CO 3 (6.04 g, 18.5 mmol, 3 eq), TBAI (22.8 mg, 61.8 umol, 0.01 eq) and KI (513 mg, 3.09 mmol, 0.5 eq). The mixture was stirred at 90 °C for 10 hours. The reaction mixture was filtered. The filtrate was diluted with water (50 mL), extrated with and ethyl acetate (30 mL × 3). The combined organic layers were washed with brine(30 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) to give di(pentadecan- 8-yl) 5-(N-ethyl-4-nitrophenylsulfonamido)nonanedioate (4.20 g, 4.67 mmol, 75.5% yield, 93% purity) as a yellow oil. LCMS [M+23] + : 859.5 1H NMR (400 MHz, CDCl 3 ) δ = 8.35 (d, J = 8.8 Hz, 2H), 8.03 (d, J = 8.8 Hz, 2H), 4.86 - 4.80 (m, 2H), 3.23 - 3.18 (m, 2H), 2.28 - 2.19 (m, 4H), 1.54 - 1.44 (m, 17H), 1.26 - 1.23 (s, 40H), 0.90 - 0.87 (m, 15H). [674] Step 2: di(pentadecan-8-yl) 5-(ethylamino)nonanedioate (31-11) [675] To a solution of di(pentadecan-8-yl) 5-(N-ethyl-4- nitrophenylsulfonamido)nonanedioate (4.20 g, 5.02 mmol, 1 eq) and Cs 2 CO 3 (3.27 g, 10.0 mmol, 2 eq) in DMF (50 mL) was added benzenethiol (1.67 g, 15.2 mmol, 1.55 mL, 3.02 eq) and then the mixture was stirred at 25 °C for 3 hours under N 2 atmosphere. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) to give di(pentadecan-8-yl) 5- (ethylamino)nonanedioate (2.50 g, 3.83 mmol, 76.4% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 2H), 2.65 - 2.60 (m, 2H), 2.54 - 2.52 (m, 1H), 2.30 (t, J = 7.6 Hz, 4H), 1.61 - 1.40 (m, 16H), 1.27 – 1.24 (m, 40H), 1.11 (t, J = 7.2 Hz, 3H), 0.95 - 0.87 (m, 12H). [676] Step 3: 2-(2-chloroethyl)-1-methylpyrrolidine (32-2A) [677] To a solution of 2-(1-methylpyrrolidin-2-yl)ethanol (45.0 g, 348 mmol, 47.3 mL, 1 eq) in CH 2 Cl 2 (500 mL) was added SOCl 2 (124 g, 1.04 mol, 75.8 mL, 3 eq) dropwise slowly at 0 °C. Then the mixture was stirred at 40 °C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give compounds 32-2A (53.0 g, crude, HCl) as a brown solid. The compound was used directly for the next step. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 11.13 (s, 1H), 3.84 - 3.80 (m, 1H), 3.71 - 3.64 (m, 1H), 3.52 - 3.48 (m, 1H), 3.39 - 3.30 (m, 1H), 3.06 - 2.97 (m, 1H), 2.75 (d, J = 4.8 Hz, 3H), 2.37 - 2.33 (m, 1H), 2.24 - 2.11 (m, 2H), 1.99 - 1.84 (m, 2H), 1.74 - 1.64 (m, 1H). [678] Step 4: 1-methyl-2-(2-(tritylthio)ethyl)pyrrolidine (32-3A) [679] To a solution of 2-(2-chloroethyl)-1-methylpyrrolidine (53.0 g, 359 mmol, 1 eq) and triphenylmethanethiol (119 g, 431 mmol, 1.2 eq) in DMF (500 mL) were added K2CO3 (198 g, 1.44 mol, 4 eq) and KI (5.96 g, 35.9 mmol, 0.1 eq). The mixture was stirred at 80 °C for 2 hours. The reaction mixture was filtered and extracted with water (1000 mL) and EtOAc (300 × 3 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) to give compound 32-3A (12.0 g, 30.7 mmol, 18.3% yield, 99% purity) as a yellow oil. LCMS [M+1] + : 388.2. 1 H NMR (400 MHz, CDCl 3 ) δ = 7.44 - 7.41 (m, 6H), 7.31 - 7.27 (m, 6H), 7.23 - 7.20 (m, 3H), 2.20 (s, 3H), 2.18 - 2.08 (m, 2H), 1.98 - 1.92 (m, 1H), 1.78 - 1.71 (m, 3H), 1.65 - 1.56 (m, 2H), 1.35 - 1.30 (M, , 1H), 1.23 - 1.15 (m, 1H). [680] Step 5: 2-(1-methylpyrrolidin-2-yl)ethanethiol (32-4A) [681] To a solution of 1-methyl-2-(2-(tritylthio)ethyl)pyrrolidine (5.50 g, 14.2 mmol, 1 eq) in TFA (10 mL) and CH 2 Cl 2 (30 mL) was added triisopropylsilane (4.49 g, 28.4 mmol, 5.83 mL, 2 eq) at 0 °C. The mixture was stirred at 25 °C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue, the residue was dissolved in methanol (10 mL), and extracted with petroleum ether (10 mL × 5). The combined methanol layers was concentrated under reduced pressure to give compound 32-4A (3.68 g, crude, TFA) was obtained as a yellow oil. The compound was used directly for the next step. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 3.57 (m, 1H), 3.33 (m, 1H), 3.06 (m, 1H), 2.82 (s, 3H), 2.64 (d, J = 15.8 Hz, 2H), 2.24 (m, 1H), 2.16 - 2.04 (m, 1H), 1.98 (m, 1H), 1.93 - 1.71 (m, 2H), 1.62 (m, 1H). [682] Step 6: di(pentadecan-8-yl) 5-(ethyl(((2-(1-methylpyrrolidin-2- yl)ethyl)thio)carbonyl)amino)nonanedioate (CAT32) [683] To a solution of di(pentadecan-8-yl) 5-(ethylamino)nonanedioate (2.50 g, 3.83 mmol, 1 eq) dissolved in dry CH2Cl2 (20 mL) were added TEA (1.16 g, 11.5 mmol, 1.60 mL, 3 eq) and triphosgene (1.07 g, 3.61 mmol, 0.94 eq) at 0° C under N 2 . The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. To a 2-(1-methylpyrrolidin-2-yl)ethanethiol (3.48 g, 13.4 mmol, 3.5 eq, TFA) in dry THF (30 mL) at 0 ℃ was added NaOH (1.53 g, 38.34 mmol, 10 eq) under nitrogen atmosphere. To this resulting solution was added carbamoyl chloride in THF (10 mL) via syringe at 0 °C under N 2 . The resulting solution was stirred at 20 ℃ for 2 hours. The reaction mixture was quenched by NH 4 Cl (50 mL) at 0 °C and then diluted with ethyl acetate (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL × 3). The combined organic phase was washed with brine (30 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum ethergradient @ 100 mL/min) and prep-HPLC (column: Welch Ultimate C18150 * 25 mm * 5 um;mobile phase: [water(HCl)- MeOH];B%: 70%-100%,10 min) to give CAT32 (400 mg, 480.48 umol, 73.26% yield, 98.9% purity) as a yellow oil. LCMS [M+1] + : 824.4. 1 H NMR (400 MHz, CDCl3) δ = 4.88-4.85 (m, 2H), 4.30 - 3.82 (m, 1H), 3.27 - 3.26 (m, 2H), 3.05 - 3.03 (m, 1H), 2.89-3.00 (m, 1H), 2.78-2.89 (m, 1H), 2.32 (s, 3H), 2.31-2.25 (m, 3H), 2.16-2.12 (m, 2H), 2.00-1.97 (m, 2H), 1.59-1.50 (m, 21H), 1.27 – 1.25 (m, 43H), 0.90 - 0.87 (m, 12H). Example 1.33: Synthesis of CAT33 [684] Step 1: 4-(chloromethyl)-1-methyl-piperidine (33-2) [685] To a solution of (1-methyl-4-piperidyl) methanol (20 g, 154.80 mmol, 1 eq) in CH 2 Cl 2 (200 mL) was added SOCl2 (22.10 g, 185.76 mmol, 13.48 mL, 1.2 eq) at 0 °C. The mixture was stirred at 40 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to give compound 33-2 (20 g, 108.63 mmol, 70.18% yield ) as a brown solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 10.96 (s, 1H), 3.56 (d, J = 5.6 Hz, 2H), 3.67-3.33 (m, 2H), 2.97-2.94 (m, 2H), 2.68 (s, 3H), 1.97-1.62 (m, 5H). [686] Step 2: 1-methyl-4-(tritylsulfanylmethyl)piperidine (33-3) [687] To a solution of 4-(chloromethyl)-1-methyl-piperidine (20 g, 108.63 mmol, 1 eq) and triphenylmethanethiol (45.04 g, 162.95 mmol, 1.5 eq) in DMF (200 mL) were added Cs 2 CO 3 (70.79 g, 217.27 mmol, 2 eq) and KI (9.02 g, 54.32 mmol, 0.5 eq). The mixture was stirred at 60 °C for 12 hr. The reaction mixture was diluted with water (300 mL x 3) and extracted with EtOAC (400 mL x 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EtOAc =20/1 to 0/1) to give compound 33-3(17 g, 43.86 mmol, 40.38% yield) as a brown oil. 1 H NMR (400 MHz, CDCl3) δ =7.50 - 7.47 (m, 6H), 7.33 - 7.27 (m, 9H), 2.64 - 2.58 (m, 2H), 2.32 (s, 3H), 1.91 - 1.88 (m, 2H), 1.66 - 1.61 (m, 3H), 1.44-1.28 (m, 4H). [688] Step 3: (1-methyl-4-piperidyl)methanethiol: (33-4) [689] To a solution of 1-methyl-4-(tritylsulfanylmethyl)piperidine (17 g, 43.86 mmol, 1 eq) and triisopropylsilane (20.84 g, 131.59 mmol, 27.03 mL, 3 eq) in CH2Cl2 (200 mL), and then TFA (32.73 g, 287.00 mmol, 21.25 mL, 6.54 eq) was added at 0 °C. The mixture was stirred at 25 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to remove TFA, it was diluted with methanol (300 mL x 3) and washed with PE (200 mL x 3). The combined organic layers were dried over sodium sulfate, the methanol layers was concentrated under reduced pressure to give compound 33-4 (4 g, 27.54 mmol, 62.78% yield) as a brown oil. [690] Step 4: 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]-[(1-methyl-4- piperidyl)methylsulfanylcarbonyl]amino]butanoate: (CAT33) [691] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (3 g, 4.92 mmol, 1 eq) dissolved in dry CH 2 Cl 2 (30 mL) were added TEA (1.49 g, 14.75 mmol, 2.05 mL, 3eq) and triphosgene (729.70 mg, 2.46 mmol, 0.5 eq) at 0 °C under N2 atmosphere. The resulting solution was stirred at 20 °C under N 2 for 1 hr. The reaction was concentrated under reduced pressure and kept under N 2. NaOH (1.38 g, 34.43 mmol, 7 eq) was dissolved in dry THF (50 mL) at 0 °C under N2, then (1-methyl-4-piperidyl)methanethiol (3.57 g, 24.59 mmol, 5 eq) was added. To this resulting solution, carbamoyl chloride dissolved in THF (50 mL) was added slowly under N2 at 0 °C. The mixture was stirred at 25 °C for 2 hr. The reaction mixture was quenched with saturated aqueous NH 4 C1 (100 mL) and then diluted with EtOAC (100 mL). The aqueous phase was extracted with EtOAC (100 mL x 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue purified by silica gel chromatography (PE / EtOAc =10/1 to 1/2) and purified by prep-HPLC (column: Welch Ultimate C18 150*25mm*5um; mobile phase: [water(HCl)-MeOH]; B%: 70%-100%,10min) to give compound CAT33 (137.8 mg, 184.39 umol, 62.63% yield, 98% purity) as a yellow oil. LCMS: [M+H] + : 781.6 1H NMR (400 MHz, CDCl 3 ) δ = 4.88 - 4.86 (m, 2H), 3.54 - 3.51 (m, 2H), 3.46-3.38 (m, 5H), 2.83 – 2.85 (m, 2H), 2.75 (s, 3H), 2.67 - 2.62 (m, 2H), 2.40-2.32 (m, 4H), 2.01 - 1.89 (m, 8H), 1.55-1.51 (m, 8H), 1.35-1.27 (m, 40H), 0.90-0.84 (m, 12H). Example 1.34: Synthesis of CAT34
[692] Step 1: (1-methylpyrrolidin-3-yl)methanol (34-2) [693] To a solution of O1-tert-butyl O3-methyl pyrrolidine-1,3-dicarboxylate (20.0 g, 87.2 mmol, 1.00 eq) in THF (350 mL) was added LiAlH4 (8.28 g, 218 mmol, 2.50 eq) in portion at 0 °C under N 2 . The mixture was stirred at 60 °C for 5 hours under N 2 . The reaction mixture was quenched by the addition of water (8 mL) at 0 °C and 15% of NaOH solution (8 mL), then water (24 mL) was added slowly, the mixture stirred for 30 min, dried over anhydrous sodium sulfate, the filtered cake washed with EtOAc (100 mL × 3), the filtrate concentrated under reduced pressure to give compound 34-2 (18.3 g, crude) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ = 4.51 (s, 1H), 3.30 - 3.22 (m, 2H), 2.44 - 2.29 (m, 3H), 2.25 - 2.21 (m, 1H), 2.19 (s, 3H), 2.17 - 2.10 (m, 1H), 1.82 - 1.73 (m, 1H), 1.37 - 1.29 (m, 1H). [694] Step 2: (1-methylpyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (34-7) [695] A mixture of (1-methylpyrrolidin-3-yl)methanol (18.0 g, 156 mmol, 1.00 eq), TEA (31.6 g, 313 mmol, 43.5 mL, 2.00 eq) and DMAP (1.91 g, 15.6 mmol, 0.10 eq) in CH 2 Cl 2 (250 mL) was degassed and purged with N2 3 times, TosCl (44.7 g, 234 mmol, 1.50 eq) was added slowly at 0 °C, and then the mixture was stirred at 25 °C under N 2 for 12 hours. The residue was diluted with CH2Cl2 (100 mL). The combined organic layers were washed with water (350 mL) and brine (250 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 100% EtOAc / PE gradient @ 100 mL/min) to give compound 34-7 (12.7 g, 47.2 mmol, 30.2% yield) as a yellow oil. LCMS [M+1] + : 270.1. 1 H NMR (400 MHz, CDCl3) δ = 7.79 - 7.77 (m, 2H), 7.34 (d, J = 8.0 Hz, 2H), 3.93 (d, J = 7.2 Hz, 2H), 2.55 - 2.47 (m, 4H), 2.45 (s, 3H), 2.42 - 2.38 (m, 1H), 2.28 (s, 3H), 1.98 - 1.89 (m, 1H), 1.44 - 1.35 (m, 1H). [696] Step 3: 1-methyl-3-((tritylthio)methyl)pyrrolidine (34-5) [697] A mixture of (1-methylpyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (12.7 g, 47.2 mmol, 1.00 eq), triphenylmethanethiol (15.6 g, 56.6 mmol, 1.20 eq), Cs 2 CO 3 (23.0 g, 70.7 mmol, 1.50 eq), NaI (707 mg, 4.71 mmol, 0.10 eq) in DMF (90 mL) was degassed and purged with N 2 3 times, and then the mixture was stirred at 50 °C for 3 hours under N 2 . The reaction mixture was partitioned between EtOAc (500 mL × 2) and water (500 mL × 3). The organic phase was separated, washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, PE / EtOAc = 3 / 1 to CH2Cl2 / MeOH = 10 / 1) to give compound 34-5 (16.9 g, 37.1 mmol, 81.5% yield, 82.0% purity) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 7.40 - 7.37 (m, 6H), 7.27 - 7.22 (m, 6H), 7.21 - 7.16 (m, 3H), 2.68 - 2.64 (m, 1H), 2.54 - 2.48 (m, 1H), 2.39 - 2.33 (m, 1H), 2.26 (s, 3H), 2.22 - 2.12 (m, 3H), 2.08 - 2.04 (m, 1H), 1.97 - 1.89 (m, 1H), 1.39 - 1.31 (m, 1H). [698] Step 4: (1-methylpyrrolidin-3-yl)methanethiol (34-6) [699] A mixture of 1-methyl-3-(tritylsulfanylmethyl)pyrrolidine (8.00 g, 21.4 mmol, 1.00 eq) in TFA (27 mL) and CH 2 Cl 2 (80 mL), the mixture was degassed and purged with N 2 3 times, then triisopropylsilane (6.78 g, 42.8 mmol, 8.80 mL, 2.00 eq) was added slowly at 0 °C, and then the mixture was stirred at 20 °C for 3 hours under N 2 . The reaction mixture was concentrated under reduced pressure. The filtrate was diluted with MeOH (20 mL) and extracted with PE ( 30 mL × 5). The MeOH layers was concentrated under reduced pressure to give compound 34-6 (5.00 g, crude, TFA salt) as a light yellow oil. 1H NMR (400 MHz, CDCl 3 ) δ = 3.95 - 3.91 (m, 1H), 3.82 - 3.69 (m, 1H), 3.15 - 2.99 (m, 2H), 2.93 (s, 3H), 2.76 - 2.64 (m, 4H), 2.39 - 2.31 (m, 1H), 1.97 - 1.88 (m, 1H) [700] Step 5: di(pentadecan-8-yl) 4,4'-(((((1-methylpyrrolidin-3- yl)methyl)thio)carbonyl)azanediyl)dibutanoate (CAT34) [701] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.50 g, 4.10 mmol, 1.00 eq) dissolved in dry CH 2 Cl 2 (30 mL) were added TEA (1.24 g, 12.3 mmol, 1.71 mL, 3.00 eq) and triphosgene (1.09 g, 3.69 mmol, 0.90 eq) at 0 °C under N2. The resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. To a solution of (1-methylpyrrolidin-3-yl)methanethiol (3.02 g, 12.30 mmol, 3 eq, TFA salt) in dry THF (35 mL) was added NaOH (2.46 g, 61.48 mmol, 15 eq) at 0 °C under N 2 . To this resulting solution was added carbamoyl chloride in THF (35.0 mL) at 0 °C under N2. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched by NH 4 Cl (100 mL) at 0 °C and then diluted with EtOAc (100 mL). The aqueous phase was extracted with EtOAc (100 mL × 3). The combined organic phase was washed with brine (200 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 120g SepaFlash® Silica Flash Column, Eluent of 0 ~ 37% EtOAc/PE gradient @ 100 mL/min), then was purified by prep-HPLC (HCl condition; column: Welch Ultimate C18150 * 25 mm * 5 um; mobile phase: [water (HCl) - MeOH]; B%: 70% - 100%, 10 min) to give compound CAT34 (179 mg, 0.227 mmol, 5.8% yield, 97.2% purity) as a yellow oil. LCMS [M+1] + : 767.6 1 H NMR (400 MHz, CDCl3) δ = 4.90 - 4.84 (m, 2H), 3.26 - 3.48 (m, 4H), 3.03 - 2.92 (m, 2H), 2.78 - 2.74 (m, 1H), 2.60 - 2.51 (m, 2H), 2.50 - 2.44 (m, 1H), 2.35 (s, 3H), 2.32 - 2.25 (m, 4H), 2.12 - 2.03 (m, 1H), 1.96 - 1.84 (m, 4H), 1.78 - 1.67 (m, 2H), 1.48 - 1.55 (m, 8H), 1.32 - 1.22 (m, 40H), 0.88 (t, J = 6.8 Hz, 12H). Example 1.35: Synthesis of CAT35 [702] Step 1: Synthesis of intermediate 2 (N-heptylheptan-1-amine) (35-2) [703] To a solution of heptan-1-amine (30 g, 260.38 mmol, 38.81 mL, 1 eq) and 1- bromoheptane (46.63 g, 260.38 mmol, 40.91 mL, 1 eq) in DMF (100 mL) was added K2CO3 (35.99 g, 260.38 mmol, 1 eq). The mixture was stirred at 80 °C for 12 hr under N 2 . The reaction mixture was quenched by the addition of water (500 mL), and then extracted with ethyl acetate (500 mL × 3). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1) to give compound 35- 2 (15 g, 70.29 mmol, 27.00% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 2.38-2.34 (m, 4H), 1.48-1.42 (m, 4H), 1.38-1.22 (m, 16H), 0.90-0.84 (m, 6H). [704] Step 2: 4-[[4-(diheptylamino)-4-oxo-butyl]-(4-nitrophenyl)sulfonyl-a mino]-N,N- diheptyl-butanamide (35-4) [705] To a solution of 4-[3-carboxypropyl-(4-nitrophenyl)sulfonyl-amino]butanoic acid (3 g, 8.01 mmol, 1 eq) in dichlormethane (30 mL) was added EDCI (4.61 g, 24.04 mmol, 3 eq), then DMAP (489.50 mg, 4.01 mmol, 0.5 eq) and TEA (2.43 g, 24.04 mmol, 3.35 mL, 3 eq) were added. After 30 minutes, the N-heptylheptan-1-amine (3.59 g, 16.83 mmol, 2.1 eq) was added. Then, the mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=30/1 to 1/1) to give compound 35-4 (2.4 g, 3.14 mmol, 39.14% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 8.27 – 8.24 (m, 2H), 8.08-7.80 (m, 2H), 3.23-3.17 (m, 4H), 3.12 -3.06 (m, 3H), 2.58-2.52 (m, 1H), 2.27-2.18 (m, 3H), 1.84-1.48 (m, 4H), 1.53-1.28 (m, 8H), 1.20-1.05 (m, 32H), 0.88-0.75 (m, 12H). [706] Step 3: 4-[[4-(diheptylamino)-4-oxo-butyl]amino]-N,N-diheptyl-butana mide (35-5) [707] To a solution of 4-[[4-(diheptylamino)-4-oxo-butyl]-(4-nitrophenyl)sulfonyl-a mino]- N,N-diheptyl-butanamide (1.8 g, 2.35 mmol, 1 eq) and benzenethiol (518.38 mg, 4.71 mmol, 479.99 uL, 2 eq) in DMF (20 mL) was added Cs2CO3 (1.53 g, 4.71 mmol, 2 eq). The mixture was stirred at 25 °C for 12 hr under N 2 . The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (300 mL x 3). The combined organic layers were washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 and Dichloromethane / Methanol=30/1 to 5/1) to give compound 35-5 (1 g, 1.72 mmol, 73.29% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ = 3.32-3.21 (m, 8H), 2.80-2.68 (m, 4H), 2.48-2.25 (m, 4H), 1.96-1.81 (m, 4H), 1.56-1.46 (m, 8H), 1.28-1.10 (m, 32H), 0.93-0.85 (m, 12H). [708] Step 4: S-[3-(dimethylamino)propyl] N,N-bis[4-(diheptylamino)-4-oxo- butyl]carbamothioate (CAT35) [709] To a solution of 4-[[4-(diheptylamino)-4-oxo-butyl]amino]-N,N-diheptyl-butana mide (1.5 g, 2.59 mmol, 1 eq) dissolved in dry dichlormethane (20 mL) were added TEA (785.11 mg, 7.76 mmol, 1.08 mL, 3 eq) and triphosgene (383.74 mg, 1.29 mmol, 0.5 eq) at 0° C under nitrogen atmosphere. The resulting solution was stirred at 25 °C under nitrogen atmosphere for 1 hr. The reaction was concentrated under reduced pressure and kept under nitrogen atmosphere. NaOH (724.11 mg, 18.10 mmol, 7 eq) was dissolved in dry THF (50 mL) at 0 °C under nitrogen atmosphere, then 3-(dimethylamino)propane-1-thiol (1.54 g, 12.93 mmol, 5 eq) was added under nitrogen atmosphere. To this resulting solution, carbamoyl chloride dissolved in THF (10 mL) was added slowly under nitrogen atmosphere at 0 °C. The mixture was stirred at 35 °C for 12 hr .The reaction mixture was quenched by the addition of water (100 mL), and then extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate=10/1 to 1/1 and Dichloromethane / Methanol=30/1 to 5/1) and MPLC (column: Welch Ultimate XB- SiOH 250*50*10um; mobile phase: [Hexane-EtOH]; B%: 0%-28%, 15min) to give compound CAT35 (181 mg, 247.84 umol, 17.97% yield, 99.3% purity) as a yellow oil. LCMS: [M+H] + : 725.6 1 H NMR (400 MHz, CDCl3) δ = 3.48-3.41 (m, 4H), 3.28-3.20 (m, 4H), 3.18-3.10 (m, 4H), 2.50-2.10 (m , 4H), 1.96-1.60 (m, 6H), 1.53-1.46 (m, 8H), 1.26-1.10 (m, 32H), 0.95-0.81 (m, 12H). Example 1.36: Synthesis of CAT2
[710] Step 1: 2-[3-(dimethylamino)propyl]isothiourea hydrochloride (36-2): [711] To a solution of 3-chloro-N,N-dimethyl-propan-1-amine (25 g, 158.16 mmol, 1 eq, HCl) in EtOH (500 mL) were added NaI (474.13 mg, 3.16 mmol, 0.02 eq) and thiourea (13.24 g, 173.97 mmol, 1.1 eq). The mixture was stirred at 80 °C for 16 hr. TLC (dichloromethane : methanol = 10:1, PMA) indicated the starting material was consumed completely and one new main spot formed. The reaction mixture was cooled to 10 °C and crystal precipitation. The reaction mixture was filtered and the filter cake were washed with ethyl acetate (100 mL×2). The filter cake was concentrated in vacuum to give compound 36-2 (29.1 g, 147.17 mmol, HCl) as a white solid. The crude product was used for next step without further purification. 1H NMR (400 MHz, CDCl 3 ) δ : 9.40 - 9.37 (m, 4H), 3.35 (t, J = 7.6 Hz, 2H), 3.12 (t, J = 7.6 Hz, 2H), 2.72 (s, 6H), 2.08 - 2.01 (m, 2H). [712] Step 2: 3-(dimethylamino)propane-1-thiol (36-3): [713] To a solution of 2-[3-(dimethylamino)propyl]isothiourea (10.0 g, 62.0 mmol, 1 eq) in H2O (10 mL) and EtOH (40 mL) was added NaOH (14.9 g, 372 mmol, 6 eq). The mixture was stirred at 90 °C for 3 hours. The reaction mixture was cooled to 25 °C, quenched by the addition of water (20 mL), and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound 36-3 (2.10 g, crude) as a yellow oil. The reaction residue was used directly for the next step. [714] Step 3: 1-heptyloctyl 4-[3-(dimethylamino)propylsulfanylcarbonyl-[4-(1- heptyloctoxy)-4-oxo-butyl]amino]butanoate (CAT2) [715] To a solution of 1-heptyloctyl 4-[[4-(1-heptyloctoxy)-4-oxo-butyl]amino]butanoate (2.00 g, 3.28 mmol, 1 eq) in DCM (20 mL) were added bis(trichloromethyl) carbonate (486 mg, 1.64 mmol, 0.5 eq) and TEA (995 mg, 9.84 mmol, 1.37 mL, 3 eq). After addition, the resulting solution was stirred at 20 °C for 1 hour. The resulting reaction was concentrated under reduced pressure. A solution of 3-(dimethylamino)propane-1-thiol (1.95 g, 16.4 mmol, 5 eq) in dry THF (20 mL) was added NaOH (918 mg, 23.0 mmol, 7 eq) at 0 °C under N 2 . Carbamoyl chloride dissolved in THF (5 mL) was added at 0 °C under N2. The resulting solution was stirred at 20 °C for 15 hours. The reaction mixture was quenched with saturated aqueous NH 4 Cl (100 mL) and then diluted with ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL×3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether : ethyl acetate = 10:1 to 1:1) to afford CAT2 (260 mg, 0.340 mmol, 65% yield, 99% purity) was obtained as a yellow oil. LCMS: [M+H] + : 756.1; 1H NMR (400 MHz, CDCl 3 ) δ : 4.82 - 4.77 (m, 2H), 3.39 - 3.29 (m, 4H), 2.84 (t, J = 7.2 Hz, 2H), 2.31 - 2.22 (m, 6H), 2.17 - 2.15 (m, 6H), 1.85 - 1.70 (m, 6H), 1.46-1.42 (m, 8H), 1.25 - 1.10 (m, 40H), 0.86 - 0.72 (m, 12H). Example 2: Synthesis of PEG-Lipids Example 2.1: Synthesis of CHM-001 [716] Step 1: Synthesis of benzyl-poly(ethylene glycol)2000 (1.1-2) [717] To a solution of PEG2000 (20 g, 10.00 mmol, 1 eq.) in THF (100 mL) at 0°C was added NaH (599.83 mg, 15.00 mmol, 60% purity, 1.5 eq.), and stirred at 0°C for 40 min. The reaction mixture was treated with bromomethyl benzene (2.57 g, 15.00 mmol, 1.78 mL, 1.5 eq.). The reaction mixture was then stirred at 25°C for 18 h. The reaction mixture was quenched with saturated NH4Cl solution (100 mL), and diluted with DCM (150 mL). The organic layer was washed with H2O (70 mL×2) and brine (70 mL×2), dried over anhydrous Na2SO4. The resulting solution was concentrated at low pressure to afford the crude product as white solid. The crude product was purified by flash silica gel chromatography (0~5%, MeOH/DCM) to afford the compound 1.1-2 (2.80 g, 1.34 mmol, 13.4 % yield) as a white solid. 1H-NMR (400 MHz, CHLOROFORM-d) δ 7.34-7.29 (m, 5H, PhCH2-), 4.57 (s, 2H, PhCH2-), 3.82-3.46 (m, 180H, poly (ethylene glycol) 2000). [718] Step 2: Synthesis of tert-Butyl 2-(Benzyl-poly (ethylene glycol) 2000)-acetate (1.1-3) [719] To a mixture of benzyl-poly(ethylene glycol)2000 (1.1-2, 2.8 g, 544.6 μmol, 1 eq.) in THF (25 mL) was added NaH (535.8 mg, 13.39 mmol, 60% purity, 10 eq.) in portions at 0°C under N2. The reaction mixture was stirred at 0°C for 30 min, and tert-butyl 2-bromoacetate (1.83 g, 9.38 mmol, 1.39 mL, 7 eq.) was added to the above mixture. The reaction mixture was stirred at 26 °C for 18 h. The mixture was quenched with H 2 O (20 mL) and diluted with DCM (50 mL). The organic layer was separated and the aqueous phase was extracted with DCM (20 mL×2). The combined organic phase was washed with brine (20 mL×2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford crude product as white solid. The crude product was purified by flash chromatography (0-5%, DCM/MeOH) to afford the compound 1.1-3 (3.94 g, 1.79 mmol, 74.7% yield) as a white wax-like solid. 1H NMR (400MHz, CHLOROFORM-d) δ 7.43-7.30, 5H, PhCH2-), 4.58(s, 2H, PhCH 2 -), 4.03, 2H, -O-CH2-CO2-), 3.82-3.46 (m, 180H, poly(ethylene glycol)2000), 1.49 (s, 9H, t Bu). [720] Step 3. Synthesis of 2-(benzyl-poly(ethylene glycol)2000)-acetic acid (1.1-4) [721] To a solution of tert-butyl-2-(benzyl-poly(ethylene glycol)2000)-acetate (1.20 g, 1.79 mmol, 1 eq.) in DCM (10 mL) was added TFA (7.70 g, 67.53 mmol, 5 mL, 37.79 eq.) in portions at 26°C. The mixture was stirred at 26 °C for 18 h. The mixture was concentered in vacuum to afford the crude product 1.1-4 (1.5 g, crude) as a yellow oil, which was directly used in the next step without further purification. [722] Step 4. Synthesis of octadecyl 2-(benzyl-poly(ethylene glycol)2000)-acetate (1.1-5) [723] To a solution of 2-(benzyl-poly(ethylene glycol)2000)-acetic acid (1.17 g, crude), octadecan-1-ol (2.95 g, 10.89 mmol, 3.63 mL, 20 eq.) and DMAP (133.06 mg, 1.09 mmol, 2 eq.) in DCM (10 mL) was added EDCI (2.09 g, 10.89 mmol, 20 eq.) in one portion at 26°C under N 2 . The mixture was stirred at 26 °C for 18 hours. TLC (DCM/MeOH=10:1) indicated a new spot with slightly lower polarity was found. The mixture was quenched with H2O (20 mL) and diluted with DCM (50 mL). The organic layer was separated and the aqueous phase was extracted with DCM (30 mL×2). The combined organic phase was washed with brine (30 mL×2), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to afford the crude product as a white solid. The residue was purified by flash chromatography (0-5%ˈ DCM/MeOH) to afford the desired product octadecyl 2-(Benzyl-poly(ethylene glycol)2000)- acetate (1.01 g, ~76% yield) as a white wax-like solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.34-7.25 (m, 5H, PhCH2-), 4.54 (s, 2H, PhCH2-), 4.14-4.09 (4H, -O-CH 2 -CO 2 -CH 2 -), 3.82-3.46 (m, 180H, poly(ethylene glycol)2000), 1.66 - 1.55 (m, 2H, Me(CH2)15-CH2-), 1.23 (s, 22H, Me(CH2)15-), 0.85 (t, J=6.8 Hz, 3H, Me(CH 2 ) 15 -). [724] Step 5. Synthesis of octadecyl 2-(poly(ethylene glycol)2000)-acetate (CHM-001) [725] To a solution of Octadecyl 2-(benzyl-poly(ethylene glycol)2000)-acetate (1.01 g, 420.66 μmol, 1 eq.) in EtOH (60 mL) was added Pd(OH)2/C (3.01 g, 10% purity) at 26 °C under H2 (15 psi) atmosphere. The mixture was stirred at 26 °C for 18 h. The reaction mixture was filtered and the filtrate was concentrated at low pressure to afford the crude product as a white solid. The crude product was purified by flash silica gel chromatography (0~6%, MeOH/DCM) to afford the desired product CHM-001 (0.29 g, 123.60 μmol, 29.38% yield) as a white wax-like solid. 1H NMR (400 MHz, CHLOROFORM-d) δ 4.18-4.12 (m, 4H, -CH 2 -(CO)O-CH 2 -), 3.75-3.56 (m, 180H, polyethylene glycol 2000), 1.69-1.60 (m, 2H, -(CO)O-CH2-CH2-), 1.27 (s, 30H, Me- (CH 2 ) 15 -), 0.89 (t, J=6.8 Hz, 3H, Me-). 13 C NMR (400 MHz, CHLOROFORM-d) δ 170.59, 72.75, 70.89, 70.55, 70.21, 68.66, 65.00, 61.67, 31.93, 29.70, 29.66, 29.52, 29.37, 25.85, 22.69, 14.13. HPLC (ELSD), RT=3.36 min, 98.49% purity. IR(υ max /cm −1 ), 3491, 2887, 1968, 1752, 1467, 1360, 1343, 1280, 1149, 1112, 963, 842, 720. Melting range, 50.7-51.7 °C. Example 2.2: Synthesis of CHM-004 [726] 1.4-1 (500 mg, 241.26 μmol, 1 eq.) was dissolved in dry DCM (10 mL). DMAP (58.95 mg, 482.52 μmol, 2 eq.) and EDCI (277.50 mg, 1.45 mmol, 6 eq.) were then added successively, followed by addition of octadecan-1-ol (391.56 mg, 1.45 mmol, 482.21 μL, 6 eq.). The reaction mixture was then stirred at 25 °C for 18 h. The reaction mixture was then concentrated in vacuum to afford the crude product as a white solid. The crude product was purified by flash silica gel chromatography (0~5% MeOH/DCM) to afford the desired product octadecyl 2-(methyl-poly(ethylene glycol)2000)-acetate as a wax-like solid (CHM-004, 430 mg, 76.6 % yield). 1 H-NMR (400 MHz, CHLOROFORM-d) 4.19 - 4.09 (m, 4H, -O-CH2-CO2-CH2-), 3.74 - 3.60 (m, 180H, poly(ethylene glycol)2000), 3.38 (s, 3H, MeO-),1.68 - 1.58 (m, 2H, Me(CH 2 ) 15 - CH2-), 1.25 (s, 30H, Me(CH2)15-), 0.88 (t, J=6.8 Hz, 3H, Me(CH2)15-). 1 HPLC (ELSD), RT=7.88, 99.93% purity. IR ( max /cm -1 ), 3479, 2887, 1750, 1467, 1360, 1343, 1148, 1112, 963, 842. Melting range, 50.6-51.3 °C. Example 2.3: Synthesis of CHM-005 [727] Step 1: Synthesis of Hexadecyl 2-(benzyl-poly(ethylene glycol)2000)-acetate (1.5-2) [728] 2-(benzyl-poly(ethylene glycol)2000)-acetic acid (1.5-1, 800 mg, 372.35 μmol, 1.00 eq.) was dissolved in DCM (10 mL), and DMAP (90.98 mg, 744.69 μmol, 2.00 eq.) and EDCI (713.80 mg, 3.72 mmol, 10 eq.) were added, followed by addition of hexadecan-1-ol (902.72 mg, 3.72 mmol, 10 eq.). The reaction mixture was stirred at 25°C for 18 h. The reaction mixture was concentrated in vacuum to afford the crude product as a white solid. The crude product was purified by flash silica gel chromatography (0~8%, MeOH/DCM) to afford compound 1.5- 2 (110 mg, 38.01 μmol, 10.21% yield, 82% purity) as a white solid. [729] Step 2. Synthesis of Hexadecyl 2-(poly(ethylene glycol)2000)-acetate (CHM-005) [730] Hexadecyl 2-(benzyl-poly(ethylene glycol)2000)-acetate (1.5-2, 100 mg, 42.14 μmol, 1 eq.) was dissolved in EtOH (5 mL), and Pd(OH) 2 (50 mg, 71.21 μmol, 20% purity) was added. The reaction mixture was stirred at 20 °C under H2 atmosphere for 18 h. The reaction mixture was then filtered and the filtrate was concentrated at low pressure to afford the crude product as a white solid. The crude product was triturated with n-hexane at 20 o C for 30 min, filtered and the filter cake was collected and dried under reduced pressure to afford the compound CHM-005 (60 mg, 26.13 μmol, 61.99% yield, 99.4% purity) as a white solid. 1 H-NMR (400MHz, CHLOROFORM-d) δ 4.19-4.10 (m, 4H, - CH 2 -(CO)O-CH 2 -), 3.77-3.57 (m, 180H, polyethylene glycol 2000), 1.70-1.59 (m, 2H, -(CO)O-CH2-CH2-), 1.26 (s, 26H, Me- (CH 2 ) 13 -), 0.93-0.81 (m, 3H, Me-). HPLC (ELSD), RT=5.93 min, 99.44% purity. IR(υmax/cm −1 ), 3474, 2887, 1749, 1740, 1467, 1359, 1343, 1148, 1114, 963, 842. Melting range, 50.6-51.1 o C. Example 2.4: Synthesis of CHM-006 [731] Step 1: Synthesis of tetradecyl 2-(benzyl-poly(ethylene glycol)2000)-acetate (1.6-2) [732] 2-(benzyl-poly(ethylene glycol)2000)-acetic acid (1.6-1) (800 mg, 372.35 μmol, 1.00 eq.) was dissolved in DCM (10 mL), and DMAP (90.98 mg, 744.70 μmol, 2 eq.) and EDCI (713.80 mg, 3.72 mmol, 10 eq.) were then added, followed by addition of tetradecan-1-ol (798.26 mg, 3.72 mmol, 10 eq.). The reaction mixture was stirred at 20°C for 18 h. The reaction mixture was then concentrated in vacuum to afford the crude product as a white solid. The crude product was purified by flash silica gel chromatography (0~5%, MeOH/DCM) to afford the compound 1.6-2 (130 mg, 23.28 μmol, 14.9% yield) as a white solid. [733] Step 2. Synthesis of tetradecyl 2-(poly(ethylene glycol)2000)-acetate (CHM-006) [734] Tetradecyl 2-(benzyl-poly(ethylene glycol)2000)-acetate (1.6-2) (120 mg, 51.2 μmol, 1.00 eq.) was dissolved in EtOH (5 mL), and Pd(OH) 2 (100 mg, 10% purity) was then added. The reaction mixture was then stirred at 20°C under H2 atmosphere for 18 h. The reaction mixture was then filtered and the filtrate was concentrated at low pressure to afford the crude product as a white solid. The crude product was triturated with n-hexane at 20 o C for 30 min. The solid was collected and dried under vacuum to afford compound CHM-006 (102 mg, 44.69 μmol, 87.33% yield, 98.79% purity) as a white solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 4.20-4.09 (m, 4H, -CH 2 -(CO)O-CH 2 -), 3.71-3.57 (m, 180H, polyethylene glycol 2000), 1.64 (q, J=6.8 Hz, 2H, -(CO)O-CH2-CH2-), 1.26 (s, 22H, Me-(CH 2 ) 11 -), 0.92-0.81 (m, 3H, Me-). HPLC (ELSD), RT=4.20 min, 98.79% purity. IR(υmax/cm −1 ), 3447, 2889, 1749, 1740, 1653, 1466, 1358, 1343, 1148, 1113, 963, 843. Melting range, 49.7-50.1 o C. Example 2.5: Synthesis of CHM-012 [735] Step 1: (Benzyl poly (ethylene glycol)2000) N-octadecylcarbamate (1.10-2) [736] Benzyl-poly(ethylene glycol)2000 (BnPEG2000, 1.00 g, 685.26 μmol, 1.00 eq.) was dissolved in pyridine (10 mL), and 1-isocyanato heptadecane (1.93 g, 6.85 mmol, 10.0 eq) was then added. The reaction mixture was then refluxed at 80°C for 18 h. The reaction mixture was then concentrated in vacuum to afford the crude product as a white solid. The crude product was purified by flash silica gel chromatography (0~5%, MeOH/DCM) to afford compound 1.10-2 (850 mg, 326.94 μmol, 47.71% yield, 89% purity) as a white solid. 1 H-NMR (400MHz, CHLOROFORM-d) δ 7.34 (d, J=4.3 Hz, 5H, PhCH 2 -), 4.57 (s, 2H, PhCH 2 -), 4.21 (br s, 2Hˈ -CH 2 -O(CO)-), 3.65 (s, 167H, poly(ethylene glycol)2000), 3.15 (br d, J=5.7 Hz, 2Hˈ-CH 2 - O(CO)NH-CH 2 -), 1.48 (br s, 2H, -O(CO)NH-CH 2 -CH 2 -), 1.26 (s, 30HˈMe(CH 2 ) 15 -), 0.88 (br s, 3HˈMe(CH 2 ) 15 -). [737] Step 2. Poly(ethylene glycol)2000 N-octadecylcarbamate (CHM-012) [738] (Benzyl-poly(ethylene glycol)2000) N-octadecylcarbamate (490 mg, 206.6 μmol, 1.00 eq.) was dissolved in EtOH (10 mL), and Pd(OH)2/C (20 mg, 10 % purity) was then added. The reaction mixture was then stirred at 20°C under H 2 atmosphere for 18 h. The reaction mixture was filtered and the filtrate was concentrated in vacuum to afford the crude product as a white solid. The crude product was purified by reversed-phase HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [H2O-MeOH]; B%: 60%-95%, 9 min) to afford compound CHM-012 (144 mg, 62.61 μmol, 30.31% yield, 99.82% purity) as a white solid. 1 H-NMR (400 MHz, CHLOROFORM-d) δ 4.22 (br s, 2H, -CH2-O(CO)-), 3.65 (s, 180H, poly(ethylene glycol)2000), 3.16 (q, J=6.5 Hz, 2H, -CH 2 -O(CO)NH-CH 2 -), 2.77 (br s, 1H, HO- or –NH-), 1.48 (br s, 2H, -O(CO)NH-CH2-CH2-), 1.26 (s, 30H, Me(CH2)15-), 0.90-0.87 (m, 3H, Me(CH 2 ) 15 -). HPLC (ELSD), RT=6.40, 99.82 % purity. IR (υ max /cm -1 ): 3307, 2916, 2887, 1963, 1694, 1548, 1467, 1360, 1344, 1149, 1113, 963, 842. Melting range, 45.5-46.3 °C. Example 3: BRIJ™ S100 Stabilizes Both the Size and Encapsulation of Lipid Nanoparticles after a Freeze/Thaw Cycle at -20 °C [739] LNPs in this example comprise a lipid composition of SS-OC : Chol : DSPC : PEG2k- DPG at 49 : 28.5 : 22 : 0.5 mol%, and encapsulate the RNA molecule encoding wild-type Seneca Valley virus (SVV) at a lipid-nitrogen-to-phosphate ratio (N:P) of 14. Total lipid concentration was set to 40 mM. RNA acidifying buffer was malic acid pH 3. LNPs were dialyzed overnight into the appropriate buffer (25 mM Tris, 50 mM sucrose, 113 mM NaCl, pH 7.4) and passed through a 0.2 μm filter after dialysis. Each of the cryo-protectants (propylene glycol (PG), BRIJ™ S100 (polyethylene glycol), Tween 80 (T80)) were spiked into LNPs during dilution to the various concentrations. Three concentrations of each cryo- protectant were examined as compared to a no excipient control. [740] For freeze/thaw experiments, 0.5 mL vial was filled with LNPs at 0.5 mg/mL RNA concentration in 2 mL glass vials. The vials were subject to freezing at -20 °C overnight, then quickly thawed in 25 °C water bath. Time 0 characterization was executed on all samples.0.5 mL sample volumes were frozen at -20 °C for at least 18 hours and subsequently thawed in a 25 °C water bath for 30 minutes. Upon complete thaw, vials were inverted to mix and post-1 freeze/thaw (F/T) characterization was executed. Size was measured by dynamic light scattering (DLS) (FIG. 1A) and encapsulation efficiency was measured by a fluorescence- based solution assay using RiboGreen RNA quantitation reagent (FIG. 1B). [741] Among these conditions, addition of 0.25 mM Brij S100 to the buffer (25 mM Tris, 50 mM sucrose, 113 mM NaCl, pH 7.4) worked best at maintaining both particle size and encapsulation after a single freeze/thaw cycle at -20 °C. Example 4: Comparison of PEG2k-DPG, PEG2k-DMG and BRIJ™ S100 as PEG-lipid Component in LNP Formulation [742] SS-OC:Cholesterol:DSPC:PEG-lipid (49:28.5:22:0.5 mol%) LNPs encapsulating non- replicating SVV RNA (SVV-neg) were prepared following similar procedures as in Example 1. The PEG-lipid was PEG2k-DPG, PEG2k-DMG or Brij S100. The N:P ratio was set to 14. Total lipid concentration was set to 40 mM. Formulations were mixed at a 3:1 aqueous:organic volume ratio at 12 mL/min with 60 °C heat applied to the organic phase syringe. Formulations were dialyzed against 1X PBS pH 7.2 for at least 18 hours. Characterization was executed post- dialysis. Formulations were concentrated using 100kD Amicon centrifugal filtration units. Characterization was executed post-concentration and compared to post-dialysis characterization. Size was measured by dynamic light scattering (FIG.2A) and encapsulation efficiency was measured by RiboGreen (FIG.2B). [743] The results showed that Brij S100 could be used in replacement of PEG2k-DPG or PEG2k-DMG for LNP formulation. In this particular example, the particle size was larger for LNPs comprising Brij S100. Example 5: LNPs Comprising Brij Displayed Altered Pharmacokinetic Characteristics in vivo upon Repeat Dosing [744] SVV-neg/SS-OC:Cholesterol:DSPC:PEG-lipid (49:28.5:22:0.5 mol%) LNPs were prepared according to Table 4 below. The PEG-lipid was either PEG2k-DPG or Brij S100. Table 4 PDI: polydispersity index; %EE: Encapsulation Efficiency. [745] Formulations were used in a repeat dose (weekly dose schedule for 2 weeks, Q7x2) intravenous (IV) mouse PK study. Copy number of RNA in serum post-dose was measured at each time point. The results are shown in FIG. 3A (for PEG2k-DPG) and FIG. 3B (for Brij S100). [746] LNP comprising PEG2k-DPG exhibited prolonged circulation post-first dose with rapid clearance within 4 hours upon the second dose. LNP comprising Brij S100 exhibited an intermediate change in exposure post-first dose but maintained similar circulation characteristic and slopes of elimination upon the second dose. Example 6: Lower Lipid Concentration and Changing RNA Buffer Reduce Size and Increase Encapsulation Efficiency of LNPs Formulated with Brij Molecules [747] LNPs comprising SVV-neg/SS-OC:Cholesterol:DSPC:Brij were prepared at four different lipid mol% ratios: 49:28.5:22:0.5, 49:27.5:22:1.5, 49:39.5:11:0.5, and 49:38.5:11:1.5. The Brij molecule was Brij C20, Brij O20, Brij S20 or Brij S100. The N:P ratio was set to 14 noting 2 ionizable amines in SS-OC. LNP preparation followed similar procedures as those in the previous examples. However, total lipid concentration was changed from 40 mM to 20 mM, and the RNA acidifying buffer was changed from 20 mM malic acid pH 3 to 25 mM acetate pH 5. Formulations were mixed at a 3:1 aqueous:organic volume ratio at 12 mL/min without any heat during mixing. Formulations were dialyzed against 1X PBS pH 7.2 for at least 18 hours. Formulations were concentrated using 100kD Amicon centrifugal filtration units. Characterization was executed. Size was measured by dynamic light scattering (FIG.4A) and encapsulation efficiency was measured by RiboGreen (FIG. 4B). Each unique composition was formulated at least two times on separate days to ensure reproducibility. [748] The results showed that reducing the lipid concentration and changing the RNA acidifying buffer collectively resulted in smaller particle size and higher encapsulation across all Brij molecules and at each molar composition as compared to the previous OC/Brij S100 formulation (40 mM total lipid, 20 mM malic acid pH 3) that was used in Example 3 for the repeat dose mouse PK study. Example 7: LNPs Comprising Brij and Oncolytic Viral RNA Demonstrate High Anti- Tumor Efficacy in Animal Models [749] SVV-wt/SS-OC:Cholesterol:DSPC:PEG-lipid LNPs were prepared and characterized according to Table 5 below. The PEG-lipid was PEG2k-DPG, Brij S100, Brij C20 or Brij S20. PDI: polydispersity index; %EE: Encapsulation Efficiency; ZP: zeta potential. Table 5 [750] Formulations were used in a repeat dose IV mouse efficacy screen in H446 tumor model. Tumor volume (FIG. 5A) and body weight (FIG. 5B) were measured at each time point. The results showed that all formulations demonstrated high anti-tumor efficacy and were well tolerated. SS-OC/Brij LNPs were similar in efficacy and tolerability as compared to SS- OC/PEG2k-DPG. [751] In another study, SVV-wt/Ionizable lipid:Cholesterol:DSPC:Brij S100 (49:28.5:22:0.5 or 49:38.5:11:1.5 mol%) LNPs were prepared according to Table 6 below. The ionizable lipid was COATSOME® SS-OC or COATSOME® SS-OP. Table 6 [752] Formulations were used in a repeat dose IV mouse efficacy screen in H446 tumor model. Tumor volume (FIG.6A) and body weight (FIG.6B) was measured at each time point. The results showed that all formulations demonstrated high anti-tumor efficacy and were well tolerated. SS-OC/Brij and SS-OP/Brij LNPs were similar in efficacy and tolerability. Example 8: Characterization of LNPs comprising Myrj [753] SVV-neg/OC:Cholesterol:DSPC:Myrj S40 (49:28.5:22:0.5 or 49:27.5:22:1.5 or 49:39.5:11:0.5 or 49:38.5:11:1.5 mol%) LNPs were prepared. A Brij S100 control was also included (49:28.5:22:0.5 mol% of OC:Chol:DSPC:Brij S100). The N:P ratio was 14 noting 2 ionizable amines in SS-OC. Total lipid concentration was to 20 mM and the RNA acidifying buffer was 25 mM acetate pH 5. Formulations were mixed at a 3:1 aqueous:organic volume ratio at 12 mL/min without any heat during mixing. Formulations were dialyzed against 1X PBS pH 7.2 or 25 mM tris, 50 mM sucrose, 113 mM NaCl, pH 7.4 buffer for at least 18 hours. Formulations were concentrated using 100kD Amicon centrifugal filtration units. LNP sizes were measured by dynamic light scattering (FIG. 7A) and encapsulation efficiency was measured by RiboGreen (FIG. 7B). Each unique composition was formulated at least three times on separate days to ensure reproducibility. [754] The results showed that LNPs formulated using Myrj S40 as the PEG-lipid yielded similar size and encapsulation efficiency as compared to Brij S100 as the PEG- lipid, across the four molar compositions tested. Example 9: Formulation of Lipid Nanoparticles for Intravenous Delivery of CVA21- encoding RNA [755] Recombinant RNA molecules comprising CVA21 genomes were formulated in lipid nanoparticles for delivery of the RNA in vivo. [756] Lipid nanoparticle production: Lipids (e.g., cationic lipid, PEG-lipid, helper lipid) used in the formulation of lipid nanoparticles are selected from the following: D-Lin-MC3-DMA (MC3); N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP) COATSOME® SS-LC (former name: SS-18/4PE-13); COATSOME® SS-EC (former name: SS-33/4PE-15); COATSOME® SS-OC; COATSOME® SS-OP; Di((Z)-non-2-en-1-yl)9-((4-dimethylamino)butanoyl)oxy)heptad ecanedioate (L-319) cholesterol; 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(pol yethyleneglycol)- 5000] (DSPE-PEG5K); 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (PEG2k-DPG); 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K); 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K) polyoxyethylene (100) stearyl ether (BRIJ S100; CAS number: 9005-00-9); polyoxyethylene (20) stearyl ether (BRIJ S20; CAS number: 9005-00-9); polyoxyethylene (20) oleyl ether (BRIJ O20; CAS number: 9004-98-2); polyoxyethylene (20) cetyl ether (BRIJ C20, CAS number: 9004-95-9); Polyoxyethylene (40) stearate (MYRJ S40, CAS number: 9004-99-3). [757] Lipids were prepared in ethanol at various ratios. RNA lipid nanoparticles were then generated using microfluidic micromixture (Precision NanoSystems, Vancouver, BC) at a combined flow rate of 2 mL/min (0.5 mL/min for ethanol, lipid mix and 1.5 mL/min for aqueous buffer, RNA). The resulting particles were washed by tangential flow filtration with PBS containing Ca and Mg. [758] Analysis of physical characteristics of lipid nanoparticles: Physical characteristics of lipid nanoparticles were evaluated before and after tangential flow filtration. Particle size distribution and zeta potential measurements were determined by light scattering using a Malvern Nano-ZS Zetasizer (Malvern Instruments Ltd, Worcestershire, UK). Size measurements were performed in HBS at pH 7.4 and zeta potential measurements were performed in 0.01 M HBS at pH 7.4. Percentage of RNA entrapment was measured by Ribogreen assay. Lipid nanoparticles that showed greater than 80 percent RNA entrapment were tested in vivo. Example 10: In Vivo Studies of LNPs Comprising CVA21-RNA [759] The anti-tumor efficacy of Coxsackievirus A21 (CVA21)-RNA encapsulated in LNP was evaluated in vivo using a murine SK-MEL-28 melanoma model. For these experiments, the CVA21-RNA viral genomes were encapsulated in LNPs comprising a molar ratio of SS- OC:DSPC:Chol:BRIJ S100 of 49:22:28.5:0.5 mol %. In some enbodiments, the size of LNPs was 94 nm; PDI was 0.19; and %EE was 91%. [760] Briefly, athymic nude mice were subcutaneously implanted with SK-MEL-28 human melanoma tumor and treated on days 1 and 8 with IV administration of one of two doses of LNP comprising CVA21-RNA (0.2 mg/kg or 0.05 mg/kg). Tumor growth (FIG. 8A and FIG. 8C) and body weight changes (FIG. 8B and FIG. 8D) were monitored. PBS buffer was used as control. [761] Complete tumor regression at a dose level as low as 0.05 mg/kg was observed (FIG. 8B). Both doses were well tolerated, as indicated by stable body weight (FIG. 8B and FIG. 8D) and no adverse clinical signs. Low levels of CVA21 replication were detected by RT- qPCR for CVA21 minus-strand and by plaque titer assay in spleen, liver, lung, heart, and kidney 2 days after injection. However, this was undetectable at 7 days (FIG. 8E) indicating that the mice had cleared the infection. The results showed that CVA21 encapsulated in LNPs comprising Brij S100 demonstrated high anti-tumor efficacy and was well tolerated. Example 11: Formulations of LNPs Comprising Different Ionizable Lipids [762] This example illustrates the encapsulation of non-replicating Seneca Valley virus (SVV) RNA (SVV-Neg) in LNP formulations. LNPs in this example comprise a lipid composition of ionizable lipid (CAT):DSPC:cholesterol:PEG 2k -DMG at 50:7:40:3 mol%. The lipid mixture in ethanol was mixed with SVV-Neg in RNA acidifying buffer (50 mM citrate, pH 4) at a lipid-nitrogen-to-phosphate ratio (N:P) of 9 using a microfluidic device (Precision NanoSystems Inc.). Total lipid concentration was set to 20 mM. [763] LNPs were dialyzed against 50 mM phosphate, pH 6.0, for 12-16 h, and secondary dialysis was performed against 50 mM HEPES, 50 mM NaCl, 263 mM sucrose, pH 7.3, for 4- 24 h at room temperature. Post-dialyzed LNPs were concentrated using 100 kDa AMICON® ULTRA CENTRIFUGAL filters (MilliporeSigma) and sterile filtered using 0.2 μm syringe filters. Samples were then characterized and diluted as needed. Upon dilution, a 5 w/v% glycerol spike was added if samples were then stored at -20 °C. [764] LNPs were characterized for particle size by dynamic light scattering (DLS) (FIG. 10A) and polydispersity index (PDI) (FIG. 10B). Encapsulation efficacy was measured using a fluorescence-based RiboGreen assay (FIG. 10C). Briefly, a standard curve was generated using the appropriate RNA; testing LNP samples were diluted 40X with TE buffer and evaluated to yield the amount of unencapsulated RNA (Rf) and diluted with Triton-X to generate the amount of total RNA (R t ). The difference between R t and R f over the total RNA (Rt) is the encapsulation efficiency (%EE): %EE = (R t - R f ) / R t × 100%. Table 7. LNP formulations and characterizations Example 12: Purified RNA Improves LNP Biophysical Properties [765] LNP formulations encapsulating SVV-Neg RNA were prepared and characterized as described in Example 11. The SVV-Neg RNA was purified using tangential flow filtration (TFF) or using oligo-dT chromatography and reverse phase chromatography. Tested LNP formulations encapsulating oligo-dT and reverse phase chromatography purified SVV-Neg RNA had reduced particle sizes and PDI (FIG.11A and 11B) with comparably high or further improved encapsulation efficiency (FIG.11C). Example 13: Modification of RNA Acidifying Buffer Improves LNP Biophysical Properties [766] LNP formulations encapsulating SVV-Neg RNA were prepared and characterized as described in Example 11 but varying the RNA acidifying buffer to determine the effect changing the citrate concentration and pH would have on the LNP biophysical properties. [767] CAT4 and CAT5 formulations were tested with RNA acidifying buffer: (1) 50 nM citrate pH4; (2) 5 mM citrate pH 3.5; (3) 15 mM citrate pH 3.5; (4) 30 mM citrate pH 3.5; and (5) 50 mM citrate pH 3.5. FIG. 12A, 12B, and 13C depict the particle size, PDI, and encapsulation efficiency of the LNPs. Further, CAT1 to CAT3, CAT6 to CAT10, and CAT35 LNP formulations were made with the 5 mM citrate pH 3.5 buffer (FIGs.13A, 13B, and 13C). [768] The results suggested changing the RNA acidifying buffer (e.g., lowering salt concentration) resulted in smaller particle size and PDI. Example 14: LNP formulations Are Stable At Both -20 °C and -80 °C [769] CAT:DSPC:cholesterol:PEG 2k -DMG (50:7:40:3 mol%) LNPs encapsulating SVV-neg RNA were prepared following similar procedures as in Example 11. The ionizable lipids tested were CAT3, CAT4, and CAT5. The RNA acidifying buffer used was 5 mM citrate, pH 3.5. Cryo-protectant (5 w/v% glycerol) was spiked into LNPs dilutions. The LNP formulations were then stored at -20 °C or -80 °C for one week or one month before the biophysical parameters were measured. [770] The results are shown in FIGs.14A (-20 °C) and FIG. 14B (-80 °C). Particle size and encapsulation efficiency remained the same for all formulations at -20 °C at the tested timepoints. Particle size decreased and encapsulation efficiency remained the same for all formulations at -80 °C at the tested timepoints. Example 15: In Vivo Studies of LNPs Comprising Different Ionizable Lipids [771] The in vivo pharmacodynamics and anti-tumor efficacy of Seneca Valley virus (SVV)- RNA encapsulated in LNP was evaluated in a mouse model for small cell lung cancer (SCLC). [772] In this example, the RNA molecules encoding SVV viral genomes and a NanoLuc luciferase (NLuc) were encapsulated in LNPs prepared according to Table 8 below. NLuc is a luciferase enzyme that produces luminescent signal when provided with the substrate furimazine. The LNPs were dialyzed overnight in 100 mM tris 300 mM sucrose 113 mM NaCl pH 7.4 at 5 °C. Alternatively, the LNPs were dialyzed against 50 mM phosphate, pH 6.0, for 12-16 h and secondary dialysis was performed against 50 mM HEPES, 50 mM NaCl, 263 mM sucrose, pH 7.3, for 4-24 h at room temperature. Post-dialyzed LNP formulations were concentrated, filtered, characterized, and optionally diluted. Table 8. LNP formulations for in vivo studies
[773] NCI-H446 human SCLC cells (5x10 6 cells/0.1 mL in a 1:1 mixture of serum-free PBS and Matrigel®) were subcutaneously inoculated in the right flank of 8-week-old female athymic nude mice (Charles River Laboratories). When median tumor size reached approximately 150 mm 3 (120-180 mm 3 range), mice were intravenously administered 0.2 mg/kg of PBS or the LNPs comprising SVV-RNA on day 1 or on days 1 and 8. Bioluminescence (BLI) was assessed 96 h post-dose utilizing optical imagine IVIS Lumina (PerkinElmer), and the signal was quantified using Molecular Imaging software (FIGs. 16A- 16F). Tumor volume and body weight were assessed 3 times per week (FIGs.17A-17E). [774] Tumor regression after two 0.2 mg/kg doses was observed for the CAT1 to CAT5 formulations (FIG. 17A, left), and all formulations were well-tolerated (FIG. 17A, right). Tumor regression at a single 0.2 mg/kg dose was observed for the CAT6-CAT9, CAT11, CAT16-CAT17, CAT19-CAT24, CAT26, CAT29, CAT32, and CAT34 formulations (FIGs. 17B-17E, left), and all formulations were well-tolerated (FIGs. 17B-17E, right). Tumor growth inhibition was observed with CAT12-CAT13, CAT15, CAT18, and CAT28 formulations (FIGs.17B-17E, left), and all formulations were well-tolerated (FIGs.17B-17E, right). Example 16: In vivo Studies of LNPs Comprising CAT7 and Different PEG-Lipids [775] The in vivo pharmacodynamics and anti-tumor efficacy of SVV-RNA encapsulated in LNP with varying lipid compositions was evaluated in a mouse model for small cell lung cancer (SCLC). The RNA molecule encoding SVV viral genomes and NLuc were encapsulated in LNPs prepared according to Table 9 below, following a similar procedure described in Example 11. Total lipid concentration was set to 20 mM, and the lipid-nitrogen-to-phosphate ratio (N:P) was 9. Table 9. LNP formulations for in vivo studies [776] The pharmacodynamics (assessed via a bioluminescence assay) and tumor growth inhibition ability of the SVV-NanoLuc-encapsulated LNPs was evaluated as described in Example 15. [777] Nanoluciferase is detectable at 72 hours post-injection, indicative of continuous SVV (FIG.18A). Complete tumor regression at a single 0.2 mg/kg dose was observed for all tested formulations, and all formulations were well-tolerated (FIG.18B). Example 17: Pharmacokinetics Evaluation of LNP Formulations [778] The pharmacokinetics (PK) of Coxsackievirus A21 (CVA21)-RNA-encapsulating LNP formulations were evaluated in rats. [779] In this example, the RNA molecules encoding CVA-21 viral genomes were encapsulated in LNPs prepared according to Table 10 below, following the similar procedure as described in Example 11. Table 10. LNP formulations for pharmacokinetics studies [780] Naïve female Sprague Dawley, JVC rats (age: 12 weeks) were intravenously administered 1 or 0.3 mg/kg of viral genomes comprised in the LNPs on days 1 and 15 (Q2W2) or on day 1 and day 8 (Q1W2). Plasma samples were collected at the predetermined times. The concentration of the ionizable lipid comprised in the LNPs (SS-OC, CAT7, or CAT11) in plasma were measured by LC-MS (FIGs. 19A-19E, 20A-20D, 21A-21F, and 22A-22E) and the pharmacokinetics parameters were calculated and summarized in Table 11. IgM and IgG levels were analyzed by enzyme-linked immunoassay (ELISA) (FIGs. 23A-23B and FIGs. 24A-24B). Table 11-1. Pharmacokinetics parameters Table 11-2. Pharmacokinetics parameters
[781] LNP formulations with different ratios and/or types of PEG-lipids display varying T1/2, exposure, and clearance after multiple doses. These data indicate that the LNP compositions can be adapted to meet the need of various therapeutic payloads for long to short exposure. [782] Anti-PEG IgM level after dosing the LNP formulations was low and decreased from day 7 to 21 (FIG. 23A and FIG. 23B). Anti-PEG IgG was also low and did not significantly increase with multiple dose, indicating a low potential for immunogenicity (FIG. 24A and FIG.24B). Among the tested formulations, LNPs comprising CAT7 as the ionizable lipid and CHM-006 as the PEG-lipid were observed with the lowest IgM and IgG levels. Example 18: Formulation of LNPs Encapsulating mRNA [783] SS-OC:Cholesterol:DSPC:PEG-lipid LNPs encapsulating mRNA at a N: P ratio of about 8:1 to 20:1 are prepared. The PEG-lipid is PEG2k-DPG, PEG2k-DMG or Brij S100. Total lipid concentration is about 10 to about 60 mM. Formulations are mixed and dialyzed, and concentrated. Size is measured by dynamic light scattering and encapsulation efficiency is measured by RiboGreen. The results show that Brij S100 could be used in replacement of PEG2k-DPG or PEG2k-DMG for mRNA LNP formulation. [784] mRNA LNP formulations in this Example are tested for pharmacokinetic characteristics upon repeat dosing via intravenous administration in mice. Copy number of RNA in serum post-dose is measured at predetermined time point. The results show that LNPs formulated using Brij S100 exhibits a reduced clearance rate upon the second dose compared to LNPs formulated using PEG-2k DPG or PEG2k-DMG. Example 19: Formulated of LNPs Encapsulating mRNAs [785] This example illustrates the encapsulation of mRNAs in lipid nanoparticle (LNP) formulations. LNPs in this example comprise a lipid composition of CAT7 : DSPC : cholesterol : CHM-006 at 54.5 : 20 : 25 : 0.5 mol%. The lipid mixture in ethanol was mixed with human erythropoietin (hEPO) mRNAs or bi-specific T cell engager (BiTE)-encoding mRNAs in RNA acidifying buffer (5mM citrate, pH 3.5). Total lipid concentration was set to 20 mM, and the lipid-nitrogen-to-phosphate ratio (N:P) was 9. [786] LNPs were dialyzed against 50 mM phosphate, pH 6.0, for 12-16 h and secondary dialysis was performed against 50 mM HEPES, 50 mM NaCl, 263 mM sucrose, pH 7.3, for 4- 24 h at room temperature. Post-dialyzed LNPs were concentrated using 100 kDa AMICON® ULTRA CENTRIFUGAL filters (MilliporeSigma) and then sterile concentrated using 0.2 μm syringe filters. Samples were then characterized and diluted as needed. Upon dilution, a 5 w/v% glycerol spike was added if samples were stored at -20 °C. [787] LNP sizes were measured by DLS, and the encapsulation efficacy was measured using a fluorescence-based RiboGreen assay (Table 12). Table 12. LNP-formulated mRNAs Example 20: Pharmacokinetics of LNP-formulated mRNA [788] The PK of mRNA-encapsulating LNP formulations (Table 12) were evaluated in mice. [789] Naïve female Balb/c mice were dosed with 1 mg/kg of the LNPs. 3 mice were bled at each predetermined timepoints and plasma was frozen at -80 °C for later analysis. Plasma levels of hEPO and BiTE were measured by Meso Scale Discovery (MSA) electrochemiluminescence (ECL) assays (FIG. 25A and FIG. 25B). High levels of protein expression and prolonged exposure were observed. Example 21: LNP-formulated RNAs with varying lengths [790] LNP formulations encapsulating RNA with various lengths were prepared according to Table 13 below, following a similar procedure as described in Example 11. Table 13. LNP formulations [791] The data show that LNPs maintained good biophysical properties (e.g., small size and PDI, high %EE) despite the variable length of the encapsulated RNA. Example 22: Formulation Studies and Modeling of LNPs Comprising CAT7 [792] A-optimal criterion (Jones et al.2021) was used to design formulation studies of LNPs comprising CAT7 (FIG.26) and yielded 20 design of experiment (DOE) runs (Table 14). The total lipid concentration was set to 20 mM and the N:P ratio to 9. The design space tested LNPs comprising 40-60 mol% ionizable lipid of CAT7, 5-20 mol% helper lipid of DSPC, 25- 50 mol% structural lipid of cholesterol, and 0.25-3% PEG-lipid of DMG-PEG2000 or CHM- 001. Table 14. Design of Experiment for CAT7 LNPs
[793] Within the parameters of the reliable design space, the DOE optimal composition was determined to be CAT7 : DSPC : Cholesterol : PEG-lipid with the mol % ratio of 54.5 : 20 : 25 : 0.5. [794] A Self-Validated Ensemble Modeling (SVEM) method (Lemkus et al.2021) was used to formulate a model for predicting biophysical characteristics of LNPs with varying compositions and identifying and fine-tuning LNP systems for different desired outcomes. In developing the model, the aim was to minimize PDI (weighted as 1) and size (weighted as 0.1). [795] The resulting prediction profilers are shown in FIG. 27. Quadratic (curvature or non- linear) relationships are seen for CAT7, DSPC, and Cholesterol. CAT7 composition seems to significantly impact the PDI, with an increasing trend initially starting from 40 mol%, followed by a downward trend which stabilized at ~55 mol%. Higher DSPC seems to favor a drop in both PDI and the size. Cholesterol follows a pattern very similar to CAT7 for both PDI and the size, but the model picks a lower molar composition. Increasing PEG-lipid composition is associated with a steep increase in observed PDI. Equivalents and Scope [796] In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The present disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The present disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. [797] Furthermore, the present disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the present disclosure, or aspects of the present disclosure, is/are referred to as comprising particular elements and/or features, certain embodiments of the present disclosure or aspects of the present disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub–range within the stated ranges in different embodiments of the present disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. [798] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the present disclosure can be excluded from any claim, for any reason, whether or not related to the existence of prior art. [799] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present disclosure, as defined in the following claims.
Next Patent: FLAME LAMINATION ADDITIVE FOR POLYURETHANE FOAM